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Abstract 
Osteoarthritis (OA) is a disease characterised by changes in the structure and 
function of articular joints, leading to pain and loss of mobility. Bone 
Morphogenetic protein 7 (BMP-7), a member of the transforming growth factor β 
superfamily, has been shown to promote anabolic events within articular 
cartilage, and confer protection from OA associated destruction in a number of 
animal models.  It has been shown that a disease-associated loss of BMP-7 in OA 
may contribute to the joint destruction. The mechanism associated with the loss 
of BMP-7 has yet to be fully elucidated. Recently, small non-coding RNAs 
(microRNAs) that participate in post-transcriptional gene regulation, have been 
identified as a potential dysregulated mechanisms in OA. It was therefore 
hypothesised that disease-associated alterations in these microRNAs could lead 
to subsequent changes in the expression of BMP-7 and its signalling family. The 
aims of this thesis were to investigate the expression of BMP-7 and other 
associated BMP signalling molecules and identify any microRNAs that may 
regulate these transcripts. Furthermore, the study aimed to elucidate the 
molecular mechanisms by which BMP-7 is able to confer protection in cartilage.  
 
The studies presented in this thesis show that both articular chondrocytes and 
the synovial membrane can express very low levels of BMP-7 transcript in a 
subset of patients. In juxtaposition, protein can be clearly detected in both 
articular chondrocytes and synovial membrane.  Interrogation of the BMP-7 
signalling family transcripts revealed that all members are detectable in OA 
cartilage. This expression was independent of the eroded nature of the 
cartilage. Evaluation of the circulating microRNAs that were predicted to target 
the BMP-7 pathway revealed that several miRNAs (including miR24-3p) were 
altered in the plasma of OA patients.  Interestingly, miR24-3p was able to target 
BMP receptors ALK2 and BMPR1B. Moreover, there was a significant negative 
correlation between the expression of miR24-3p and the ALK2 receptor in OA 
patients. Thus suggesting there is a role for this miRNA in the negative 
regulation of BMP-7 signalling in OA cartilage. 
 
3 
 
 
To complement the work evaluating the endogenous signalling pathway, studies 
were also undertaken to investigate the impact of exogenous BMP-7 stimulation 
on chondrocytes. BMP-7 was able to promote its own transcriptional expression 
in a patient specific manner and induce expression of IL-1β in all of the donors 
investigated. In addition to the induction of IL-1β, BMP-7 was also able to up-
regulated the IL-1β antagonist, IL-1Ra. Taken together this data suggests a role 
for BMP-7 in the regulation of the inflammatory mediator IL-1β.  Finally, BMP-7 
was able to up-regulate several pro-inflammatory cytokines and chemokines in 
both primary OA chondrocytes and in vitro differentiated macrophages. 
 
In summation, the work presented in this thesis suggests that BMP-7 may be 
contributing to the promotion of inflammation and subsequent repair as part of 
the cartilage homeostatic mechanisms. Further to this, miR24 has been 
highlighted as a regulator of cartilage homeostasis via the direct targeting of 
ALK2.  Changes in the expression of this miRNA over the course of OA disease 
progression may be involved in driving disease pathogenesis. Therefore 
understanding the targets for this disease-associated miRNA may help in the 
development of disease modifying therapies.    
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1 Introduction 
1.1 Osteoarthritis  
 General Overview 1.1.1
Osteoarthritis (OA) is the most common form of arthritis (2,3) with hip and knee 
OA being one of the leading  causes of global disability (3). Arthritis Research UK 
estimate that at least one in six people are affected by the disease and the 
American Arthritis Society state that there are more than 10 million people 
suffering from OA in the USA.  This disease imposes a colossal strain on the 
government due to reduced mobility, which can affect an individual’s ability to 
work. This effect can be quantified as loss of economic production annually, 
where in the UK is it estimated that due to OA the loss is over £3.2 billion.  The 
National Health Service (NHS) also suffers economically with the prescription of 
non-steroidal, ant-inflammatory drugs and surgeries relating to OA contributing 
an estimated £900 million to the national budget annually.  The strain on the 
NHS is not limited to finance, as there is also strain on staff and resources from 
the increasing numbers needing treatment and care for OA.  This, in part, can be 
attributed to the aging population of the UK and to the increasing problem of 
global obesity.  In 1990, the median age of the population was 36 years (with 
half the population being below and half being above this age).  This number has 
been increasing and it is currently estimated that by 2035 the median age will be 
42 years (Office of National Statistics, 2012). It can be theorised that the 
number of OA sufferers will only increase in accordance with the aging 
population. Obesity is a major health problem across the UK.  It is estimated 
that across Scotland, England, Ireland and Wales 58 -65% of the population are 
overweight and of these 22-28% are clinically obese(5).  Thus with this current 
obesity level and the aging population the prevalence of this disease is likely set 
to increase and as a result will become an unmanageable social and economic 
burden.  Therefore increased research and better treatment strategies are 
needed in the management of the disease along with new therapies that can 
prevent or delay the need for surgical intervention and potentially reduce the 
disability caused by this disease.  
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 Articulating and Non Articulating Joints.   1.1.2
The human body has 360 joints which can be classified into three types; ones 
that cannot move at all- synarthroses (i.e. the joints in the skull), joints that 
have a small range of motion amphiarthroses (i.e. vertebral discs) and joints 
that can be moved freely with a wide range of motion- diarthroses (i.e. the hip). 
The variation in the movement of each classification of joint can be attributed 
to the surrounding tissue structure;  fixed joints are fibrous, joints with a limited 
movement are cartilaginous and joints with the most motion are synovial.  
Synovial joints include the shoulder, elbow, hip and knee. The elbow and the 
knee are examples of a hinge joint (can move primarily in one plane) whereas 
the shoulder and hip are ball and socket joints (can move in more than one 
plane).  All of these joints were designed to allow effortless, pain free 
movement. 
According to the National Institute of Arthritis and Musculoskeletal and Skin 
Disease the knee is one of the major weight bearing joints within the body and is 
the most common site of OA. It consists of two bones, the femur and the tibia. 
At the lower end of the femur there are 2 rounded protrusions of bone known as 
condyles.  The inner is known as the medial condyle and the outer is the lateral 
condyle. The condyles of the femur rest on the tibial plateau and aid the 
articulation of the joint. When the leg is in extension, it is the distal sections of 
the femoral condyles that make contact with the tibial plateau, whereas in 
flexion it is the posterior femoral condyles that make contact. The condyles are 
covered in cartilage, a substance made of extracellular matrix (ECM) that 
facilitates articulation of the bones during movement.  Other components of the 
joint, such as the synovial fluid along with the menisci, absorb shock and help to 
facilitate movement- distributing load evenly throughout the joint.   
1.1.2.1 Cartilage 
Articular cartilage is a specialised tissue that covers the surfaces of bones that 
form joints. The main function of the cartilage is to facilitate the movement and 
to distribute load, enabling the joint to withstand extreme biomechanical stress 
on a daily basis.  The cartilage covering bones is commonly 2-4 mm thick and is 
composed of a specific type of cartilage, hyaline cartilage. This tissue is unique 
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in that it has no blood vessels, nerves or lymphatics and has only one cell type 
present, chondrocytes (section 1.1.2.2).  The ECM makes up the majority of the 
cartilage (Section 1.1.2.3), comprising collagens and proteoglycans, along with 
some other molecules such as non-collagenous proteins and glycoproteins.  
1.1.2.2 Chondrocytes 
Chondrocytes are the cellular component of the cartilage and are the only cells 
resident in the tissue. They function to maintain the ECM via secretion of 
anabolic and catabolic factors within their vicinity and account for about 1-2% of 
the cartilage volume (8).  Chondrogenesis is the differentiation of Chondrocytes 
from precursor mesenchymal stem cells (6). Following on from chondrogenesis 
the chondrocytes can either remain in a resting state in the articular cartilage 
where they maintain the ECM or they go through chondrocyte maturation, which 
occurs over several steps and results in new bone formation at the endochondral 
growth plate. Firstly, mesenchymal stem cell differentiate into slowly 
proliferating periarticular chondrocytes and then into fast proliferating, column 
chondrocyte (10) both of which can produce type II collagen. If the cells remain 
in the slowly proliferating state they will be articular chondrocytes. These steps 
are thought to be under the control of the transcription factor Sox5/6/9. From 
here, non articular chondrocytes exit the cell cycle and become hypertrophic 
and begin to produce the less structurally useful type X collagen and matrix 
metalloproteinases (MMPs) which break down the matrix. Vascular endothelial 
growth factor (VEGF) which promotes angiogenesis is also produced at this point. 
Through these factors the hypertrophic chondrocytes help to facilitate the 
formation of new bone before becoming apoptotic (12,13).  Chondrocyte 
apoptosis is essential in endochondral bone formation, as when these cells die, 
osteoblasts (bone forming cells) occupy the space that is left behind and begin 
to lay down new bone(10,14). 
1.1.2.3 The Extracellular Matrix Composition 
The three major components of the ECM  are water, collagen and proteoglycan.  
Water accounts for 80% of the total cartilage wet weight (6). The abundance of 
water from the deep layer to the superficial layer increases from 65% to around 
80% (17).  Water does not move easily though the cartilage and requires either a 
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pressure gradient across the tissue or compression of the matrix to facilitate this 
movement. Through this resistance to water flow and resultant pressure of 
water in the matrix, the articular cartilage is able to resist biomechanical stress 
greater than that of individuals own body weight.  There are 7 collagens known 
to be present in the cartilage, however, it is type II collagen that accounts for 
95% of the ECM collagen. The other collagens (types I, IV, V, VI, IX and XI) make 
up the remaining 5%.  Collagen forms a triple helix structure that provides the 
sheer and tensile properties of this tissue.  Proteoglycans make around 10-15% of 
the wet weight of the cartilage and include the macromolecules, aggrecan, 
decorin, biglycan and fibromodulin.  They are all protein monomers that have 
been heavily glycosylated, with the largest of the group being aggrecan. 
Specifically the proteoglycan aggrecan can be found in the spaces between the 
collagen fibrils and is responsible for the osmotic properties that aid the 
cartilage in withstanding compressive forces (6).  
1.1.2.4 The Extracellular Matrix Structure and Organisation 
The cartilage is composed of 4 zones: the calcified zone directly next to the 
subchondral bone, the deep zone, the middle zone and the superficial tangential 
zone at the surface of the tissue (6). The size and structural arrangement of the 
zones has been shown to be significant in the functional properties of the 
cartilage (8). The superficial tangential zone primarily protects the deeper zones 
from sheer stress and makes up between 10 -20% of the cartilage.  The cells of 
the superficial zone have been shown to produce less collagen and proteoglycans 
than the cells of the middle and deep zones, however, the ECM that they do 
produce tends to be collagen based rather than proteoglycan (8). The superficial 
zone also has the highest concentrations of water and fibronectin, aiding its 
ability to resist sheer and compressive forces. The chondrocytes in this zone are 
flattened and parallel to the articular surface. In this way they are in line with 
the tightly packed collagen fibres that are mainly composed of type II and type 
IX collagen.   
The middle zone is the intermediate between the deep and superficial zones and 
contains higher concentrations of proteoglycans and the collagen fibres are also 
denser. The chondrocytes in this zone are sparse compared to the superficial 
layer and are more spherical in shape.  They also possess a greater capacity to 
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produce ECM macromolecules as they have increased numbers of protein 
processing organelles such as golgi apparatus and endoplasmic reticulum. The 
fibrils produced in this zone are thicker than those of the superficial zone. 
 The deep zone gives the most protection from compressive forces, facilitated by 
arranging the very thick collagen fibrils in a perpendicular manner to the 
articular surface.  This zone has the highest proteoglycan concentration and the 
lowest water concentration aiding its protective properties from compressive 
forces. The chondrocytes remain spherical in shape but begin to form columns. 
An anatomical feature called the tidemark separates the deep zone from the 
calcified zone.  The calcified zone acts to secure the cartilage onto the 
subchondral bone. There are few chondrocytes in this zone and those that are 
present are hypertrophic and aid the formation of new bone.     
In addition to the zonal classification of cartilage, the ECM in each zone can be 
further classified into regions. This is based on the matrix composition, 
organisation, proximity of the matrix to the chondrocytes and diameter of the 
fibrils. These three regions are the pericellular matrix, the territorial matrix and 
the interterritorial matrix.  
The pericellular matrix binds to the chondrocytes and is predominantly made 
from proteoglycans and non-collagenous matrix proteins.  It is thought that this 
matrix may play a role in signal transduction during load bearing episodes (6). 
Chondrocytes can produce other factors that are important in the organisation of 
the pericellular matrix by facilitating extracellular binding of macromolecules to 
the chondrocytes, such as glycoprotein CD44 (19).  It has also been shown that 
CD44 can also act as a receptor for hyaluronic acid which acts as a scaffold 
allowing aggrecan aggregates to form, furthermore its receptor, CD44, is 
involved in anchoring these aggregates to the chondrocytes (20-22).  
The territorial matrix, composed of thin collagen fibrils, surrounds chondrocytes 
and the pericellular matrix .  It has been suggested that the territorial matrix 
provides protection from mechanical forces and may also add to the overall load 
bearing capacity of the cartilage. In the deep zone, where the chondrocytes can 
be found in columns, the territorial matrix surrounds the whole column instead 
of the individual cells.   The interterritorial matrix accounts for the majority of 
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the ECM and is composed of the largest collagen fibrils. In the superficial zone 
the fibrils are arrange parallel to the articular surface whereas the arrangement 
is diagonal in the middle zone and perpendicular to the articular surface in the 
deep zone. 
1.1.2.5 Synovium  
The synovium is a soft tissue that lines the spaces of the diarthrodial joints (23). 
It is made up of 2 sections, the intimal lining layer and a subintima layer (23). In 
health the intimal lining layer is comprised of fibroblast like synoviocytes (FLS)  
and is generally 1-2 cells thick and therefore is regarded as a relatively low 
cellular abundance tissue(23).  The subintima or sublining layer contains mainly 
blood vessels, adipose cells, FLS and macrophages.  The synovium is thought to 
be a main source of chondrocyte nutrition providing essential molecules such as 
glucose (25). A vast proportion of the articular surface lies within 50mm of the 
synovium, thus allowing nutrients from the blood vessel in the synovium to pass 
to the chondrocytes within the matrix via the synovial fluid. With regards to the 
areas of cartilage that are not in close contact with the synovium, movement of 
the fluid caused by articulation of the joint will allow the nutrients to reach 
these areas (23).  The synovial fibroblast appears to be the main source of 
hyaluronan, which further to its role in aggrecan aggregation outlined previously 
(section 1.1.2.2), can also inhibit adhesion of the synovial surface by retaining 
the fluid volume in the joint (28).  
1.1.2.6 Synovial Fluid 
Synovial fluid (SF) is an essential part of the joint, facilitating ‘frictionless’ 
movement of the bones. Human synovial fluid was first analysed by Ropes, 
Rossmeisl and Bauer in 1940. From their study, it was concluded that the 
synovial fluid was a relatively cell-poor, clear/pale yellow and viscous liquid 
(29).  They also reported that the most abundant cell present was the 
mononuclear phagocyte and that albumin and globulin were also present in the 
fluid (29).  Our understanding of synovial fluid composition has become more 
comprehensive over time. It is now evident that most of the same proteins found 
in plasma are present in SF, including glucose and uric acid.  Furthermore, 
additional proteins that are known to help with lubrication of the joint include, 
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proteoglycan and hyaluronic acid (which as previously mentioned can be 
secreted by the synovium) are also found in the S.F (32). In disease the balance 
of the S.F constituents can alter; for example the presence of lactic acid can be 
used to diagnose septic arthritis. Similarly lactate dehydrogenase can be used as 
an indicator of rheumatoid arthritis, gout or infectious arthritis. Rheumatoid 
factor, an antibody to immunoglobulins within the joint, is present in the 
synovial fluid of more than half of the patients diagnosed with RA (33). However, 
currently there are no OA specific alterations in the S.F.   
 OA Disease Classification 1.1.3
There are no current identifiable biomarkers for OA diagnosis or classification.  
Generally symptoms of OA, for example joint stiffness and pain, are commonly 
the first diagnosable signs of disease (34).  However, by this point irreversible 
damage has often already occurred in the joint, as disease onset is likely to 
considerably predate the onset of these symptoms. 
To date there are only two real classifications of OA: primary and secondary. 
Secondary OA, as the name suggests, is a secondary consequence of an initial 
trauma or primary disease leading to OA. Here the aetiology of the disease can 
normally be ascertained, due to a specific event that generally results in 
mechanical distortion of the joint and subsequent erosion. Unlike secondary OA 
the aetiology of primary OA remains elusive. In the hand, primary OA has been 
further subcategorised depending on the joints affected and the damage 
associated: nodal OA, erosive OA and inflammatory erosive OA.  When the 
disease manifests as nodes over the interphalangeal joints of the hand it is 
referred to as nodal OA, however if there is erosion of the interphalangeal joints 
this is termed erosive OA.  Finally erosive inflammatory OA has characteristic 
inflammatory flares and erosion of the joint (36).  Therefore, these 
subcategories encompass a substantial range of disease phenotypes and hence 
provide no insight into how to stratify patients for treatments. Despite these 
subclassifications for hand OA, there is still very limited classification of primary 
OA in the larger joints.   
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 OA Disease Pathogenesis  1.1.4
Osteoarthritis is the most common form of arthritis with disease incidence on 
the rise.  It has long been considered a degenerative disease of the joint 
associated with the elderly and very limited treatment options.  Arthritis 
Research UK states that there are currently 8.75 million people in the UK 
seeking or having sought treatment for OA (38) with over half of these cases 
relating to the knee (38).   Furthermore, as previously stated OA has a 
substantial impact on the UK economy as 2.36 million of these individuals are of 
working age.  This problem is expected to grow as it is estimated that by 2020 
the disease incidence will hit 6.5 million with knee OA alone (38).   
OA is a heterogeneous disease and is now being recognised as a group of 
diseases, all with a common manifestation of symptoms (44,45). Historically, 
due to a lack of knowledge, OA has been considered a non-inflammatory, 
mechanical disorder associated with age, thus giving rise to the ‘wear and tear’ 
theory of disease progression. Over the past decade this has changed and there 
has been considerable effort to better understand and define this disease, 
leading to an acceptance of the role of inflammation in the disease process. 
OA is characterised by joint destruction and remodelling which is a 
manifestation of cartilage degradation, osteophyte formation and bone 
remodelling (47) (Figure 1.1). It is now also recognised that synovitis also plays a 
role in the disease process (48,49)(Figure 1.1). This destruction, remodelling and 
inflammation is thought to develop over many years, with several risk factors 
including, age, obesity, trauma and genetic susceptibility (51) being attributed 
to the etiology of the disease.   
1.1.4.1 Bone remodelling in OA 
 In 1986 Rose and Radin suggested that subchondral bone changes initiate 
cartilage damage (54), thus being one of the first to highlight bone remodelling 
as one of the earliest features of the osteoarthritic joint (55,56). These changes 
were highlighted in the Dunkin-Hartley strain of guinea pig that spontaneously 
develop OA in a fashion that is biochemically, histologically and radiographically 
similar to that of humans (55). These guinea pigs had significant increased bone 
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density and subchondral bone thickness at both 24 and 36 weeks when compared 
to the non-OA control (Bristol strain 2 Guinea pigs).  It was also noted that these 
changes in the bone preceded any changes in the cartilage in the Dunkin-Hartley 
guinea pigs (55). Similar remodelling of the bone has also been noted in human 
studies.  Using macroradiography thickening of the subchondral cortical plate 
and the subadjacent horizontal trabeculae as been observed prior to joint space 
narrowing in the hand (57).     
Osteophytes, another feature of bone remodelling in OA, are fibrocartilage-
capped bony outgrowths. There are three types of osteophyte; two which are 
associated with tendon and ligament insertion sites and a third which is found in 
OA, the osteochondrophye, and is commonly located at the junction between 
the bone and the cartilage(58) . Osteophytes have been identified as being 
chonrdocytic in origin expressing chondrocyte specific transcription factors SOX-
9 and RUNX2 (59).  The development of osteophytes in mice can be seen in as 
little as 7 days post OA inductive surgery (59) and in humans is often seen before 
any radiographic evidence of joint space narrowing (58). Osteophytes can have 
severe clinical impact and can be a primary cause of pain or restricted 
movement, as has been highlighted in a study looking at osteophyte formation at 
the medial tibial condyle in knee OA (60).  It should be noted that for some 
individuals the presence of osteophytes does not cause pain or impingement of 
the joint (58) and for others they have been reported to improve symptoms by 
increasing the surface area of the articulating joint and spreading the load 
through the joint more evenly (58).   
1.1.4.2 Cartilage degradation in OA 
During the disease process chondrocytes attempt to repair damaged cartilage 
(caused by an initial insult or stimuli in the case of secondary OA) by up-
regulating anabolic processes that will increase ECM synthesis. However, the 
cells will also begin to form clusters and differentiate into hypertrophic 
chondrocytes due to the damage.  The hypertrophic cells can produce MMP-13 
consequently adding to the destruction of the cartilage and further stimulating 
catabolic responses from the chondrocytes. At this point, the cartilage can 
become fully disrupted and the chondrocytes become apoptotic (53). 
Degradation of the cartilage can occur not only via the up-regulation of matrix 
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degrading enzymes such as MMPs, but also A Disintegrin and Metalloproteinase 
with Thrombospondin Motifs (ADAMTS). These mediators are able to breakdown 
matrix macromolecules, enabling turnover of the ECM, which in a homeostatic 
environment is of great importance. In disease, however, this is not the case: 
the matrix is not replenished at the same rate it is being broken down and this 
ultimately leads to the ECM structure becoming weak and disorganized, aiding 
erosion. Fragments of the cartilage may also be lost into the synovial fluid of the 
joint where they may activate immune cells, causing an unwanted inflammatory 
reaction that can perpetuate disease (62) (1.1.7).  MMPs have been shown to be 
a major contributor to cartilage erosion.  MMP-3 knock out (KO) mice are 
protected from cartilage damage in murine models of OA and are also less likely 
to develop severe spontaneous OA in old age, however, it is also acknowledged 
that other MMPs are also important in disease development (35). MMP-13 has 
been highlighted as a potent degenerative enzyme in the disease process, with 
co-localisation of both MMP-13 and disease associated type I collagen in OA 
tissue (65). Piecha et al have shown that selective MMP-13 inhibition can prevent 
collagen degradation by up to 80% in human cartilage explants (67). Furthermore 
MMP-13 appears to be directly up-regulated via IL-1β, a prominent pro-
inflammatory cytokine found in OA (1).      
 
 
 
  
 
  28 
 
 
Figure 1.1 General Joint Changes Observed in OA. 
Comparison of healthy and OA joint highlighting the anatomical changes in OA pathology that 
contribute to symptomatic disease;  cartilage degradation, bone erosion, synovitis and osteophyte 
formation.  
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 Pain in OA 1.1.5
Pain is one of the primary symptoms that result in disability in OA, yet there is 
commonly little correlation between the severity of joint pain experienced and 
the radiographic evidence of structural damage (4,39). Generally pain is 
regarded as beneficial, as when we sense pain the action that is responsible for 
this can be terminated.  However, if a more dramatic injury or chronic 
inflammation occurs, then this will not only produce pain through the local 
stimulation of the nociceptors but also peripheral stimulation outwith the 
affected area.  The peripheral stimulation can result in innocuous stimuli such as 
walking or standing resulting in pain, as is seen in OA. A release of inflammatory 
mediators is associated with more extensive damage that may account for the 
peripheral sensitisation and may also help to explain why pain does not always 
remain localised in those suffering from OA (4).  Pain studies suggest that the 
source of pain can be of synovial and/or bone origin (4), as even though 
cartilage erosion is one of the key characteristics of OA, the cartilage is not 
innervated and is therefore not likely to be a source of pain.  
Nerve growth factor (NGF) is a protein that has been associated with increased 
pain in OA. It has been found that those with OA have increased expression of 
NGF in the synovial fibroblasts and to a lesser extent the synovial macrophages 
(6). Additionally, chondrocytes have also been shown to up-regulate NGF upon 
stimulation with the prominent OA cytokine IL-1β and upon mechanical stress 
(9). NGF has been implicated in the sensitisation of peripheral neurons in a 
disease setting, thus lowering the pain threshold in those with OA (11). A proof-
of-concept clinical trial has been conducted showing that by blocking NGF with a 
monoclonal antibody, Tanezumab, patients reported a significant reduction in 
pain when walking compared to the placebo (14). Therefore, it would appear 
that NGF is highly associated with disease and may play a prominent role in the 
pain sensation associated with OA.  
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Cytokines have also been implicated in pain, with specific focus on TNFα as a 
driver of peripheral pain within the joint. A positive correlation between 
synovial TNFα and the western Ontario and McMaster Universities Arthritis Index 
(WOMAC) pain measurement has been established (15). Circulating c-reactive 
protein and IL-6 in the blood have also been associated with worsening of knee 
pain over 5 years thus again highlight the potential contribution both growth 
factors and cytokines can have in the perpetuation of pain in OA (16).     
It is now also believed that central pain, through the spinal cord and brain, may 
be playing a role in OA(11). It has been shown that elevated central pain can be 
reversed following total knee replacement (TKR). Data demonstrated that 
patients with OA were shown to have reduced pain thresholds when compared to 
a control group.  However, following joint replacement, the pain threshold was 
returned to normal(18), thus suggesting that central pain is dependent on the 
presence of a peripheral stimuli in those with OA (18,77). 
 OA Comparison with Other Forms of Arthritis 1.1.6
Joint destruction is not an OA specific phenomenon and is key in the 
development and pathogenesis of many diseases such as rheumatoid arthritis 
(RA), ankylosing spondylitis (AS), systemic Lupus Erythematosus (SLE) and 
psoriatic arthritis.  OA has commonly been used as a control disease to RA and 
other joint related autoimmune diseases, as it was considered to be non-
inflammatory. Recent advances however, now suggest that this is not the case 
and that inflammation is involved in OA pathogenesis too. To this end, the way 
in which the comparison is interpreted must change, as the inflammatory 
phenotype in OA can no longer be ignored.  
 Inflammation in OA 1.1.7
Our understanding of the immune system and dysregulation in autoimmune 
disease is a currently expanding area, with the role of immune mediators in OA 
now being a more prominent focus of this field.  In 1990 a study was carried out 
to determine if the inflammation was associated with early or moderate OA.  
Using biopsies from individuals with arthroscopic evidence of OA it was 
determined that 55% of those presented had synovitis, suggesting there may be 
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an inflammatory component driving OA in a subset of patients (79). The cause of 
OA associated inflammation remains elusive, however, some theories as to the 
initiation of this response have been put forward.  The most accepted hypothesis 
has been summarised in a review by Berenbaum in 2013.  Here it is suggested 
that cartilage fragments (created through either trauma or age related joint 
erosion) become dislodged and are detected as danger associated molecular 
patterns (DAMPs) by the synovial cells through Toll Like Receptors (TLRs). The 
immune system then recognises these fragments as danger signals which results 
in the initiation of an immune response (80) and ultimately inflammation. This 
inflammation leads to vasodilation and permeabilisation of blood vessels 
facilitating increased blood flow to the necessary area, increased immune cell 
infiltration and migration of monocytes and granulocytes (83). 
Cytokines produced by cells at the site of injury (and also by recruited members 
of the immune system) normally function to initiate, maintain and terminate the 
immune response.  They are secreted in a highly controlled manner in order to 
ensure that immunity is carried out in a regulated fashion. Current dogma 
suggests that a major aspect of cartilage destruction in OA is associated with an 
imbalance of catabolic and anabolic cytokines produced by chondrocytes (Table 
1.1).  Of these cytokines associated with OA, IL-1β is one of the most studied.  
IL-1β is produced as an inactive protein and is cleaved to its active form by the 
interleukin-1 converting enzyme, caspase-1 (85). Upon stimulation with IL-1β in 
vitro, chondrocytes have been shown to switch from normal ECM collagen 
production (type II) to the production of type I and type III collagen. This 
promotes the production of inferior pseudo-cartilage that is ineffective at 
withstanding load and movement (24,26). The IL-1β mediated dampening of type 
II collagen production is thought to be facilitated by repression of the 
transcription factor SOX9, which has been shown to be involved in cell-specific 
production of type II collagen (27).  Thus, IL-1β does not only positively regulate 
catabolic factors, but also negatively regulates anabolic factors. Interestingly, 
chondrocytes that are clustered due to stress are more likely to express IL-1, 
cleavage enzyme caspase-1 and the IL-1 receptor (IL-1R).  Additionally these 
cells have been reported to produce concentrations of IL-1β capable of inducing 
MMP expression aiding degradation (1). 
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IL-1β and TNFα have been implicated in the recruitment of other pro-
inflammatory cells and extending the inflammatory damage in OA. They have 
been shown to induce both nitric oxide (NO) and prostaglandin E2 as well as IL-6 
and IL-8 (1).  TNFα expression in chondrocytes is increased immediately after 
impact, thus may be involved in the initial inflammatory insult in the joint in 
secondary OA resulting from trauma (30). The role of these cytokines in OA 
pathogenesis is further supported by the neutralisation of both TNFα and IL-1β 
inhibiting the induction of other pro- inflammatory mediators from fibroblasts 
(31).    
The synovial macrophage is considered to play a prominent role in the 
perpetuation of inflammation in OA (31).  It has more recently been suggested 
that macrophages contribute to the increased level of IL-1β and TNFα that can 
subsequently stimulate the production of other pro-inflammatory cytokines and 
MMPs from synovial fibroblasts (31). If the CD14+ macrophages of the synovium 
are depleted, then fibroblast production of OA associated cytokines (i.e. IL-1, 
TNFα, IL-6 and IL-8) and monocyte chemoattractant protein 1 (MCP-1) along with 
MMP-1 and 3 are reduced. Further studies also report that synovial lining 
macrophages not only induce MMP-1 and MMP-3, but also MMP-2 and MMP-9. 
Moreover, the expression of these MMPs was down-regulated in a mouse model 
of OA when the synovial lining macrophages were depleted (35).  Further to the 
macrophages role in perpetuating degradation and inflammatory mediators, they 
have also been shown to have an impact on osteophyte formation in OA. Studies 
have shown that if synovial lining macrophages are depleted, osteophyte size is 
decreased by 84% (37).  
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Anabolic Catabolic Anti-catabolic 
IGF-1 IL-1β IL-4 
TGFβ 1,3 TNFα IL-10 
FGF 2,18 IL-8 IL-11 
BMP 2, 7 IL-18 IL-13 
PDGF IL-6 1L-1ra 
 NO  
   
Reference (39-42) 
Table 1.1 Overview of Anabolic, Catabolic and Anti-Catabolic factors that are Prominent in 
OA. 
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 Angiogenesis in OA 1.1.8
Angiogenesis, the formation of new capillary blood vessels from the already 
established vascular network, is known to be essential for several processes in 
the body such as growth, development and tissue repair. The articular cartilage 
is not vascularised and is therefore a hypoxic tissue. This is most likely due to 
the biomechanical stress which does not make the joint the ideal location for 
capillary vessels (43). In a diseased environment such as an OA joint, this has 
been shown to change (43) with an increase in vascular networks contributing to 
and exacerbating the disease process.  The contribution of angiogenesis to the 
disease process has also been noted in other disease states such as cancer, 
facilitating tumour growth via promotion of proliferation, and chronic 
inflammation, providing an entry route for increased numbers of cells to 
infiltrate the affected area - perpetuating the inflammatory process (46) . 
There are several sites in the joint that appear to be subject to increased 
angiogenic activity: the synovium, osteochondral junction, articular cartilage 
and menisci (43).  With regards to the synovium, the extent of angiogenesis has 
been reported to be comparable to that seen in RA (50) and positively correlates 
with infiltration of macrophages (52) .  Macrophages are known to contribute to 
angiogenesis through the production of the angiogenic factor, vascular 
endothelial growth factor (VEGF), which promotes angiogenic activity in other 
cells such as fibroblasts and endothelial cells. Under normal physiological 
condition, chondrocytes have been shown to produce antiangiogenic factors 
(61), however, it is  thought that OA associated inflammation may promote the 
expression of VEGF from the chondrocytes and hence angiogenesis. It has been 
shown that the vascularisation of the articular cartilage is associated with a loss 
of proteoglycans and a shift in collagen production towards the structurally 
inferior type I and X collagen (43,63). This phenotypic change in collagen and 
loss of aggrecan can disrupt and weaken the ECM, leaving the cartilage more 
permeable to neovascularisation (64).  
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 Risk Factors in OA development 1.1.9
1.1.9.1 Mechanical Loading  
OA has long been regarded as a mechanical disease that occurs due to wear and 
tear overtime and is therefore considered an inevitable process of ageing. The 
mechanical theory of OA aetiology relates to the disease being driven by 
movement and physical force on the joint. Mechanical stress is essential for 
homeostatic matrix turnover in the articular cartilage.  Studies carried out in 
1986 by Slowman and Brandt show that proteoglycan content is higher in areas 
that have been exposed to normal mechanical load compared to areas that are 
completely unloaded (66). However, mechanical injury has been shown to 
decrease the biosynthetic capacity and viability of the chondrocytes (39). It is 
not only the cells surrounding the area affected by the mechanical stress, as 
nitric oxide (NO) released from the damaged cells has been shown to cause 
apoptosis in cells distant from this area (39). Due to chondrocytes being sparsely 
scattered throughout the cartilage, a decrease in the biosynthetic ability or 
survival of these cells could have a profound effect on the ECM in their 
immediate vicinity. Furthermore increased expression of MMP-1, MMP-3, MMP-8, 
MMP-9 and MMP-13 have been observed in the remaining viable chondrocytes 
after impact, which together with a loss of anabolic capabilities could aid in the 
breakdown of local cartilage.  
Secondary OA associated with sporting injuries is generally connected with 
prolonged mechanical stress.  It has been suggested that injury to the knee, 
either to the anterior cruciate ligament or meniscus, in those under thirty, does 
not result in radiographic signs of OA for at least 15 years post injury. However, 
in those over thirty this can lead to radiographic signs of OA within 5 years of 
injury (68). This suggests that age related changes may contribute to OA 
progression in secondary OA. Furthermore the number of injured sites in the 
joint can also play a significant role in the development of OA. If an isolated 
injury is incurred in the anterior cruciate ligament then the prevalence of OA is 
between 0-13%.  However, if the injury occurs at both the anterior cruciate 
ligament and the meniscus then the prevalence dramatically increases to 
between 21 -48% (69).   
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1.1.9.2 Obesity 
Obesity is also thought to contribute to disease development. As weight 
increases, the load that runs through both the hip and knee also increases, 
resulting in an unmanageable load and ultimately erosion of the joint. In this 
way obesity has been strongly linked to OA.  Studies have been conducted 
demonstrating that weight is the most modifiable factor that contributes to the 
development of OA, with weight loss correlating with a reduction in cartilage 
volume loss (70). A total body weight loss of 1kg  has been calculated to result in 
a decrease of 2.2kg load through the knee (72). Therefore, there is clear 
evidence that weight gain can contribute to mechanical load and that weight 
loss may be an effective means of preventing further disease progression (73). 
However, it should be noted that others have suggested that modulations in 
weight, i.e normal Body Mass Index (BMI), to high BMI back to normal BMI, may 
be more detrimental than a constant high BMI.  It has been suggested that the 
joint may adapt to cope with the increased load and that changes to this may 
cause more harm and increase the need for arthroplasty later in life (71).  
Obesity does not only increase the load that is exerted on the joint, but may 
also contribute to disease at the molecular level by altering adipokines; 
metabolic factors produce by fat tissue (74). The infrapatellar fat pad (IPFP) in 
the joint capsule of the knee could contribute to the dysregulated secretion of 
adipokines in OA specifically related to the knee (75). It has been suggested that 
the IPFP may be a more potent source of adipokines than subcutaneous adipose 
tissue.  When compared directly it has been shown that the IPFP from obese 
women suffering from OA produce more of the adipokine, adiponectin, when 
compared to the subcuanteous fat control. Additionally, another adipokine, 
leptin has been associated with cartilage destruction. Data shows that leptin can 
up-regulate  MMP1 and MMP-13 and furthermore, that this up-regulation can be 
partially inhibited using an anti-leptin antibody (76). Thus taken together this 
highlights a role for the IPFP in contributing to inflammation and joint 
destruction OA patients (108).    
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1.1.9.3 Age Related Alterations 
 OA has been classically defined as a disease of the elderly as symptoms tend to 
manifest in those over 50 years of age.  It has been found that OA related 
molecular factors may be slightly decreased in aged cartilage, however when 
age matched OA cartilage is examined these factors are dramatically reduced 
(78).  Suggesting that the extreme symptoms observed in OA cannot be 
attributed solely to the natural process of aging, even though it is likely to be a 
predisposing factor that contributes to disease aetiology.  
 Loeser reviewed the age related changes that may contribute to the 
development of OA in 2012 (80). It is suggested that a decrease in general 
physical activity that could lead to sarcopenia (loss of skeletal muscle and 
strength) and increased fat mass.  This may then result in muscle weakness, 
increased joint loading and an increase in adipokine expression from the fat 
cells, all of which have been linked to OA. An increase in pro-inflammatory 
mediator secretion is also described, which may contribute to the catabolic 
destruction of the joint.  Furthermore an age related decrease in growth 
hormones and sex steroids has been linked to a decrease in anabolic factors 
within the joint. A study was carried out in the Netherlands looking at 
determinants in OA disease onset in a cohort of individuals over 90 years of age. 
It was shown that 16% of the participants were free from OA; attributes such as 
being male, having a normal BMI and an absence of familial predisposition for OA 
were associated with disease prevention in the aged cohort (82). 
 Importantly, this disease is now being regarded as a multifactorial disease with 
many contributing factors such as injury, age, obesity, genetics and 
inflammation. Therefore, as alluded to, there are several age related changes 
that may contribute to OA, however, they alone could not be solely responsible 
for pathological change. 
 Clinical assessment of OA 1.1.10
Assessment of OA is not easy as there are no biomarkers or tests available for 
diagnosis. Orthopaedic specialists have to rely on patient questionnaires, along 
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with x-ray and MRI scoring for diagnosis and assessment of disease. A range of 
these questionnaires and scoring systems are detailed below.  
1.1.10.1 WOMAC  
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
score is an assessment of the patients perceived pain, stiffness and physical 
function. In accordance with the American college of rheumatology (ACR) this 
questionnaire is comprised of 24 questions which the patients are asked to 
respond to with the following answers: none, mild, severe or extreme. The first 
5 questions refer to pain, asking the individual to rate their pain when walking, 
using stairs, in bed, sitting and standing. Stiffness is then assessed when the 
patient first wakes and then later on in the day. Finally, 17 questions regarding 
physical function are addressed.  The answers can then be culminated in an 
overall score to assess disease severity.  One of the major draw backs of this 
survey is the reliance of the patient to answer the questions, therefore 
circumstances at the time of questionnaire completion may have an affect on 
the answers given.  
1.1.10.2 Kellgren-Lawrence score 
The Kellgren-Lawrence scoring system for diagnosis of OA from radiographic 
images was first proposed by Kellgren in 1957. This is a non invasive system of 
determining joint damage in patients with OA and is therefore the most 
informative tool in the diagnosis and assessment of OA. The modified scoring 
system is again measured on a 5 point scale (84,86): 
Grade 0: No radiographic signs of OA.  
Grade 1: Doubtful narrowing of joint space and possible osteophytic 
lipping. 
Grade 2: Definite osteophytes and possible narrowing of joint space.  
 Grade 3: Moderate multiple osteophytes, definite narrowing of joint space 
and some sclerosis and possible deformity of bone ends. 
Grade 4: Large osteophytes, marked narrowing of joint space, severe 
sclerosis and definite deformity of bone ends. 
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1.1.10.3 Outerbridge Classification 
The Outerbridge classification, used to assess cartilage breakdown, was first 
described by Outerbridge in 1961(87).  This analysis of disease progression can 
only occur if the cartilage surface is exposed during surgery and therefore is not 
a useful clinical tool for disease assessment. However, it can be very informative 
for the ex vivo assessment of tissue obtained during surgery.  This modified 
Outerbridge classification consists of a 5 point grading system (87-89); 
Grade 0: Normal cartilage.  
Grade I: Cartilage with softening and swelling. 
Grade II: A partial-thickness defect with fissures on the surface that do not 
reach subchondral bone or exceed 1.5 cm in diameter 
 Grade III: Fissuring to the level of subchondral bone in an area with a 
diameter more than 1.5 cm  
Grade IV: Exposed subchondral bone.  
 Treatment of OA  1.1.11
1.1.11.1 Analgesics 
Analgesics / painkillers are currently the first line therapy for those suffering 
from OA, as pain is one of the most common symptoms of the disease. The 
National Institute of Health and Care Excellence (NICE) guidelines for OA state 
that OA related pain should initially be treated with over the counter analgesics 
such as paracetamol.  If this is not sufficient to relieve pain, then it is suggested 
non steroidal anti-inflammatories such as ibuprofen, or selective COX2 inhibitors 
such as celecobix, should be given.  If pain worsens (or is still not controlled 
with these measures) then drugs from the opioid family can be given. Generally, 
starting with co-codamol (paracetamol/codeine) and increasing to more potent 
formulations (i.e morphine) if the pain is deemed severe enough.  These are 
currently the only form of medication that are prescribed for OA and can only 
abate symptoms for a short period of time.  They are unable to halt or reverse 
the underlying structural damage causing pain in OA.  
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1.1.11.2 Exercise 
The American College of Rheumatology (ACR), along with the European league 
Against Rheumatism (EULAR), also suggest that exercise should be prescribed in 
order to combat OA progression. Exercising the surrounding muscles is known to 
provide support to the damaged joint (90) and is also undeniably associated with 
weight loss. Therefore with the strong link between obesity and OA, exercise 
may in turn help to alleviate some of the load through the joint (91,92).  
Exercise prescriptions have however come under scrutiny in the past as they are 
often vague, leaving the patient unsure of the levels of activity they should 
engage in (93).  
1.1.11.3 Surgery 
When symptoms become severe and an individual’s quality of life is significantly 
affected the physicians may then consider joint replacement surgery.  This 
involves complete removal of the joint (including both eroded and non-eroded 
sections) and replacing it with a metal/plastic prosthesis. In the majority of 
cases this restores quality of life and greatly reduces pain.  The prosthesis has a 
finite life span and generally has to be replaced after 15 -20 years.  The 
prosthetic joint can only be revised a limited number of times, thus the total 
therapeutic duration for joint replacements is limited.  For this reason, delaying 
the need for arthroplasty as long as possible is essential.  Other drawbacks to 
the procedure include the risk of infection from the surgery and the potential 
that the prosthesis will not improve the symptoms of disease. Studies have 
shown that 10-20% of patients undergoing total knee joint replacement surgery 
(TKR) will be dissatisfied with the results of their surgery (94). 
1.1.11.4 Stem Cell Therapy 
Mesenchymal stem cells (MSC) are a potential new therapy for OA. MSCs were 
first described as a potential reparative mechanism in OA by Murphy et al in 
2003 (95). The study used a combined anterior cruciate ligament transection 
(ACLT) and medial meniscectomy in goats to mimic OA. MSCs were injected into 
the intra-articular space and left for 20 weeks before the animals were 
sacrificed and analysed.  The results were encouraging, showing regeneration of 
the meniscus and a reduction in OA related cartilage and bone changes (95). This 
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study has lead to further work being carried out with regards to the therapeutic 
potential of these cells in OA.  As of June 2014 there have been 5 other studies 
looking at the effect of MSC therapy in an osteoarthritic setting.  These studies 
have looked at a variety of species including porcine, rabbit and guinea pig using 
a variety of approaches to investigate disease; partial thickness cartilage defect, 
osteochondral defect, spontaneous OA and ACLT models. All of the studies that 
have been conducted using animal models of disease have reported positive 
outcomes and support the use of MSCs as a potential therapy for OA (96). 
Following on from the success of MSCs in animal models there have been several 
clinical trials, all of which have reported significantly improved outcomes for 
patients. The injections of the cells appeared to improve a variety of symptoms 
including pain, range of movement and walking time, along with reported 
cartilage and meniscus growth in some trials (110).    
An alternative way of potentially utilising MSCs comes from the procedure known  
as micro-fracture. This technique, where small holes are made in the damaged 
area, releasing bone marrow (potentially containing MSCs) into the eroded area, 
is currently being used in order to slow down cartilage damage.  The bone 
marrow released clots and creates a plug in the affected area.  New cartilage is 
thought to be synthesised from the bone marrow cells (MSCs) however, the 
resulting new cartilage is the less resilient fibrocartilage instead of the normal 
hyaline cartilage. Thus, this pseudo cartilage is likely to erode faster, meaning 
that surgical intervention is almost inevitable. This therapy however may buy 
time, which maybe extremely beneficial for younger individuals who are 
unsuitable for joint replacement surgery because of their age.  
1.1.11.5 Anabolic Agents 
Anabolic therapies are urgently required for the treatment of OA as these offer a 
modality that will not just deal with the symptoms of OA, but will help to 
combat the underlying disease pathology or at least delay the degradation of the 
joint.  
Hyaluronic acid (HA) is an anabolic agent that has been recommended by both 
EULAR (97) and ACR (98) for the treatment of OA under certain circumstances. It 
is thought that the therapeutic benefits of HA are down to several mechanisms 
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including increased proteoglycan synthesis and decreased protease expression, 
hence helping to maintain the cartilage integrity.  HA has also been shown to 
reduce pro-inflammatory mediators and have an effect on immune cells, thus 
reducing overall inflammation.  However, there is controversy over it’s 
effectiveness as a treatment, with concerns over both efficacy and safety profile 
(99). 
Growth factors are also being investigated as potential treatments for OA, such 
as TGFβ, BMP-7, platelet derived growth factor (PDGF), Insulin-like growth 
factor-1 (IGF-1), and fibroblast growth factor 18 (FGF-18) (99).  To date most 
studies have focused on the therapeutic potential of BMP-7 (section 1.2.1) and 
FGF-18.  It was found that FGF-18 could promote repair in damaged 
chondrocytes (100).  Additionally, results from a randomised, double blind, 
placebo-controlled trial revealed that FGF-18 was able to reduce cartilage loss 
and prevent joint space narrowing, thus meeting the secondary end points of the 
trial. There were also no local or systemic safety concerns raised from the study, 
therefore it shows promise as a potential treatment for OA (101).   
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1.2 Bone Morphogenetic Protein -7 
Marshall Urist was the first person to discover BMPs within the bone in 1965. 
Urist elegantly demonstrated that extracts from the matrix of the bone 
contained mediators that were capable of inducing ectopic bone formation in 
soft tissues of rabbit and rats (102).  Later, it was more specifically discovered 
that BMP-7 played a role in bone development via the differentiation of bone 
forming osteoblasts from stem cells (143,152).      
The names given to this protein, bone morphogenetic protein and osteogenic 
protein, are derived from where it was first discovered and therefore do not 
fully encompass the vast range of functions this protein is now known to have. 
With BMP-7 being shown to be critical in the growth, development, maintenance 
and repair of other organs, tissues and cells including: Kidney, eye, cartilage, 
vasculature, adipose tissue and stem cells (115). 
 Bone Morphogenetic Proteins 1.2.1
The transforming growth factor-β(TGFβ) superfamily are a large family of 
structurally related regulatory proteins. The superfamily can be subdivided into 
four groups: the decapentaplegic-Vg-related subfamily (including Bone 
Morphogenetic Proteins (BMPs) and growth differentiation factor (GDFs), the 
activin/inhibin subfamily, the TGFβsubfamily and the divergent member 
subfamily.  All of the ligands form either a homodimer or a heterodimer 
complex, initiating signalling via activation of heterodimeric receptor complex 
containing serine threonine kinase regions, which can recruit Smad proteins 
within the cell.  BMPs are a subset of the TGFβ superfamily and as previously 
stated were first discovered by Marshall Urist in the 1960’s. The BMP subfamily 
also includes the growth differentiation factors (GDFs) due to their structural 
similarity. With this taken into account, 22 BMPs have been identified; however, 
of these 22 only 21 belong to the TGFβ superfamily, BMP-1 is classified as a 
metalloprotease. An extensive list of BMP family members can be found in Table 
1.2 (excluding the GDFs), together with an overview of their function. 
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BMP Function Ref. 
BMP-2 (BMP-2α) • Induction of cartilage and bone  
formation and osteoblast differentiation.  
• Heart formation 
(117)  
(119) 
BMP-3 (Osteogenin) • Antagonist of osteogenic BMPs in 
skeletal development  
(119,) 
BMP-3b (GDF-10) • Involved in adipocyte differentiation. 
• Inhibition of osteoblast differentiation.  
(106,107) 
 
BMP-4 (BMP-2b) • Embryonic formation of limbs, teeth 
and bones. 
 
(117) 
BMP-5 • Role in cartilage development (117) 
BMP-6 (Vrg-1) • Developed joint homeostasis. 
• Nervous system development 
(117, 119)  
 
BMP-7 (OP-1) • Involved in kidney development and 
homeostasis. 
• Involved in cartilage repair and 
homeostasis 
• Role in osteoblast differentiation.  
• Eye formation 
(117, 119) 
 
 
 
BMP-8 (BMP-8a/OP-2) • Involved in bone and cartilage 
homeostasis.  
(117) 
BMP-8b (OP-3) • Spermatogenesis (119) 
BMP-9 (GDF-2) • Promotes MSC differentiation into 
chondrocytes 
(117) 
BMP-10 • Involved in embryonic heart 
development. 
(117) 
BMP-11 (GDF-11) • Embryonic development (119) 
BMP-12 (GDF-7/CDMP-3) • Tendon and ligament development (119) 
BMP-13 (GDF-6/CDMP-2) 
BMP-14 (GDF-5/CDMP-1) 
• Joint and bone formation 
 
• Skeletal repair and regeneration 
(119) 
  (119) 
BMP-1 • Thought to play a role in early 
embryogenesis.  
  (117) 
Table 1.2 Overview of the BMP signalling family members and their functions  
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 BMPs have analogues found in invertebrates, such as the decapentaplegic (Dpp) 
and 60A/Glassbottom boat (Gbb) found in Drosophila. These are of interest as 
Dpp has been shown to be structurally similar to BMP-2 and BMP-4 and with Gbb 
being similar to BMP-6 and BMP-7 (103). It has been reported that BMP-2 and Dpp 
have 75% sequence identity and BMP-7 and Gbb have 70% sequence identity 
(104).  Given these similarities, it is not completely surprising that Dpp and Gbb 
can induce bone and cartilage formation in mammals (104). BMPs can exert one 
of three actions upon secretion from the cell.  They can act locally at the site of 
secretion, they can be bound and sequestered by antagonists or they can bind 
ECM components to enhance BMP mediated effects (105). 
1.2.1.1 Structure 
There is strong homology between the members of the TGFβ /BMP signalling 
family.  This homology can be attributed to a variety of common features that 
are shared by this family of proteins. These features facilitate processes such as 
secretion, folding and stability of the protein as well as ensuring effective 
signalling. BMP proteins are first expressed as large precursor molecules that 
contain 3 distinct sites: a single peptide domain, a pro-domain and a mature 
peptide domain (Figure 1.3).  The precursor peptide needs to be cleaved at RXXR 
sites by a cleavage enzyme before the protein is in a mature and active 
conformation; a dimer composed of 2 disulphide linked monomer units. 
Following the first enzymatic cleavage the complex is regarded as unstable and a 
likely target for degradation and only upon the second cleavage and release of 
the mature motif is the protein regarded as  stable (109). After the cleavage of 
the single peptide domain, the rest of the peptide undergoes glycosylation and 
dimerization (Figure 1.2), either as a homodimer with the same BMP or a 
heterodimer with another BMP. A second processing event then occurs where the 
pro-domain is cleaved releasing the active mature peptide (109,117). The pro-
protein convertase furin  (also known as paired basic amino acid cleaving 
enzyme – PACE) has been shown to cleave the pro-domain of the protein (111).  
It has also become apparent (in the context of BMP-4) that the cleavage of the 
pro-domain is essential for the mature peptide to be able to leave the 
endoplasmic reticulum. The pro-domain of BMP-7 may act in a similar fashion as, 
after the pro-domain is cleaved it facilitates BMP-7 solubilization by shielding 
the exposed hydrophobic regions on the surface of the protein (112).  
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Figure 1.2 Structure, Post-Translational Modifications and Cleavage Sites for BMP-7.  
The structure of BMP-7 along with post transcriptional modifications along with the amino acid 
sequence for the BMP-7 pre, pro and mature, (106).  1) Amino acid terminal sequences; facilitates 
excretion of the protein from the endoplasmic reticulum. The amino acid sequence for this portion 
of the protein has been shown in purple. Both the red line and the P on the amino acid sequence 
highlight the cleavage site for the removal of this section. 2) Pro-domain latency- associated 
peptide; allows appropriate folding, increases solubility and helps to facilitate quaternary 
interactions.  This domain shown in blue and is cleaved from the mature peptide, highlighted gain 
by the red line on the diagram and in the amino acid sequence at SIRS.  3) Mature signalling 
peptide; Mediates the effector functions of BMP-7, shown in the amino acid sequence in orange. 4) 
Glycosylation sites (pink triangles); four are present on the BMP-7 protein and are thought to be 
used for correct folding, protein-protein interactions and secretion of the peptide after sorting in the 
Golgi.  5) Intra-peptide disulphide bonds; six conserved cysteine residues (CyS) essential in the 
formation of the  cysteine knot tertiary structure involved in the stabilisation of BMP-7. 6)  Inter-
chain disulphide bonds; facilitate homodimer and heterodimer formation.  The full-length protein is 
first cleaved at the end of the amino acid terminal, a second cleavage then takes places releasing 
the mature protein from the pro-domain.  
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Further studies on the structure and processing of BMP-7 by Gregory et al, have 
shown that after the second cleavage the pro-peptide remains non-covalently 
associated with the mature protein, which is considered to facilitate binding to 
fibrillin.  This is similar to TGFβ1, where latency is conferred via β1 latency 
associated peptide remaining non-covalently associated to the mature peptide 
after cleavage (112). This non-covalent association also allows interaction with 
latent TGFβ binding protein 1, which facilitates secretion of the protein into the 
matrix. The mature BMP protein also contains seven cysteines (Figure 1.2), six of 
which are involved in the formation of a cysteine knot in the protein, whilst the 
seventh is used as a dimerization point with another BMP monomer (117).  
1.2.1.2 Signalling Cascade 
BMPs signal through a type I and type II serine threonine kinase receptor 
complex.  Three type I BMP receptors have been identified: Activin-like Kinase 2 
(ALK2), ALK3 and ALK6 (BMPR1B).  All of the receptors have been shown to bind 
BMPs, with BMP-2 and BMP-4 preferentially binding ALK3 and ALK6, whereas 
BMP-7 preferentially binds ALK2 and ALK6.   The type II receptors, bone 
morphogenetic protein receptor II (BMPRII), activin receptor II (ActRII) and 
activin receptor IIb (ActRIIb) all recognise BMPs (113).    
BMP signalling has been depicted (Figure 1.3) highlighting that BMP binding to 
the type II receptor, which is constitutively active, causes recruitment and 
phosphorylation of the type I receptor.  The activation of the type I receptor 
results in the phosphorylation and release of receptor regulated Smads (R-
Smads), which are then free to form a complex with Smad4. This complex then 
translocates to the nucleus to modulate gene transcription via specific 
regulatory elements (105).  This is considered the canonical signalling pathway 
(Figure 1.3). Smads can be divided into two categories based on R-Smad 
activation. Ligands binding to activin/nodal/TGFβ type I receptors recruit Smads 
2 and 3, whereas BMP type I receptor binding is associated with Smads 1/5/8 
(114).  Receptor binding can also result in the activation of a Smad independent 
non-canonical pathway (Figure 1.3), which induces the mitogen activated 
protein kinase (MAPK) pathway (116).  
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Figure 1.3 BMP Canonical SMAD Signalling and Non Canonical SMAD Independent 
Signalling.   
Canonical signalling (136) : BMP-7 binds to the Type II BMP receptors which is constitutively 
active. The type I receptor is then phosphorylated and intracellular mediators SMAD1/5 and 8 
move to the activated type I receptor where they are also phosphorylated.  From here they join with 
common SMAD4 and translocate to the nucleus modulating gene transcription. Non- Canonical 
signalling (136): The activated receptors in this case activate the MAPK signalling cascade, this 
can ultimately lead to the activation of chondrocyte associated transcription factor RUNX2 via the 
specific activation of TAK1, MKK3/6 and P38K.   
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Following receptor phosphorylation after ligand binding, TAK1 and MKK3/6 are 
activated, these then phosphorylate p38α/β, which in turn activate the runt 
related transcription factor RUNX2 (116).  
There is promiscuity in the ligand receptor interactions in the BMP signalling 
family, with more than one BMP  being capable of binding each receptor.  This 
would suggest that ligand binding to a receptor might not be the only signal 
necessary to initiate a specific response from the cascade.  It has been 
suggested that the R-Smads that partners with the type I receptor may confer 
specificity.  There is data to support this hypothesis which relies on only one R-
Smad pathway being regulated by each receptor ligand interaction (105,135).  
1.2.1.3 BMP Regulation 
 
Interaction between BMPs and their inhibitors is essential for embryonic 
development and the appropriate signalling that is required for cellular 
processes in which BMPs are involved (118). 
There are several groups of endogenous antagonists that target the BMP 
signalling cascade. These include the CAN (ceberus and DAN) family proteins, 
the twisted gastrulation proteins and the chordin family (120).  Noggin is a 
member of the chordin family and is a specific inhibitor that has been implicated 
in neuronal differentiation by blocking BMP signalling (121). BMP-2 and BMP-4 
have been shown to have the highest affinity for noggin, whereas BMP-7 binds 
with a lesser affinity to the inhibitor and TGFβ does not interact with it at all 
(122). Due to the generation of crystal structures, it is now known that noggin 
binding blocks the sites required for interaction with both the type I and type II 
BMP receptors (118).   
Follistatin (FST) is another BMP inhibitor that can directly interact with BMPs. 
However, unlike noggin it does not prevent BMP binding to its receptors (123). 
Instead it is thought that conformational changes elicited by FST binding 
prevents receptor activation (123). FST has been shown to bind both BMP-2 and 
BMP-7 and this binding has been shown to be reversible (124). Animal models 
have shown that FST is up-regulated in OA-like cartilage at the transcript level 
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(125). Similarly, BMP inhibitor Gremlin (grem), a member of the CAN family of 
BMP inhibitors, has also been shown to be up-regulated in OA (125).This 
antagonist has recently been identified as a marker for osteochondroreticular 
stem cells in the bone marrow, a cell population that can be utilised for bone 
remodelling and fracture repair (126). Grem has been shown to bind both BMP-2 
and BMP-4 over BMP-7, and prevents signalling in three ways. Firstly, by direct 
binding of the BMPs, secondly, by blocking BMP secretion and finally, by 
increasing BMP endocytosis (127).   
Cytokines and growth factors can influence the expression of grem and FST in 
chondrocytes.  Specifically, various anti-inflammatory cytokines have been 
shown to inhibit the expression of FST including IL-4, IL-13 (125), whilst BMP2 
and 4 have been shown to induce grem (128).   
 BMP-7 KO Mice 1.2.2
BMP-7’s role in foetal development has been investigated in mice.  It has been 
shown that BMP-7 knock out mice die postnatally with several developmental 
abnormalities, including: defects in kidney development, abnormalities in eye 
development, ineffective skeletal patterning, impaired corticogenesis, 
decreased brown fat and diminished Langerhans cell number (115). This suggests 
that BMP-7 signalling plays a comprehensive role in the development of many 
systems throughout embryogenesis, however, these mice are of restricted use 
for studying the deletion of the gene in vivo. To this end, BMP-7 mutant mice 
were created using deletions of either the first exon (129) or the sixth and 
seventh exon of the gene (130). Both groups found that by mutating BMP-7, mice 
had severe abnormalities in kidney and eye development (129,130) along with 
skeletal patterning defects in the rib cage, skull and hind limbs (130). This was 
further validated by an accidental deletion of BMP-7 that was found in the F2 
offspring of bcl2α transgenic mice. These pups again died postnatally and 
displayed defects in skeletal, kidney and eye development. Conditional limb 
specific knock out mice have been generated using a flox-cre system whereby 
the mice with a floxed BMP-7 allele were bred with mice containing the cre 
recombinase in the paired related homeobox 1 gene (PRX1::cre mice). It has 
been shown that the conditional knock down of BMP-7 had no effect on limb 
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growth or bone mass and it also had no effect on cartilage formation or fracture 
healing (131). It has been suggested that other BMP’s may be able to 
compensate for the absence of BMP-7 in the limb (131).  The idea of the BMP 
family members being able to compensate for one another has been elegantly 
shown in kidney development (132). BMP-7 deletion has previously been 
reported to produced catastrophic abnormalities in the kidney, however, if BMP-
4 is expressed under the control of the BMP-7 promoter, this can prevent these 
BMP-7 associated kidney abnormalities, highlighting the ability of this family to 
compensate for the loss in expression of one of its members (132). It is also 
interesting to note that BMP-7 and BMP-4 are structurally divergent but appear 
to be interchangeable in kidney development. It was less surprising that BMP-6, 
which is more structurally comparable to BMP-7, is also interchangeable in the 
context of kidney development. The interchangeable nature of the BMPs appears 
to be tissue specific as BMP-4 is unable to rescue eye defects known to be 
related to an absence of BMP-7(132). The concept of redundancy with regards to 
BMP-7 signalling has been further supported by two studies demonstrating that 
the BMP-7 null phenotype is exacerbated in mice lacking the closely related 
BMP-5 or BMP-6 (132).  BMP-7 null and conditional knock out mice have added 
valuable knowledge to the literature, confirming BMP-7 role in development and 
showcasing complex interplay between the different BMPs in specific tissues. 
 Role of BMP-7 in the Body 1.2.3
1.2.3.1 Kidney 
Postnatally, BMP-7 is most abundantly expressed in the kidney (133), with 
murine embryo studies naming the kidney as the main site of synthesis for BMP-7  
(134). BMP-7 homozygote mutant mice have helped to  demonstrate the 
proteins’ fundamental role in kidney development in mammals (129).  A lack of 
BMP-7 in the developing kidney has been shown to result in a severe lack of 
architectural organisation and limited epithelial and mesenchymal continuity 
(129).  At this anatomical location, it has been implicated in the maintenance of 
nephron progenitors and also in the sensitization of these cells to ureteric bud-
derived differentiation signals (129).  Furthermore, BMP-7 may have therapeutic 
potential for the treatment of kidney disease.  In 2003, BMP-7 was shown to 
reverse epithelial –mesenchymal transition (EMT) in renal tubular epithelial 
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cells, which ultimately leads to chronic renal failure (137). The data presented 
defines a role for BMP-7 in reintroducing E-cadherin, an epithelial adhesion 
molecule, that is dampened in the presence of disease derived TGFβ1 (137). 
Thus BMP-7 has been shown to be a potential therapeutic candidate for renal 
failure.  Further work with the BMP-7 enhancer, kielin/chordin – like protein 1 
has also highlighted a role for BMP-7 in protection from renal fibrosis (138). If 
mice lack this enhancer they become more susceptible to fibrosis in the kidney. 
Additionally, inhibition of a renal BMP antagonist, uterine sensitisation–
assocaited gene-1 (USAG1), has been shown to be protective in renal injury 
(129). Taken together, this evidence showcases a strong role for BMP-7 in the 
maintenance of renal homeostasis and protection against renal disease.     
1.2.3.2 Vasculature 
BMP-7 expression has been reported in the vasculature with a distinct decrease 
in protein expression being noted in several disease states that are associated  
with calcification, such as chronic kidney failure. It is thought that BMP-7 more 
specifically prevents the trans-differentiation of the smooth muscle cells (SMC) 
into an osteoblast like phenotype that can result in vascular calcification. BMP-7 
treatment has been shown to limit osteoblastogenesis via the down regulation of 
osteoblast function marker osteocalcin, thus preventing calcification  (133).  
Further to this, Dorai et al suggest an anti-inflammatory role for BMP-7 in the 
vasculature as well as showing that BMP-7 is an essential regulator of its own 
superfamily member, TGFβ, via up-regulation of inhibitory Smads (139).  
1.2.3.3 Stem Cell Regulation.  
Due to BMP-7s extensive role in embryogenesis, it may not be too surprising that 
it has been reported to successfully expand hematopoietic stem cells. Yeu-Han 
et al demonstrated that umbilical cord derived stem cells were significantly 
expanded in vitro when cultured in the presence of BMP-7, but not BMP-2 (140).  
It was also found that the BMP-7 mediated expansion had no effect on the 
colony-forming ability of the cells or on the lineage of the cells comprising the 
population (including CD3+ T cells, CD19+ B cells, CD33+ myeloid cells or 
CD71+erythroid cells) (140). Immuno-deficient mice were used to investigate the 
engraftment of the stem cells in vivo, demonstrating that the BMP-7 expanded 
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population had increased CD45+ cells in both the bone marrow and the spleen, 
therefore demonstrating the improved reconstitutional properties of the BMP-7 
expanded cells (140). BMP-7 is also reported to play a role in human MSC 
differentiation into osteoblasts (the cells responsible for bone 
formation)(141,142).  BMP-7 has been shown to alter gene expression during 
early osteoblastic differentiation, up-regulating a number of osteogenic marker 
genes and down regulating genes associated with the cell cycle – thus facilitating 
the differentiation of the MSCs into osteoblasts (143).  
 The data generated in the vasculature, reporting that BMP-7 inhibits 
osteoblastogenesis (section 1.2.3.1), along with the data regarding BMP-7 
function in the bone, reporting the induction of osteoblastogenesis, suggest that 
BMP-7’s function is cell specific.  
1.2.3.4 Immune Cell Regulation 
BMP-7 has been linked to the activation of immune cells including, B cells and 
macrophages.  It has been shown that the human monocytic leukemia cell line 
(THP-1) can be polarised into an anti-inflammatory M2 macrophage-like 
phenotype upon stimulation with BMP-7 (144). In this context, BMP-7 drove 
increased expression of anti-inflammatory cytokines such as IL-10 and IL-Rα 
along with decreased expression of pro-inflammatory cytokines IL-6 and TNFα.  
Furthermore, Rocher et al describe a BMP-7 mediated increased in BMP receptor 
BMPR2 (144).  Evaluation of the underlying mechanism of this unique polarisation 
revealed that BMP-7 phosphorylated SMAD and PI3K, leading to subsequent 
activation of Akt and mTOR (145). Therefore, the PI3K-Akt-mTOR pathway has 
been implicated in THP-1 (monocyte) polarization, however this has yet to be 
confirmed in primary cells.   
BMP-7 has also been shown to have a role in in B cell functioning.  Numerous 
BMPs have been shown to inhibit IgG, IgA and IgM production in both memory 
and naïve B cells (146). It has been surmised that the inhibition of IgG may be 
attributed to a BMP-7 mediated inhibition of proliferation and increased cell 
death. It was noted that this was a BMP-7 specific mechanism as even though 
BMP2/4 and 6 were all able to dampen IgG, IgM and IgA release from B cells, 
only BMP-7 had any effect on apoptosis (146).   
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These data, taken together highlight a role for BMP-7 in the regulation of the 
immune system, mainly in macrophage and B cell functioning.  This role is just 
beginning to be uncovered and there are still significant gaps in our 
understanding of BMP-7’s full role within this complex system.   
 BMP-7’s Role in the Joint and OA 1.2.4
Various studies have attempted to identify patterns of expression for BMP-7 in a 
normal and an osteoarthritic joint (predominantly in the cartilage).  In 2000, 
Chubinskaya et.al were the first to demonstrate that BMP-7 was expressed by 
human articular chondrocytes (147) using nested primers and In Situ 
hybridization.  Quantification of the RT PCR suggested that there were increased 
levels of transcript in OA chondrocytes compared to newborn cartilage and adult 
articular cartilage (148). There is some controversy in the literature, regarding 
BMP-7 expression in human chondrocytes as it has also been reported that BMP-7 
transcript is only detectable in foetal cartilage and not in OA or normal adult 
tissue (149).  The discrepancies between these two studies may lie within the 
methods used for mRNA detection, as Chubinskaya detected the transcript using 
methods optimised for low-level transcript detection.  Therefore, it is plausible 
that Chen et al have failed to locate the transcript as the methods implemented 
were not sensitive enough for this purpose. 
 Building on the work demonstrating detectable BMP-7 in chondrocytes, 
Chubinskaya et.al. also revealed that there is a negative correlation between 
age and BMP-7 expression in the cartilage. This was reported at both a transcript 
and protein level (148).  This correlation potentially suggests that an age related 
decrease in BMP-7 in chondrocytes may predispose some individuals to OA via an 
alteration in the homeostatic balance between anabolic and catabolic pathways 
(148).  Furthermore, it has been reported that BMP-7 protein expression is also 
decreased in OA, contrary to the previous finding by Chubinskaya (150). Levels 
of the BMP-7 transcript were also reported to decrease with increasing cartilage 
erosion i.e. OA severity (150). However, it must be noted that the control 
cartilage used in this study was reported to be of Collins grade II-III, which would 
typically be regarded as eroded. Therefore, this questions the interpretation of 
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these results as the cartilage has not been compared to a true healthy control 
tissue.    
In 2006, Chubinskaya et al reported that OA synovial fluid contained in the 
region of 50ng/ml of BMP-7 - a similar concentration to control groups (151). 
Whilst other data suggests that OA synovial fluid contains a lower concentration 
of BMP-7, approximately 10pg/ml (153). This data must be interpreted carefully, 
as the concentrations at which BMP-7 was reported were at times below the 
limit of detection for the assay (Human BMP-7 Quantakine ELISA kit, R & D 
Systems). BMP-7 protein expression has also been reported in RA synovial fluid at 
higher concentrations than in the OA and non arthritic joints, with RA synovial 
fluid containing around 100ng/ml BMP-7 (twice as much as the OA fluid) (151). It 
is possible that this increase in readout from the ELISA analysis could be due to 
non-specific binding of rheumatoid factor in the RA synovial fluid, as the 
methods do not state if an appropriate block was carried out to prevent this 
interference. Additionally, a positive correlation between BMP-7 protein and 
severity of OA in both plasma and synovial fluid in patients has been reported 
(154). However, this correlation opposes that which was found in the cartilage, 
whereby BMP-7 protein is decreased with increasing OA severity(150).  
Moreover, studies have also investigated the consequence of activating BMP-7 
signalling in chondrocytes; Chubinskaya et al used a gene array to describe BMP-
7s potential role in cartilage homeostasis (155). The transcriptional signature 
revealed that several genes were under the control of BMP-7 including: 
chondrocyte cytoskeleton constituents, matrix production proteins and catabolic 
factors such as matrix degrading enzymes and cell death components (155). 
Further to this, there is also evidence to suggest that BMP-7 is able to upregulate 
hyaluronic acid synthase (HAS), hyaluronic acid (HA) and CD44, all of which are 
components in extracellular matrix  production in primary human chondrocytes 
(156). Additionally, BMP-7 can increase proteoglycan expression in articular 
chondrocytes and further to this at low concentrations it can also reverse the 
inhibitory effects of IL-1βon proteoglycan expression (157). 
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1.2.4.1 BMP-7’s Therapeutic Potential in OA: Animal Models 
BMP-7 has been shown to be chondroprotective in several animal models of OA 
including, a rat inflammatory model, a sheep impact model and a rabbit 
mechanical model of arthritis.   
Inflammatory arthritis was emulated by intra-articular injection of zymosan into 
the joint of rats (158). It was shown that BMP-7 prevents the zymosan driven loss 
of type II collagen, as well as preventing the expression of MMP-3. Overall joint 
swelling was significantly decreased in rats receiving the higher doses of BMP-7 
compared to the control and the low dose group conferring a dose dependent 
anti-inflammatory aspect to BMP-7 therapy. Moreover, IL-1β concentrations were 
also decreased following the BMP-7 treatment (158).  The data also goes on to 
suggests that therapeutic BMP-7 up-regulates endogenous BMP-7 at the protein 
level.  However, the expression of the BMP-7 transcript following the treatment 
was not investigated and therefore it cannot be confirmed if the increase was 
due to an increase in BMP-7 from the chondrocytes or synoviocytes or just due to 
remnants of the therapeutic protein administered.  
A mechanical model of arthritis known as the anterior cruciate ligament 
transection (ACLT) has also been utilised to mimic the mechanical stress exerted 
on the joint in OA. The anterior cruciate ligament is surgically cut, causing 
destabilisation and eventually erosion of the joint due to uneven mechanical 
load. Hayashi used this model in 2010 to demonstrate BMP-7s protective effect 
in this OA like disease. BMP-7 was administered therapeutically via intra-
articular injection on a weekly basis from 4 weeks post transection of the ACLT 
to 12 weeks, at which point the animals were sacrificed (159). It was found that 
BMP-7 was effective in protecting the cartilage at macroscopic levels when the 
tissue was scored according to the Osteoarthritis Research Society International 
(OARSI) cartilage grading system.  Furthermore, micro computed tomography 
was used to demonstrate that BMP-7 had no adverse effects on etopic bone 
formation, a side effect which was expected due to BMP-7 ability to promote 
bone growth via the promotion of osteoblast differentaion (143).  
An impact injury model was used in sheep to establish the efficacy of intra 
articular BMP-7 and to explore the time window for therapeutic intervention 
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following injury (160). It was concluded that the chondroprotection conferred 
from BMP-7 is markedly increased if the intervention is received immediately 
after the injury.  Additionally, BMP-7 was able to significantly decrease the 
number of apoptotic cells, this was most significant if treatment was received on 
the same day as the as the injury was sustained. A more modest reduction in 
apoptosis was seen in the group that received intervention three weeks post-
surgery, however, this was still regarded as significant.  It must be taken into 
account that administration of any therapeutic agent at the time of injury is 
unlikely as it can take months for an individual with joint damage to be referred 
to specialist orthopaedic department and to undergo the necessary examinations 
to identify the problem.  Therefore, in this respect, treatment 3 months post 
injury is a more accurate reflection on the likely timescale for NHS patients 
(160).  
All three animal models demonstrate a chondroprotective effect of BMP-7 in OA 
like disease, despite all three having differing aetiology. This provides data on 
which to drive forward BMP-7 as a potential disease-modifying agent in the 
treatment of OA.  
 Clinical Applications of BMP-7 1.2.5
1.2.5.1 OA: Phase I Clinical Trial 
A phase I safety and tolerability study has been carried out for BMP-7 (161).  The 
study found that there were no dose limiting toxicities and no difference in 
adverse events compared to placebo (161). Due to BMP-7s involvement in bone 
formation, it was essential to ensure that ectopic bone formation (osteophytes) 
was not increased in the BMP-7 treated cohort. Radiographic analysis in the 
follow up report showed no such effects in the BMP-7 treated individuals (161).  
In addition to evaluating safety and tolerability, patient outcome was also 
assessed.  To do this, investigators measured pain and functional improvement 
using both the WOMAC scoring system and improvements in the OARSI responder 
criteria.   Optimal WOMAC measured responses (50 -70% improvements) were 
observed in those patients that received high dose BMP-7.  The OARSI responder 
criteria, which assess pain, was also improved with BMP-7 treatment (161). In 
summation, using the evaluation techniques in this study BMP-7 treated 
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individuals reported a self-assessed improved response with regards to their OA 
symptoms after BMP-7 treatment.          
1.2.5.2 Fractures 
The levels of BMP-7 are significantly decreased in non-union fractures when 
compared to normal callus tissue (162).  In addition to BMP-7, other members of 
the BMP family are also dysregulated in non-unionised tissue, including a 
decrease in BMP8 and an increase in BMP4, BMP5 and BMP-6. BMP-7 is a licenced 
agent for the treatment of non-unionised fractures (163). Clinical trials have 
demonstrated that recombinant BMP-7 inserted in a rod with a type I collagen 
carrier has a comparable outcome to bone autograft and is therefore successful 
in treating non unionised fractures (164).  The mechanism underlying this ability 
of BMP-7 in facture healing is thought to be related to its role in proliferation 
and osteogenic differentiation of MSCs (165) (section 1.2.3.1), which results in 
faster healing and increased mechanical strength of the bone (166). 
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1.3 Gene Regulation  
Genes can be regulated in many ways including at the epigenetic level. These 
epigenetic mechanisms can include histone modification (methylation, 
acetylation), AU rich elements for degradation motif binding, non-coding RNAs 
(section 1.3) and methylation of the gene promoters. In health, all of these 
regulatory mechanisms enable homeostasis to be achieved, however, in disease 
they may become dysregulated and contribute to pathology.  
 AU Rich Elements  1.3.1
AU rich elements (AREs) are sequences in the mRNA rich in the bases adenine 
and uridine, that signal transcripts for degradation(167). These regions are 
commonly found on the 3’UTR of many transcripts and are bound by AU binding 
proteins such as tristetraprolin (TTP), butyrate response factor 1 (BRF1) and 
butyrate response factor 2 (BRF2), which are all zinc finger proteins. Recognition 
of the mRNA via AUUUA motif by AU binding proteins, leads to the activation of 
the mRNA decay machinery and thus the destruction of the transcript. Under 
normal physiological conditions this mechanism can act to maintain homeostasis, 
however, disease associated dysregulation can be catastrophic and has been 
implicated in several cancers and autoimmune disease processes (167). 
Furthermore, a role for 3’UTR regulation in autoimmune disease was highlighted 
using TNFα transgene mice (168,169), showing that specific modification of the 
3’ UTR, altering the AU binding sequences, can change the expression pattern of 
TNFα that results in chronic inflammatory polyarthritis (168,185). It was later 
confirmed that these mutations in the 3’UTR of the TNFα transcript were 
interfering with TTP regulation of the mRNA (170) and had a functional 
consequence that manifested in inflammatory arthritis (171).     
 Methylation 1.3.2
DNA methylation is another form of transcript regulation and occurs when a 
methyl group is added to the 5th carbon of a cytosine nucleotide in the gene 
promoters in the CpG islands region, which is present in 60% of gene promoters 
(172). The modification is regarded as highly stable and can be detected in easily 
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accessible fluids such as plasma, saliva and urine (172). If too much methylation 
occurs, this can be referred to as hypermethylation and conversely, if there is 
not enough methylation then this is hypomethylation, both of which have been 
associated with a vast number of pathologies (173). Moreover, hypomethylation 
has been associated with facilitation of catabolic processes, whereas 
hypermethylation has been connected to the prevention of anabolic action in OA 
(172).   
Methylation of the BMP-7 promoter has been proposed as a mechanism for the 
age related decrease in the protein that is reported in the literature (174). 
Furthermore, inhibition of promoter methylation in chondrocyte cultures has led 
to an increase in BMP-7. Thus hypermethylation may predispose some individuals 
to OA by preventing BMP-7s homeostatic actions. This age related phenomenon 
of increased methylation is consistent with that found in the epidermis where it 
has been shown that there are significant age-associated changes in the 
methylation (175). 
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1.4  MicroRNAs 
 Non-Coding RNAs 1.4.1
For years it was believed that the genome encoded only proteins, hence the 
central dogma of protein synthesis: DNA leads to RNA, RNA leads to protein.  
Whilst this does indeed hold true, it was believed that the remaining DNA that 
did not code protein was “junk  DNA” that  higher eukaryotes had evolved to no 
longer need. This however, is not the case and these genomic regions, referred 
to as non-coding regions, can be transcribed into non-coding RNA (ncRNA) with 
the resultant RNA having a range of biological functions.  In 1961 Francois Jacob 
and Jacques Monod published a review article describing some of these functions 
(176). They looked at the regulation of protein synthesis and concluded that the 
mechanisms of control were inhibitory, operated at the genetic level and the 
mechanism itself was genetic in origin (176). They were describing epigenetic 
regulation of coding RNA, however, they were not the 1st to come across this 
type of RNA regulation - Waddington published a book in the 1940s, Organisers 
and Genes, that coined the term epigenetics in reference to this RNA regulation. 
Waddington was fundamental in merging the fields of genetics and embryology 
(with outstanding success) and challenged the current thinking of protein 
regulation at the time (177).  
Over the past decade, the general understanding with regards to genetic 
regulation has vastly improved, with miRNA’s being a major focus. More 
recently, long non-coding RNA (lncRNA) have been brought to the forefront as 
the latest form of functional RNA.  These lncRNA are defined as noncoding 
regions of over 200 nucleotides in length.  The function of many of these 
lncRNAs have yet to be elucidated but, it is thought that they may fit into one of 
4  functional categories; signal, decoy, guide and scaffold (192). If the lncRNA is 
thought to be in the signal category it may play a role as a molecular signal that 
can be used as an indicator of gene activity, whereas the decoy classification is 
for lncRNA that act as a sponge, competing for binding of other regulators such 
as miRNA. The third classification, termed as guide lncRNA, are thought to aid 
chromatin modification by guiding ribonuclear proteins to their targets. Finally, 
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scaffold lncRNA can act as stabilising structures at certain points along a 
gene(192) facilitating gene transcription.    
 miRNA Discovery 1.4.2
MicroRNAs (miRNAs/miRs) are short non-coding RNA sequences, commonly 
around 22 nucleotides in length, that are able to target specific mRNA 
transcripts for degradation based on complementary base pairing, thus modifying 
the expression of the target transcript. In 1981 miRNAs were first discovered in 
worms, more specifically C.Elegans. Their function was deciphered and it was 
reported that the identified RNA was able to decrease the expression of the lin4 
protein via imperfect binding to the 3’ untranslated region (UTR) of the lin4 
mRNA (178).  This research led to the identification of a second C.Elegans 
miRNA, Let 7(179). However, this miRNA was well conserved between flies and 
human and thus research on miRNAs moved into higher species (180).  It is now 
well documented that miRNAs display great evolutionary conservation and our 
knowledge regarding these small RNAs has expanded rapidly over the past two 
decades.  There are currently over 2000 identified miRNA (180) and in silico 
analysis predicts that combined, they target over 50% of the human genome.  
The levels of expression of miRNAs in a cell varies greatly, from as little as 10 
copies up to 80,000 copies per cell (180). MiRNA can be transcribed from introns 
that have no protein coding function (intergenic miRs) or can be located in the 
introns of protein coding regions (intragenic miRs). Further to this a smaller 
proportion are also located within exons (180).The expression of miRNAs are also 
tightly regulated and often  miRNAs can be involved in complex networks of 
regulation. For example, if a miRNA caused repression of a target gene, this 
could lead to subsequent dowstream alterations in the expression of the miRNA 
itself (181).     
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 miRNA Biogenesis and Function.  1.4.3
The synthesis of miRNAs can be broken down into 4 main stages: transcription, 
processing, maturation and strand selection by the RISC complex (181).  Initially, 
RNA polymerase II transcribes pri- miRNA from the genomic DNA. The pri-miRNA 
has a specific tertiary structure (containing either one or several hairpin loops) 
and the transcript is capped at the 5’UTR with a 7 methyl guanosine cap, and 
polyadenylated at the 3’UTR (180). The pri-MiRNA is processed into smaller pre-
miRNA fragments by drosha, a RNase II type molecule, along with its co-factor 
digeorge syndrome critical region gene 8 (DGCR8).  From here, the pre-miRNA is 
actively exported to the cytoplasm by exportin 5, which utilises nuclear pores 
for transport (180,181).  A second RNase III type protein, dicer, then generates a 
double stranded duplex miRNA from the pre-miRNA generating a mature miRNA. 
From here, one strand (the guide strand) will be selected for incorporation into 
the RNA–induced silencing complex (RISC) and the other strand, the passenger 
strand, will be degraded.  
The mature single stranded miRNA can then lead the RISC complex to the target 
mRNA (182). The seed region of the miRNA normally binds to a complementary 
microRNA response element (MRE) sequence in the 3’ UTR of the mRNA, 
however, binding to the 5’ UTR or even the protein coding region itself has been 
noted. The miRNA seed regions that binds to the mRNAs are often between 
positions 2-8 of the mature miRNA sequence (183). Furthermore, seed length has 
been linked to specificity of miRNA binding, i.e. the longer the seed sequence 
the more specific the binding.   After binding, there are two mechanisms for 
protein synthesis interference, the mRNA  can be translationally repressed, 
mainly through the interruption of either the initiation or elongation stages of 
protein synthesis. Alternatively, the mRNA is degraded and this commonly occurs 
via the removal of the polyA tail via de-adenylase activity (184). The proposed 
mechanism for the binding of a miRNA to a target mRNA is based on 
complementarity, of seed regions. It has been established that if the miRNA and 
the target mRNA have near complete complementarity then the mRNA is 
targeted for degradation. However, if there is only partial complementarity then 
the mRNA may be translationally repressed.  A study carried out in 2006 
questioned the reliability of the 3’UTR seed regions as a predictor of mRNA-
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miRNA interaction (185). Based on this study (and subsequent work) it is now 
hypothesised that the complementarity of the seed region along with seed 
region accessibility and perhaps co-expression of other RNAs or nuclear/cytosolic 
proteins might be more indicative of miRNA binding to a target. Therefore, this 
ultimately suggests that the binding of the miRNA to a mRNA is context specific 
and not solely based on complementary (185).  
 miRNA in OA 1.4.4
MiRNA dysregulation has been strongly associated with OA, with the first 
systematic profile miRNA discrepancies identifying 17 miRNA that were 
differentially expressed between OA and healthy cartilage (186). A review 
published in 2015 went on to further profile all of the miRNA that are predicted 
to be dysregulated in OA, creating an extensive list of cartilage derived disease 
associated miRNAs (Figure 1.4). The exact role that these modulators play in 
disease has not been fully elucidated.   
Further to miRNA being associated with molecular pathways and cell 
differentiation within the joint environment, they have also been associated 
with aging and mechanical loading (187) (known to be risk factors for OA). To 
date, four miRNA have been reported to be deregulated with ageing, resulting in 
changes to both collagen and ADAMTS production: miR320c, miR199a-3p, 
miR193b and miR21 (187).  A further two miRNA, miR365 and miR222, have been 
associated with mechanical loading (187).  MiR365 is a mechano-responsive 
miRNA that plays a role in chondrocyte cell proliferation and differentiation 
(188) and is up-regulated in OA (189).  
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Figure 1.4 OA Associated miRNA Alterations in the Joint.  
miRNA that are thought to be altered in the articular cartilage during OA pathology and their 
predicted mRNA targets  (187,194,202).  
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1.4.4.1 miR140 
Of all the miRNA that have been shown to be dysregulated in OA miRNA 140 is 
one of the most intensely studied. Mice lacking miR140 have a subtle skeletal 
phenotype; slightly shorter body length and reduced body weight, along with 
abnormalities in the skull (a shorter snout and domed shaped skull).  
Furthermore, these mice also have articular cartilage abnormalities. Work has 
been carried out to show that miR140 is essential for chondrogenesis, with levels 
of the miRNA increasing significantly between the precursor human 
mesenchymal stem cells and differentiated chondrocytes (190). This increase in 
expression was observed over chondrogenesis and was consistent with other 
increased chondrocytic markers such as aggrecan, type II collagen and SOX9 
(190). It has been further suggested miR140 expression is decreased when SOX9 
is deleted, demonstrating that transcription factor SOX9 controls the expression 
of miR140  (191). However, this requirement for miR140 in the cartilage 
postnatally is not the same in embryogenesis, as miR140 knock out mice have 
normal cartilage at birth. As the mice age, the miR140 knock out (but not the 
wild type) develop spontaneous OA like symptoms; by 12 months they show 
severe structural damage to the joint with almost a complete loss of cartilage 
(191). Therefore, this miRNA appears to be required for the regulation and 
homeostasis of the cartilage and not the development.  Furthermore, this miRNA 
has also been shown to confer protection against OA by transgenic 
overexpression (191).  
The role of miR140 may extend past cellular differentiation. Miyaki et al went 
on to show that miR140 is negatively regulated by the OA dominant cytokine IL-
1β. Conversely, if human chondrocytes were transfected with a mimic of 
miR140, a suppression of IL-1β induced ADAMTS5 was observed along with a 
reversal of IL-1β induced aggrecan repression (190).  
Taken together, these data suggest a role for miR140 in cartilage homeostasis 
and protection from OA , furthermore dysregulation of this miRNA may be a 
contributing factor to OA pathogenesis.  In humans it has been robustly shown 
that miR140 is decreased in the cartilage of OA patients compared to normal 
controls (190,193).  
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1.4.4.2 miR22 
To date there is only one miRNA that has been shown to regulate BMP-7: miR22 
(194). MiR22 was shown to be increased in OA cartilage and was highlighted as a 
regulator of not only BMP-7, but also of the peroxisome proliferator-activated 
receptor alpha (PPARA) protein, known to be involved in lipid metabolism. In 
vitro validation demonstrated that both BMP-7 and PPARA are directly regulated 
by miR22. Via this direct regulation it is also thought that miR22 can indirectly 
modify the expression of catabolic modulators IL-1β and MMP-13 (194). 
Furthermore, over expression of miR22 in chondrocytes can cause an increase in 
both IL-1β and MMP-13.  Conversely, transfection with 50nM miR22 inhibitor can 
lead to increased expression of both BMP-7 and PPARA and a down-regulation in 
IL-1β and MMP-13 (194). Data from the sample cohort revealed a robust 
correlation co-efficient between miR22 and both BMP-7 and PPARA in the 
healthy and OA cartilage, thus revealing a pathological role for this miRNA in OA.   
 MicroRNA 24 1.4.5
MiRNA 24 has been previously linked to OA, with a significant decreased in 
expression being noted in OA cartilage (195).  MiR24 belongs to a miRNA cluster 
that is transcribed in tandem. There are two clusters in which miR24 can belong, 
cluster 1: miR24a~27a~24-2 located on chromosome 9q22 and cluster 2: 
miR23b~27b~24-1, located on chromosome 19p13. These clusters are both very 
similar as  both miR23a and miR27a only differ by one base pair form miR23b and 
miR27b respectively (196) and miR24 is identical in both clusters. Due to the 
sequence similarity, these miRNAs are predicted to share many common targets. 
However, they are located on different chromosomes and therefore their 
regulation is likely to differ, with multiple factors within the local environment 
most likely determining  which of the clusters are activated at a given time 
(196). 
Suppression of miR24 is thought to contribute to several different cancers 
including lung, gastric, colorectal, breast, prostate, ovarian and pancreatic 
cancer, along with leukaemia and squamous cell carcinoma.   A range of target 
genes associated with cancer processes such as proliferation, cell cycle arrest, 
apoptosis and differentiation, have been validated as targets of miR24.  There is 
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strong evidence for miR24 mediated regulation of the cell cycle, with the 
nuclear phospho protein MYC and E2F2 (a protein known to be involved in 
controlling cell cycle) being targets of the miRNA.  Other targets involved in the 
cell cycle that are considered to be down stream of these two proteins are also 
regulated by miR24 (197).  It is interesting to note that even though these 
targets have been validated using a luciferase assay, conferring direct binding of 
the miRNA to the mRNA, they did not have a complementary 3’UTR seed region, 
but were instead recognised by another seedless (non complementary) microRNA 
recognition site (197). Due to the intricate role this miRNA plays in cell cycle 
regulation and the clinical evidence supporting a down regulation of miR24 in 
several cancers including colorectal cancer (196), this miRNA may offer a new 
therapeutic avenue for the treatment of cancer (196,198). 
Other studies have looked at the relationship between miR24 and the TGFβ 
superfamily. TGFβ family receptor ALK4 is modulated directly by miR24, 
preventing erythrocyte proliferation and differentiation. Furthermore, the 
expression of miR24 is conversely correlated with ALK4 over the process of 
erythropoiesis (115).   Cross talk between the TGFβ/BMP signalling pathways and 
the platelet derived growth factor –BB (PDGF-BB) signalling has also been linked 
to miR24 with regards to vascular smooth muscle cell (vSMC) phenotype (199).  
Following vascular injury, the vSMC must change from a contractile to a 
synthetic phenotype, with TGFβ/BMP and subsequent SMAD signalling being 
associated with the former and PDGF-BB associated with the latter.  The switch 
from contractile to synthetic vSMCs is thought to be mediated through a PDGF-
BB induced down regulation of Tribbles-like protein-3 (Trb3), known to facilitate 
SMAD signalling downstream of TGFβ/BMP binding. Therefore, it has been 
proposed that PDGF-BB up-regulates miR24, which then diminishes Trb3 
expression and prevents SMAD signalling. Ultimately, this promotes the switching 
to PDGF-BB signalling resulting in a synthetic and reparative phenotype of the 
vSMCs (199).    
Investigation into the role of miR24 with regards to OA has also been conducted. 
Most notably a link between miR24 and tumour suppressor protein, p16INK4a has 
been established, a relationship that has already been shown in the cancer field 
(196). Philipot et al have reported that miR24 is a negative regulator of P16INK4a 
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which is associated with the senescence-associated secretory phenotype (SASP). 
The SASP is a collection of catabolic agents including matrix remodelling 
enzymes MMP1 and MMP-13, along with pro-inflammatory cytokines, IL-8 and IL-
6. Data demonstrate that OA associated cytokine IL-1β can increase the 
expression of P16INK4a along with the other SASP elements via the down-
regulation of miR24. Transfection of primary chondrocytes with P16INK4a can also 
significantly up-regulate MMP-1 and MMP13 and can modulate the expression of 
IL-8. Furthermore, the OA associated reduction in miR24 expression negatively 
correlates with P16INK4a. Finally, Philipot demonstrates that if miR24 is 
downregulated in vitro, there is a subsequent increase in both P16INK4a  and  
MMP1 expression (195).  Therefore, the disease associated drop in miR24 could 
be contributing to the catabolic insult observed in OA.  
Other members of both clusters containing miR24 have also been implicated in 
OA pathology.  MiR27b has been shown to inhibit IL-1β induced MMP-13 
expression (200), however, in OA miR27b expression has been shown to be 
decreased. Transcripts that are known to promote anabolic signalling, such as 
Insulin-like growth factor binding protein -5 (IGFBP-5), have been shown to be 
targeted by miR27a (193). MiR27a  inhibition in primary chondrocytes, results in 
increased IGFBP-5 expression after 72 hours, which in the cartilage can lead to 
decreased ECM breakdown (193).   
 MicroRNA 342  1.4.6
MiR342 has not been directly linked to OA, but has been studied with regards to 
obesity which is considered one of the major risk factors for OA.   Murine miR342 
was shown to be up-regulated during the development of obesity (201). Further 
work has brought to the forefront miR342’s ability to induce adipogenesis in 
human derived adipose MSCs (203) which have also been linked to OA disease 
development.  
In a similar fashion to miR24, miR342 has also been predominantly studied in the 
cancer field, with a downregulation of the miRNA being noted in cancer derived 
tissue compared to normal comparator tissue. Furthermore, miR342 has been 
recently highlighted as having tumour-suppressing properties, via direct 
targeting of the 3’UTR of both forkhead box (FOX) superfamily proteins, FOXM1 
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and FOXQ1. These particular FOX proteins are highly expressed in colorectal 
cancer inducing invasiveness, migration and proliferation of the colorectal 
cancer cells. The discovery that miR342 can supress the activities of these 
proteins could be harnessed therapeutically leading to new treatment strategies 
(204).  There are also implications for miR342 in breast cancer through the 
modulation of inhibitor of differentiation 4 (ID4) and subsequently the breast 
cancer gene BRCA, which is known to be implicated in the heritability of breast 
cancer (205). 
 miRNA in the Circulation 1.4.7
Biomarker discovery for disease is a large area of intensive research.  There are 
certain criteria that are critical for biomarker identification: disease specificity, 
ease of access, stability and responsiveness to treatment. Disease specific 
proteins in the plasma have been the most widely used biomarkers to date, 
however, they are not always best suited to the task (206). They have been 
shown to be subject to a variety of post-translational modifications, have 
complex structural composition in the blood and have relatively low abundance; 
thus detection can be difficult. There is a need for new and better biomarkers to 
be identified enabling better diagnosis and prognosis (206) especially for OA. 
MiRNAs may be the new biomarkers that are being sought. MiRNAs have been 
shown to be actively transported from the cells in which they are synthesised 
(207) and can therefore not only be found in circulating cells but also in bodily 
fluids. In 2010, Weber et al looked at the miRNA expression profile of 12 
different bodily fluids, including plasma and urine.  From this it was concluded 
that there were both common and fluid specific miRNAs. Therefore, as a 
potential biomarker they would be easy to measure in blood and/or urine 
samples. MiRNAs have also been shown to be stable within the plasma as they 
can secreted in membrane bound particles called exosomes, preventing then 
from being degraded by ribonucleases (208). Alternatively, the miRNA may be 
protected via other mechanisms such as association with RNA protein complexes 
or modification rendering the miRNA non detectable by the ribonucleases. 
Importantly, miRNAs have been shown to be disease specific, with a large 
literature detailing the specificity of certain miRNA to disease processes. A 
recent review has collated all the miRNA that have been proposed as disease 
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specific biomarkers for a variety of different cancers, including prostate cancer, 
breast cancer, colon cancer, lung cancer and also for myocardial infarction 
(206). 
In 2015, Beyer et al used the Bruneck cohort in order to identify Let7e as a 
predictor for future need for arthroplasty(209). The cohort contained 816 
individuals who had a baseline visit for the study in 1995. At this visit blood 
samples were taken and these patients were then followed until 2010. A total of 
12 miRNA were identified from an initial screen using a subgroup of the cohort, 
these miRNA were identified as being altered in the plasma of those who had 
went on to develop OA. These miRNA were then taken forward in the whole 
cohort and when further analysis was conducted, Let7e was found to be 
decreased in the individuals who went on to receive one or more joint 
replacements (209). The Bruneck cohort has now been used to successfully 
investigate plasma miRNA alterations in diabetes, cardiovascular disease and 
osteoarthritis.  
A miRNA signature has also been determined by Li et al between early and late 
stage OA SF (210). Early OA was defined by the presence of a meniscal tear 
requiring arthroscopy and late stage disease was defined by the need for 
arthroplasty. A total of 752 miRNA were screened with 14 being taken forward 
for validation in a larger cohort. It was found that 7 miRNA were differentially 
regulated: miR24-3p, miR29c-3p, miR34a-5p, miR23a-3p, miR27b-3p, miR186-5p 
and miR27a-3p(210). These miRNA remained significantly up-regulated in late 
stage disease when normalised to gender, age or BMI.  Therefore this panel 
could serve as biomarkers for differentiation between early and late stage OA. 
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1.5 Aims and Hypothesis 
The expression of BMP-7 in OA is negatively correlated with disease severity. 
Recombinant BMP-7 has been considered as a potential therapy for OA, this is 
based on its chondroprotective properties which have been robustly established 
in animal models of OA.  A human clinical trial has highlighted the safety and 
tolerance of BMP-7 and demonstrated improved clinical outcomes as determined 
by improved WOMAC scores and OARSI responder criteria. However, the 
expression pattern of BMP-7 in articular chondrocytes is still controversial and 
the impact of BMP-7 stimulation on chondrocytes and macrophages biology is 
unknown.  Therefore it has been hypothesised that a disease derived loss of 
BMP-7 and its signalling pathway in OA is mediated by disease-associated miRNA. 
Further to this, it has been hypothesised that BMP-7 promotes anabolic processes 
in chondrocytes, via modulation of it’s own signalling family, and has an anti-
inflammatory impact on macrophages in the joint.  
In order to robustly test these hypotheses the following aims were proposed;  
• To investigate BMP-7 expression and the expression of associated 
signalling cascade members, at both the transcript and protein level, in a 
well-defined cohort of OA patients.  
• To deduce if BMP-7 or any of the related transcripts are controlled by OA 
associated miRNAs.  
• To delineate the effect of exogenous BMP-7 on chondrocytes and 
macrophages. 
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2 Materials and Methods 
2.1 Sample Acquisition  
Samples were acquired from patients undergoing Total (TKR) or 
Partial/Unilateral  (UKR) knee replacement at the Glasgow Royal Infirmary. This 
study was approved by the ethical committee at the Glasgow Royal Infirmary, 
Scotland.  Patients were consented at the clinic prior to elective surgery.  On 
the day of surgery samples were collected in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco® Life Technologies) with 1% penicillin/streptomycin (P/S) 
(Sigma Aldrich) and transported back to the laboratory for processing.  
For cohort analysis the following samples were acquired from TKR (Figure 2.1). 
• Peripheral blood 
• Cartilage femoral notch biopsy 
• Cartilage from 
o Distal medial condyle (DMC) 
o Distal lateral condyle (DLC) 
o Posterior medial condyle (PMC) 
o Posterior lateral condyle (PLC) 
o Medial tibial plateau (MTP) 
o Lateral tibial plateau (LTP) 
• Synovial membrane 
• Synovial fluid.  
Patients undergoing UKR did not have any of the lateral samples listed or the 
DMC. 
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Figure 2.1: Anatomical location of the cartilage samples from total knee replacement.  
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 Peripheral Blood Processing 2.1.1
OA patient peripheral blood or blood from healthy controls was layered over 
histopaque (Sigma Aldrich) and centrifuged at 300g for 30 minutes (mins), with 
no break, isolating plasma from red blood cells and peripheral mononuclear 
cells.  Plasma was aliquoted and stored at -80°C.  
 Synovial Fluid Processing 2.1.2
Synovial fluid was aspirated from the joint at the time of initial incision during 
surgery. Fluid was stored in an EDTA vacutainer to prevent coagulation.  
Synovial Fluid was centrifuged at 400g for 5 mins at  room temperature (RT) to 
pellet the cells present in the fluid. The synovial fluid was then aliquoted and 
stored at -80°C.   
 Cartilage and Synovium Processing  2.1.3
Cartilage and synovial membrane samples were either processed for RNA 
extraction (section 2.2/2.6) or placed in formalin for fixation and subsequent 
Immunohistochemical (IHC) analysis (section 2.8). Femoral notch biopsy was 
processed for RNA extraction only.  
 Cartilage and X-Ray Grading 2.1.4
At the time of excision, the cartilage was scored using the Outerbridge grading 
system for cartilage degradation outlined in Table 2-1. Patient joint X-rays were 
also scored using the Kellgren and Lawrence outlined in Table 2-2.   
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Outerbridge Grade Description 
0 Normal 
I Cartilage with softening and swelling. 
II A partial – thickness defect with fissures on the 
surface that do not reach subchondral bone or 
exceed 1.5cm in diameter 
III Fissuring to the level of subchondral bone in an area 
with a diameter more that 1.5cm 
IV Exposed subchondral bone 
Table 2-1 Outerbridge classification (87-89)   
 
Kellgren and 
Lawrence Grade 
Description 
0 No radiographic features of OA present 
1 Unlikely narrowing of the joint space, possible 
osteophytes 
2 Possible joint space narrowing, small osteophytes 
3 Joint space narrowing, multiple moderately sized 
osteophytes, some sclerotic areas and possible 
deformation of the bone ends. 
4 Severe joint space narrowing, multiple large 
osteophytes, marked sclerosis and definite bony end 
deformity 
Table 2-2 Kellgren and Lawrence Scoring system (84,86).  
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2.2 Cartilage Processing 
 Mortar and Pestle  2.2.1
Samples were cut into small sections and placed in a mortar and liquid nitrogen 
was poured over the samples in order to snap freeze the tissue.  Once frozen the 
samples were crushed into a powder with a pestle. The powder was transferred 
into an eppendorf and 700µl QIAzol® (QIAGEN®) was added. A 7mm steel bead 
(QIAGEN®) was placed in the tube and the powder was further homogenised for 
30 min using a TissueLyser LT (QIAGEN®). 
 Liberase™ Digest  2.2.2
Cartilage and synovium samples were cut into small sections and placed into 5ml 
Roswell park memorial institute medium (RPMI) (Gibco® Life Technologies), 
supplemented 1% P/S. 150µg/ml Liberase™ (Roche Diagnostics) was added and 
the tissue was incubated overnight at 37°C with gentle shaking. For femoral 
notch biopsy samples, the cartilage was removed from the bone and the whole 
cartilage biopsy was placed in the Liberase™ supplemented media. The Liberase™ 
solution was passed through a 70µM cell strainer (BD Falcon™) to obtain a single 
cell suspension. Cells were centrifuged at 400g for 5mins, the pellet was 
resuspended in Phosphate buffered saline (PBS) (Gibco® Life Technologies) and 
centrifuged again. Following the centrifugation, the pellet was either lysed in 
700µl QIAzol® for subsequent RNA analysis (section 2.6), or cells were plated for 
in vitro cultures (section 2.3).  
2.3 Primary Human Chondrocyte Cell Cultures 
Following Liberase™ digestion (section 2.2.2) primary human chondrocytes were 
plated at 1.5x 105/ml in complete DMEM (cDMEM) comprised of DMEM 
supplemented with 1% P/S, 1% L-Glutamine (Sigma Aldrich), 10% Heat inactived 
foetal bovine serum (FBS) (Invitrogen) and Fungizone® Antimycotic (Life 
Technologies). Cell were left for 48hrs at 37°C, 5% CO2 to settle onto the plastic.  
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 Cytokine Stimulations 2.3.1
Primary chondrocytes were stimulated with a variety of cytokines in order to 
assess any associated changes in transcript and protein expression. Human 
recombinant BMP-7, IL-1β and TGFβ (PreproTech) were used at a concentration 
of 100ng/ml or 10ng/ml. Cells were stimulated for 8 hours before cells were 
either lysed in Qiazol® for RNA analysis or placed in fresh cDMEM for a further 24 
or 48 hours. At each of the subsequent time points the cells were lysed in 
Qiazol® for RNA analysis (Section 2.6) and the supernatants were harvested for 
subsequent analysis (section 2.9).   
 miRNA Mimic/Inhibitor Transfections 2.3.2
In order transfect primary human chondrocytes, the following transfection 
reagents were tested: Lipofectamine® (Thermo fisher), DharmaFECT 3 
(Dharmacon) and TransIT TKO ® (Mirus Bio LLC). Transfection efficiency was used 
to determine which reagent was optimal for transfecting the miRNA mimic into 
the cell. Analysis of the transfection efficiency was conducted by evaluating the 
percentage of cells that were positive for the control inhibitor conjugated to 
alexa fluor 488 (imaged using the MAQSQuant flow cytometer). The most 
efficient transfection reagent was determined to be DharmaFECT 3.   
2.3.2.1 DharmaFECT 3 
DharmaFECT 3 was used according to the manufacturers instructions.  MiRNA 
mimics were all used at a final concentration of 25nM. Briefly, DharmaFECT 3 
(2µl) was diluted into 50µl serum free media (DMEM, 1% P/S and 1% L-Glutamine) 
and incubated at RT for 5mins. MiRNA mimic or control mimic were diluted in 
serum free media to obtain a concentration of 250nM and incubated for 5 mins 
at RT. DharmaFECT 3 and the miRNA or control mimic were combined to  create 
a transfection solution and incubated at RT for a further 20 mins.  Fresh   
complete media (400µl) was added to the cells along with 100µl of the 
transfection solution, creating a final concentration of 25nM mimic or control in 
each well.  
 
  79 
 
2.4 SW1353 Cell Stimulations 
SW1353 cells (human chondrosarcoma cell line) were plated at a variety of 
seeding densities depending on the passage of the cells.  Cells were plated and 
left O/N at 37C before being stimulated for either 3, 8 or  24 hours with the 
following cytokines BMP-7, IL-1β, TGFβ, IL-6 or TNFα (PreproTech) at a variety 
of concentrations: 5, 10, 50 and 100ng/ml or in combination (see figure legend 
for specific details for each experiment). Cells were lysed in Qiazol® and stored 
at   -20C for mRNA analysis (section 2.6).     
2.5 Primary Human Macrophage Cultures 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood using a 
histopaque (Sigma Aldrich) density centrifugation (section 2.1.1).  The Scottish 
National Blood Transfusion Service supplied concentrated blood, increasing the 
numbers of PBMCs available. Monocytes were isolated from the PBMCs using a 
CD14/CD16 negative selection kit (carried out by Simone Kidger or Lewis 
Rodgers). The monocytes were plated at 1 x 106/ml and in complete RPMI with 
the addition of 100ng/ml M-CSF (PreproTech). Cells were then left to 
differentiate into macrophages for 6 days at 37°C, 5% CO2.  On day 6, cells were 
either primed with IFNγ (PreproTech) 20ng/ml overnight (M1), or placed in fresh 
M-CSF supplemented media as appropriate. On day 7,cells were stimulated as 
required with either IL-4 (PreproTech) 100ng/ml (M2), BMP-7 100ng/ml 
(M0+BMP-7) or M-CSF 100ng/ml (M0/M1). At this point some cells were also 
challenged with lipopolysaccharides (LPS) from Salmonella Minnesota (Sigma 
Aldrich) 15ng/ml. Stimulations were carried out for 24 hours before supernatants 
were harvested and stored at -20C for subsequent analysis (section 2.9).  Cells 
were lysed in Qiazol® and processed for RNA extraction (section 2.6).   
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2.6 RNA Extraction and cDNA Synthesis 
 miRNeasy Mini Kit    2.6.1
RNA was extracted using the miRNeasy mini kit (QIAGEN®) following the 
manufacturers protocol. All centrifugation steps were at RT unless otherwise 
stated. In short, 140µl chloroform (Sigma Aldrich) was added to the sample 
which had previously been lysed in QIAzol®. This was then shaken at RT for 5 
min. Samples were then spun at 12,000g for 15mins at 4°C and the resulting 
upper aqueous phase was transferred to a new eppendorff.  Ethanol was added 
at approximately 1.5X the volume of the aqueous phase and mixed thoroughly by 
pipetting.  The sample was transferred to an RNeasy® mini column and spun at 
>8000g for 30sec. Flow through was then discarded. RWT Buffer was added to 
the spin column and the spin step was repeated. Flow through was again 
discarded. RPE buffer was then added to the spin column and spun as before. A 
further 500µl RPE buffer was added to the column and this was spun at >8000g 
for 2 min, flow through was then discarded.  The column was transferred to a 
new 2ml collection tube and spun for 1min at full speed to dry the column. The 
RNeasy® Mini column was placed in a new 1.5ml collection tube and 30µl RNase 
free water was added to the center of the RNeasy® Mini column membrane. This 
was spun for 1 min at full speed to elute the purified RNA. RNA concentration 
was determined (section 2.6.4) and was then stored at -20C.  
 DNase Digest 2.6.2
For all primary chondrocyte RNA extractions carried out for MRNA analysis a DNA 
digest step, using DNase Set – RNase Free kit (QIAGEN®), was included. RNA was 
processed as previously described up to the addition of the RWT buffer. At this 
point 350µl RWT was added to the column and centrifuged at >8000g for 30 secs 
at RT. Flow through was then discarded. 10µl DNase1 and 80µl RDD buffer were 
then added to the column and left at RT for 15 mins.  A further 350µl RWT 
buffer was added to the column before it was spun >8000g for 30 secs at RT. The 
flow through was then discarded. The RNA extraction then proceeded as outlined 
above with the addition of RPE buffer.  
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 Serum and Plasma Extraction with C.Elegans miR39 Spike 2.6.3
Plasma and synovial fluid from OA patients (sections 2.1.1/2.1.2) was taken and 
subject to RNA extraction.  The columns from the miRNeasy® kit (detailed 
previously) were used with the QIAGEN® protocol for their serum and plasma kit.  
In short, 200µl plasma or synovial fluid was added to 1ml Qiazol®. To this, 
1.6x108 copies/µl of miR 39 (miRNeasy® Serum/Plasma Spike-In Control, 
QIAGEN®), were also added. Choloroform, 200 µl, was added and tubes were 
shaken and incubated for 3mins at RT before being spun at 12,000g for 15min at 
4°C.  The upper aqueous layer was then transferred to a fresh tube and mixed 
with 1.5X 100% ethanol. The resulting mixture was then added to a spin column. 
The column was spun at >8000g for 30 secs at RT and the flow through was 
discarded. RWT buffer was added to the column and spun as before.  RPE buffer 
was added and the column spun as before. Flow through was again discarded. 
500µl 80% ethanol was added to the column and spun at 8000g for 2 mins at RT.  
The spin column was then transferred to a fresh 2ml collection tube and 
centrifuged at full speed for 1min at RT to dry the membrane.  The column was 
then placed in a 1.5ml eppendorf and 14µl RNase free water was added to the 
membrane to elute the RNA. RNA was stored at -20C.  
 RNA Quantification 2.6.4
RNA concentration was assessed using a NanoDrop 2000 spectrophotometer 
(Thermo Scientific) and the NanoDrop™ software (Thermo Scientific). The 
260/230 values were used to assess RNA purity and 260/280 to assess 
contamination.  
 cDNA Synthesis 2.6.5
2.6.5.1 AffinityScript™ 
RNA was converted to cDNA using AffinityScript™ cDNA synthesis kit (Agilent) 
following the manufacturers instructions. Unless otherwise stated cDNA was 
synthesised at 5ng cDNA/µl.  A volume of  10µl RNA at a concentration of 
10ng/µl was added to 3µl random primers (0.1µg/ml) and 2.7µl RNase® free 
water. This was incubated at 65°C for 5mins then cooled to 20°C for 10mins.  To 
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this, 0.5µl RNase block ribonuclease inhibitor (40U/µl), 0.8µl dNTP’s (100mM), 
2µl AffinityScript RT Buffer (X10) and 1µl AffinityScript multiple temperature 
reverse transcriptase RT were added, bringing the total volume to 20µl. This was 
then incubated at 25°C for 10 mins, 42°C for 5mins, 55°C for 60mins, 70°C for 
15mins and finally cooled to 4°C. All temperature adjustments were made using 
a 2720 thermal cycler (Applied Biosystems).   
2.6.5.2 Miscript ® 
cDNA synthesis from the cartilage for miRNA analysis was carried out using 
MiScript® reverse transcription kit (QIAGEN®). In short, 10µl RNA at a 
concentration of 10µg/µl was added to 4µl miScript® HiFlex buffer (5X), 2µl 
miScript® nucleics mix (10X), 2µl RNase™ free water and 2µl MiScript® reverse 
transcriptase.  This was incubated at 37°C for 60mins followed by 95°C for 
5mins. Incubations were carried out using a Veriti 96 well thermal cycler 
(Applied Biosystems).  After the incubation 200µl RNase® free water was added 
to the RNA, resulting in a final cDNA concentration of 0.45ng/µl.    
For plasma 10µl of the RNA at an unknown concentration was used to make the 
cDNA using the same protocol.  This was carried out in order to keep the 
concentration of the spike in control, miR 39, consistent over all the samples.   
2.7 Polymerase Chain Reaction (PCR) 
 Endpoint Polymerase Chain Reaction (PCR) 2.7.1
2.7.1.1 Nested PCR 
PCR for endpoint analysis was carried out using MyTaq Red™ (Bioline) following 
the manufacturers instructions.  In short, 10ng cDNA was added to 25µl MyTaq 
Red™ master mix along with 1nM final concentration of ‘outside’ BMP-7 forward 
(3’GACGCTGGTCCACTTCATC5’) and reverse primers 
(5’GAGCAATGGAGGATCCAGAAA3’), and 21µl of RNase® free water. A non 
template control (NTC) which included all the components of the reaction 
excluding the cDNA was also set up. In the NTC, cDNA was substituted by 2µl 
RNase® free water.  A PCR reaction was carried as follows; samples were 
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incubated at 94 °C for 5 mins, followed by 35 cycles of 94°C for 15sec, 55°C for 
30secs and 72°C for 30sec and a final incubation at 72°C for 10mins before 
cooling to 4°C. All temperature-controlled incubations were carried out in a 
2720 thermal cycler (Applied biosystems). Samples were run on a 1.8% agrose gel 
containing 0.015% ethidium bromide with 10µl of sample loaded per well. The 
gel was run for approx. 45 mins with a current of 110V in Tris-base, acetic acid 
and EDTA (TAE) buffer.  The product from the 1st PCR (2µl) was added to fresh 
myTaq red™ master mix and RNase® free water as before. However ‘inner’ BMP-
7 forward (3’CCACTTCATCAACCCGGAAA5’) and reverse primers 
(5’GAGCAATGGAGGATCCAGAAA3’) were added to the samples. Another PCR 
reaction was run using the same conditions as previously stated. This resulted in 
a total of 70 PCR cycles. A second NTC was also set up using 2µl of the NTC 
reaction from the first PCR. The product for the second PCR was then taken and 
run on a 1.8% gel containing 0.015% ethidium bromide. The gel was run for 1hour 
at 110 volts in TAE buffer and visualised as before using the AlphaImager ™ 
(Alpha Innotech).     
 Quantitative Polymerase Chain Reaction (qPCR)  2.7.2
2.7.2.1 TaqMan® Analysis 
Transcript analysis with TaqMan® primer probes was carried out as follows. 5µl 
TaqMan® master mix, without uracil N-glycosylase (UNG) was combined with 0.5 
µl TaqMan® primer probe and 3.5 µl RNase® free water. cDNA at a 
concentration of 5ng/ul was added to the 9µl of the above combined reagents, 
and the total 10µl solution was added to a 384 well plate for each sample in 
triplicate. A NTC was also set up for each gene analysed. The following thermal 
cycle was applied to the plate using a 7900 HT fast real-time PCR machine 
(Applied Biosystems); 10 minute incubation at 95°C followed by 40 cycles of 
95°C for 15 secs and 60°C 1 min, using SDS software (version 2.4). Analysis was 
conducted using RQ manager (version 1.2.1) (Applied Biosystems).  
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2.7.2.2 Power SYBR® Analysis 
Power SYBR® green was used for analysis of mRNA transcripts. A total of 3ng 
cDNA (equivalent of 0.6µl cDNA) was added to 5µl power SYBR® green, and 1nM 
of forward and reverse primers (0.1µl of each primer) see table 2.3 for primer 
sequences. This mix was added to each well in a 384 well plate and was made up 
to 10µl with RNase free water. Each sample was run in technical triplicate, and 
each gene run had an associated NTC. Plates were run on a 7900 HT fast real-
time PCR machine (Applied Biosystems), using SDS (version 2.4) software and 
analysed using RQ manager (version 1.2.1) both from Applied Biosystems. The 
following thermal profile was applied to all samples, 50°C 2mins, 95°C 10mins 
then 40 cycles of 95°C 15secs and 60°C 1min.   
2.7.2.3 MiScript SYBR Green Analysis 
MiScript SYBR® green allows the quantification of miRNAs following MiScript® 
reverse transcription cDNA synthesis. cDNA at a final concentration of 
0.025ng/µl  was added to 5µl MiScript SYBR® green, 1µl miRNA specific primer 
(QIAGEN®), 1µl universal primer (QIAGEN®). This was added to each well of a 384 
well plate and brought to a final volume of 10µl with RNase® free water. Each 
sample was analysed as a technical triplicate and a NTC was also set up for each 
gene analysed. Plates were run on a 7900 HT fast real-time PCR machine 
(Applied Biosystems), using SDS (version 2.4) software from Applied Biosystems. 
The plate was incubated for 15 mins at 95C  before being subject to 40 rounds 
of PCR with the following conditions, 94°C for 15secs, 55°C for 30secs and 70°C 
for 30secs. All data collection was carried out at the final step in each cycle.  
Analysis was carried out using RQ manager (version 1.2.1) from Applied 
Biosystems.  
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Gene Size Forward Primer Reverse Primer  
BMP-7 216 GACGCTGGTCCACTTCATC GAGCAATGGAGGATCCAGAAA 
BMPR2 120 GACAGGAGACCGTAAACAAGG CCATATCGACCTCGGCCAATC 
COL1A1 140 GAGGGCCAAGACGAAGACATC CAGATCACGTCATCGCACAAC 
COL2A1 244 TGGACGATCAGGCGAAACC GCTGCGGATGCTCTCAATCT 
FOLLISTATIN 128 GAGCAATGCAAACCTCACAAG CAGTGTCCATCGTAATCAACCTG 
AGGRECAN 81 ACTCTGGGTTTTCGTGACTCT ACACTCAGCGAGTTGTCATGG 
CD44 109 CTGCCGCTTTGCAGGTGTA CATTGTGGGCAAGGTGCTATT 
ACVR1 77 GTGAAGGTCTCTCCTGCGGTA GCCATCGTTGATGCTCAGTGA 
GREMLIN 1 151 TCATCAACCGCTTCTGTTACG GCTGTAGTTCAGGGCAGTT 
BMPR1B 130 TTTTGCGAAGTGCAGGAAAAT TGTTGACTGAGTCTTCTGGACAA 
Furin 187 CCTGGTTGCTATGGGTGGTAG AAGTGGTAATAGTCCCCGAAGA 
 
Table 2-3 Primers sequences as found using the online resource Primer Bank 
(https://pga.mgh.harvard.edu/primerbank/).  
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 Digital ddPCR™ (Bio-Rad) 2.7.3
Digital PCR was carried out on the cartilage and synovium. Bio-Rad supplied all 
machines for this protocol. cDNA (2µl) from cartilage or synovium at a 
concentration of 2ng/µl, was added to 10µl ddPCR™ master mix with Taqman® 
specific probe and 8µl RNase® free water.  This solution was then added into the 
droplet generator cartridge along with 70µl ddPCR™ droplet reader oil. This was 
then placed into the QX200 droplet generator, creating 20,000 droplets for each 
sample, with a random distribution of target positive and negative cDNA in the 
droplets. The droplets were then transferred to a 96 well plate where they were 
subject to PCR using a thermal cycler (C100 touch, Bio-Rad).  The droplets now 
with the amplified cDNA were then read by the QX200 droplet reader. Positive 
droplets contain target cDNA are detected based on the incorporation of the 
fluorophore from the TaqMan® primer. Quantasoft software then measured the 
number of positive and negative samples and the Poisson algorithm was used to 
calculate the number of copies per µl of cDNA.  
 qPCR Data Quantification 2.7.4
Analysis for qPCR data was conducted as follows. CT values for the gene of 
interest were subtracted form the CT values from the housekeeping gene giving 
the ΔCT.  This was then either converted into 2-ΔCT or was used to calculate fold 
change 2-ΔΔCT (2-((ΔCT) (gene of interest )- ΔCT ( control))) . 
2.8 Immunohistochemistry 
 Sample Fixation and Processing  2.8.1
Cartilage and synovium samples were fixed in 10% neutral buffered formalin 
(Leica Biosystems) for approximately 2 weeks before either being stored in 70% 
ethanol (synovium) or being decalcified (samples containing bone). 
Decalcification was carried out via rotation in EDTA buffer for approximately 2 – 
4 weeks. EDTA was refreshed every 2-3 days for the first week then every week 
thereafter. Following decalcification, samples were stored in 70% ethanol.  All 
samples were then penetrated with wax using a Shandon CITADEL 1000 (Thermo 
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Scientific). The samples are placed into cassettes and subject to the following: 
30mins 70% ethanol, 1hour 70% ethanol, 1 hour 90% ethanol, 1hour 95% ethanol, 
2 hours 100% ethanol, 2.5 hours 100% ethanol, 3 hours 100% ethanol, 2 hours 
xylene, 2 hours xylene, 2.5 hours xylene, 5 hours wax, 6 hours wax (When the 
same reagent is used in subsequent stages, fresh solution is used unless 
otherwise stated).  After wax penetration, the samples were embedded into wax 
blocks and cooled to 4C , allowing the wax to set. The blocks were then stored 
at room temperature until needed.  Blocks were pre-cooled to 4C  before 2-
4µm sections were cut using a stainless steel feather microtome blade, N35HR 
(PFM Medical). In some cases Mollifex® (VWR) was used to soften the cutting 
edge of the tissue.     
 IMMPRESS Method 2.8.2
Sections were placed in a 60C  oven for 1 hour to allow the wax to soften. 
Sections were then hydrated as follows: xylene 5mins, xylene (fresh) 5mins, 
100% ethanol 3mins, 95% ethanol, 90% ethanol 3mins, 70% ethanol 3mins, running 
water 5mins. The sections were then washed in Tris-buffered saline, 0.05% 
Tween20 (TBST) for 5mins. For all cartilage sections, antigen retrieval was 
carried out with an overnight incubation in Unitrieve (Gentaur) at 42C . 
Synovial sections were exposed to heat induced antigen retrieval method. Slides 
were immersed in boiling 0.01M citrate buffer and boiled for a further 8mins. 
Peroxidase activity was then quenched using a 30min incubation in 0.5% 
hydrogen peroxide in methanol (both Sigma Aldrich). Sections were blocked with 
2.5% horse serum (Vector) and 2.5% human serum for 30mins followed by a 
30mins FC block (Innovex Biosciences). The BMP-7 primary antibody either raised 
against the whole protein (ab54904 Abcam) or against the pro region of  BMP-7  
(ab56023 Abcam) was added at 6µg/ml along with the appropriate isotype 
control either mouse monoclonal IgG1 or rabbit polyclonal DA1E mAB IgG (Cell 
Signalling) respectively.  These were then incubated in a humidity chamber at 
4°C O/N. Slides were brought back to RT and washed for 5mins in TBST then 
5mins in distilled water. A species specific ImmPRESS™ (Vector) kit was then 
added to the slides for 1hr: total BMP-7 – mouse ImmPRESS™ or pro BMP-7 – 
rabbit IMMPRESS. Sections were then washed as before then incubated with 
ImmPACT™ DAB peroxidase substrate kit (Vector) until the desired stain intensity 
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developed. The sections were then rinsed in running water.  Nuclear staining 
was carried out with haematoxylin (Cell Path) before the sections were 
dehydrated through alcohol back to xylene as follows. 70% ethanol (2 dips), 90% 
ethanol (20secs), 100% ethanol (2X 3mins) and finally xylene (2X 5min).  Finally 
slides were mounted with a cover slip in DPX mountant (Raymond A Lamb) and 
left to dry before images were taken with an Olympus BX41 microscope and 
analysed using Olympus cell B imaging software.  
2.9 Enzyme Linked Immunosorbent Assay (ELISA) 
 IL-6, IL-10, and TNFα  ELISA 2.9.1
IL-6, IL-10 and TNFα secreted into the supernatants from cultured macrophages 
under a variety of differentiation conditions were analysed using Cytoset assays 
(Life Technologies), following the manufacturers protocol. In short, plates were 
incubated with specific capture antibody at 4 °C overnight, followed by a PBST 
(Phosphate Buffered Saline, 0.05% Tween) wash.  Plates were then blocked in 
assay buffer (PBS + Bovine serum Albumin 0.5%) for 1hr at RT followed by PBST 
wash (X5).  Samples and standards were added to the plates, along with 
detection antibody and incubated on a shaker for 2hrs at RT. Plates were then 
washed as before. The top standards were diluted to 1000pg/ml for both IL-6 
and IL-10 and to a concentration of 2000pg/ml for TNFα. Strepavidin-horse 
radish peroxidase (HRP) was then added to the plates for 30mins and washed as 
before. Tetramethylbenzidine (TMB) (E-Biosciences) substrate was added to the 
plate. Once the assay had developed to the desired intensity, the reaction was 
terminated with the addition of 4N Sulfuric acid.  The plates were then read on 
a Tecan Sunrise™ absorbance reader and analysed with Magellan™ data analysis 
software. 
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  BMP-7 ELISA 2.9.2
Human BMP-7 Duoset ELISA development kit (DY354) (R&D Systems) was used to 
assess BMP-7 levels in plasma and synovial fluid samples, manufacturers protocol 
was followed.  In brief, plates were coated with capture antibody overnight at 
room temperature. Plates were then washed (X3) in PBST (Phosphate Buffered 
Saline, 0.05% Tween) in order to remove the excess capture antibody. The wells 
were blocked in reagent diluent (1% BSA in PBS) for 1 hour.  The plates were 
then washed (X3) before the addition of the patient samples and recombinant 
BMP-7 standards.  The top standard was diluted to a concentration of 4000pg/ml 
and all patient samples were incubated with heteroBlock (Omega Biologics) to 
eliminate non-specific binding before being added to the plate. Following 
standard and sample addition the plate was placed on a shaker at RT for 2 hours. 
The wash step was again repeated (X3), and the detection antibody at a 
concentration of 0.5µg/ml was added (reagent diluent supplemented with 2% 
heat inactivated normal goat serum was used to dilute the detection antibody). 
Plates were left to shake for 2 hours at RT, before being washed as previously 
stated. Streptavidin-HRP was then added into each well and incubated for 
20mins with shaking at RT. This was followed by a final wash and the addition of 
TMB substrate to the plate. Once the assay had developed to the desired 
intensity, the reaction was terminated with 4N Sulfuric acid.  The plates were 
then read on a Tecan Sunrise™ absorbance reader and analysed with Magellan™ 
data analysis software.  
2.10 Western Blot 
Protein lysates were created using RIPA buffer (Thermo Scientific) containing 1X 
HALT™ protease and phosphatase inhibitor cocktail (Thermo Scientific). The 
buffer was added on ice and the samples were shaken for 10mins before being 
spun at 20,000g for 10min at 4°C. Supernatant was then removed and stored at -
20°C.  Samples were loaded according to volume, with 40µl protein lysate being 
added to 1X NuPAGE sample reducing agent (Novex Life Technologies) and 1X 
NuPAGE sample buffer (Novex Life Technologies).  The solution was then boiled 
at 95°C for 5mins, denaturing the protein content of the sample. A NuPAGE 4 -12 
% Bis Tris gel (Novex Life Technologies) was loaded with 30µl of sample per well, 
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NOVEX® Sharp pre-stained protein ladder (10µl) (Novex Life Technologies) was 
also loaded onto the gel.  Samples were run in 1X NuPAGE MOPS SDS running 
buffer for 1hour using a 200V current.  Following this, gels were transferred onto 
a nitrocellulose membrane using the iBlot system (Thermofisher).  Efficiency of 
transfer was assessed using Ponceau Red (Sigma Aldrich) staining.   
For specific protein detection the membrane was blocked in 5% milk (Marvel) in 
TBST for 1 hour at RT with shaking. Membranes were then incubated with BMP-7 
antibody raised against the pro region of BMP-7, 1µg/ml (ab56023 rabbit 
polyclonal, Abcam) at 4C  O/N with shaking. Membranes were then washed (X3) 
in PBST before the appropriate secondary antibody conjugated to HRP was 
diluted at 1:1000 in TBST and added to the membrane shaking for 1 hour at RT. 
Secondary antibody was a polyclonal goat anti rabbit immunoglobulin/HRP 
(Dako). The membrane was washed as previously stated, the HRP substrate 
WestPico (Thermofisher scientific) was added to the membrane and the 
chemiluminescence was visulaised using the C500 gel imager (Azure Biosystem) 
and the C series software program (Azure Biosystem).  
Membranes were stripped using Restore™ western blot stripping buffer (Thermo 
Scientific). Stripping buffer  was incubated with the membrane for 15 mins at 
37°C then for 15 mins at RT shaking.  Housekeeping analysis was then carried 
out on the membrane. The membrane was blocked in  5% milk, followed by the 
addition of the HRP conjugated GAPDH (D16H11) XP (R) Rabbit antibody (Cell 
Signalling) for  approximately 2 hours shaking at RT.  WestPico addition and 
analysis was conducted as previously stated.   
2.11 Luminex Assay 
Analysis of a panel of inflammatory cytokines in the supernatants from primary 
chondrocyte cultures was carried out using a human cytokine 14 plex assay (Life 
Technologies). Analytes included IL-1β, IFNα, IL-6, IL-12, RANTES, MIP-1α, MIP-
1β, GM-CSF, MCP-1, IL-Rα, IL-17, IP-10 and IL-2R, IL-8.  The assay was carried 
out as per manufacturers instructions.  Analysis was conducted using the Bioplex 
systems platform (Biorad).  
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2.12 In Silico Analysis 
In Silico analysis was carried out on ATTA binding sites for the 3’UTR of the BMP-
7 transcript using AREsite2 (http://nibiru.tbi.univie.ac.at/AREsite2/welcome).   
2.13 Statistics 
All statistical analysis was carried out using Graphpad Prism version 6e. The 
specific tests that have been applied are outlined in each figure legend.  Where 
appropriate, D’Agostino-Pearson normality test was applied in order to 
determine if the data displayed a Gaussian distribution. In this study a P value of 
0.05 was considered significant, with * P<0.05, ** P<0.01 and  *** P<0.001.  
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3 Optimisation of cartilage analysis techniques for 
ex vivo and in vitro studies 
3.1 Introduction 
Osteoarthritis (OA) is a common degenerative disease of the joint, whereby all 
elements of the joint can display pathology. However, one of the overarching 
features of this disease is cartilage erosion. Cartilage is a fundamental 
component of the joint and is mainly comprised of ECM. The ECM constitutes 90% 
of the total cartilage volume (211), with the remaining 10% being comprised of 
chondrocytes, the only cell present in the cartilage.  As cartilage is one of the 
main tissues involved in OA pathogenesis it is imperative to understand what is 
happening to this tissue in a disease setting.  To this end, acquisition of tissue 
from OA patients undergoing total or partial knee replacement offers great 
insight into the end stage of OA. There are, however, challenges within the field 
regarding the acquisition of high quality genetic information from this tissue due 
to its sparse acellular nature. 
Previously, other groups have tried several methods of RNA extraction from 
cartilage with all reporting varying levels of success. As stated above, one of the 
main issues facing extraction of good quality RNA is the scarcity of cells (212). 
However, this is not the only problem, the high abundance of proteoglycans 
present in the tissue also poses difficulties as these are often co-purified along 
with the RNA (212). Historically this has hindered the study of transcripts in 
these cells in a direct ex vivo setting, with many studies resorting to culturing 
the cells before molecular analysis (212). As this study aims to look at the 
cartilage in an ex vivo capacity it is essential to determine and optimise the 
most efficient method for RNA extraction.  Over recent years, groups have 
worked on new protocols for the extraction of RNA from cartilage.  A popular 
technique is to freeze the tissue in liquid nitrogen and grind it into a powder 
before the addition of lysis buffer and subsequent RNA analysis (212-214). 
Alternatively, the ECM can be enzymatically digested releasing the 
chondrocytes, which can then be lysed.   
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Grinding the tissue before homogenisation is a popular method of ex vivo 
analysis, with a various versions of this method that that have been optimised. It 
has been suggested that all equipment should be kept at a steady temperature 
via incubation in liquid nitrogen (212,213), thus making the tissue more brittle.  
This works well if a tissue mill is available, however, if a mortar and pestle are 
the only available tools for grinding the tissue, this is not always practical for 
the user, as only the tissue can be snap frozen. Further to this, many protocols 
suggest that once the tissue had been ground and the lysis reagent had been 
added, the sample should be spun at a high speed for a prolonged period of time 
ranging from 10mins – 60mins (212,213). Most of the optimisation for grinding 
the tissue has been done in order to facilitate the extraction of RNA from small 
tissue samples, thus the time taken to carry out the homogenisation is not a 
limiting factor. However for the current study, large tissue samples are to be 
obtained, which must be taken into consideration, as time to homogenise the 
tissue may become a limiting factor. Due to impracticalities the incorporation of 
all of these factors into a protocol for RNA extraction is not always feasible.   
Enzymatic digestion has been used as a method of chondrocyte release from the 
ECM before RNA extraction.  Manning and Bonner detailed a protocol for this 
method in 1967. The use of a short trypsin incubation followed by a longer 
collagenase (6-18hr) incubation has been widely reported for the release of the 
cells from the tissue (214).  Further work has been carried out in the field to 
define the optimal method of digestion with one group comparing combinations 
of collagenase II, trypsin/EDTA and tosyl-lysyl-chloromethane. They reported 
that when used in combination the yield of chondrocytes from cartilage samples 
was not improved, but the time taken to digest the cells was reduced. One of 
the drawbacks of digesting the cells in a collagenase mix is that the most of the 
traditional commercially available collagenase is distilled as a by-product of 
bacterial fermentation (Sigma-Aldrich). This may cause issues if the cells that 
are being digested can be activated or altered by bacterial stimuli.  Liberase™ is 
an alternative enzyme blend of both collagenase I and collagenase II that has not 
been purified from bacteria (Roche). Therefore does not run the risk of 
activating the cells.  Previous data generated in the McInnes lab have confirmed 
that digestion with Liberase™ is as effective as digestion with conventional 
digestion reagents.  
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For the study of ex vivo chondrocytes it is essential to determine what 
processing method is optimal with the practical restraints in place, whether 
mortar and pestle processing or Liberase™ digestion will give the optimal RNA 
quality.  By ensuring the best possible isolation of the RNA, better analysis of 
both the mRNA and miRNA of interest from the chondrocytes can be conducted. 
Isolating high quality genetic information from the cartilage for ex vivo analysis 
is not the only hurdle that must be overcome.  It is known that during the 
prolonged culture of primary chondrocytes dedifferentiation of the cells can 
occur. Here, primary chondrocytes will be not only be analysed ex vivo, but they 
will also be cultured in vitro in order to perform functional studies to ascertain 
the role of exogenous BMP-7. Hence, it is important to ensure to that the 
primary chondrocyte cultures phenotypically resemble in vivo chondrocytes as 
much as possible. Current literature suggests that after isolation from the 
cartilage, chondrocytes can lose their phenotype over time. This is most notably 
observed in changes to ECM components, with type II collagen and aggrecan 
decreasing as passage number increases and type I collagen expression 
increasing. This suggests an alteration in phenotype in proliferative chondrocytes 
(215). Many other studies have looked at the loss of the differentiated 
phenotype in chondrocytes in long term culture. It has been shown in both rabbit 
and human epiphyseal chondrocytes that long term culture again results in loss 
of phenotypic type II collagen and proteoglycans, as well as up-regulation of 
type I pro collagen (216,217).  Previous studies tended to look at phenotypic 
drift in chondrocytes that are encouraged to proliferate over increasing 
passages, however looking at the phenotypic profile of the cells in a confluent 
environment over short term cultures has not been well defined.    
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3.2 Aim 
There are several methodological challenges to be addressed in order to obtain 
good quality RNA for molecular analysis of human articular cartilage ex vivo, as 
well as issues with phenotypic drift with primary chondrocyte cultures for 
functional in vitro studies. Therefore the overall aim of this chapter was to 
identify and optimise the most appropriate techniques for working with the 
cartilage over the duration of the study.  The aims were further broken down as 
follows, 
1) Determining optimal technique for extraction of high quality RNA from 
cartilage. 
2)  Deducing the most appropriate method of cDNA synthesis and 
determining the optimal housekeeping genes for qPCR analysis.  
3) Defining the chondrocytic phenotype in short term cultures and 
identifying the optimum window for use for in vitro assays before 
dedifferentiation occurs.  
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3.3 Results 
 Optimisation of Cartilage Processing for Molecular Analysis. 3.3.1
In order to analyse cartilage ex vivo from OA patients, it first had to be excised 
from individuals under going total or partial knee replacement.  From here 
samples were either processed via mortar and pestle homogenisation or by 
Liberase™ digestion (Figure 3.1). Mortar and pestle homogenisation was carried 
out after the tissue was snap frozen in liquid nitrogen. This process involves the 
lysis of the whole tissue, including ECM. The tissue was ground into a powder 
and dissolved in Qiazol (phenol based lysis solution). When the tissue was 
processed using Liberase™ digestion, the extracellular matrix was dissolved 
releasing the chondrocytes. Digestion resulted in removal of the ECM and thus 
only cells of interest were lysed in Qiazol. The caveat to this method is that it 
took a considerable period of time for adequate digestion to occur. In order to 
evaluate which method produced purer RNA, determination of the most stable 
housekeeping genes was first carried out using qPCR analysis (Figure 3.2A). The 
resulting data suggested that individual patient CT values for the housekeeping 
gene β-actin were more consistent and displayed less variation from the 
median CT value when Liberase™ digestion was applied.  This was also reflected 
in the 260/280   values for RNA (Figure 3.2B) as Liberase™ gave significantly purer 
RNA, with less variation from the desired value of 2.   
From the data shown above, Liberase™ digestion was taken forward as the 
system of choice for tissue processing. Next, housekeeping genes were 
investigated to determine the optimal normalisation control for mRNA analysis 
with regards to chondrocytes.  In the first instance, the housekeeping genes β-
actin, GAPDH and ribosomal RNA (rRNA)18s were investigated (Figure 3.3A).  The 
data show that the CT values for rRNA 18s were detected between cycles 5-9, β
-actin between 15-18 and GAPDH between 31-35.  Variation in housekeeping CT 
values across the patients was minimal (Figure 3.3Bi).  The effect of chondrocyte 
origin, e.g. from eroded versus non-eroded regions of cartilage, was also 
investigated in order to determine if this would impact housekeeping expression 
(Figure 3.3 Bii). Tissue was classified as follows, eroded cartilage had an 
Outerbridge score between II-IV and non-eroded had a score between 0-I (Table 
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2.1). Regardless of whether or not chondrocytes were harvested from non-
eroded or eroded tissue, extraction of RNA from the isolated cells resulted in 
good quality RNA that again displayed minimal disparity in the CT values for 
each gene. As all genes were consistent across the different patients and in 
eroded and non eroded cartilage, β-actin was taken forward as the candidate 
housekeeping gene for all further studies, as it had the most optimal CT value 
range compared with 18S (which was too low) and GAPDH (which was too high). 
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Figure 3.1 RNA Extraction Methods from Human Articular Chondrocytes. 
Diagrammatic representation of two RNA extraction methods used for human articular cartilage: 
mortar and pestle homogenisation and Liberase™ digestion. A 12-hour digestion was carried out 
with the Liberase™ as shorter incubations resulted in insufficient breakdown of the ECM.  
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Figure 3.2 Liberase Digestion Offers Optimal Cartilage Processing Compared to Mortar and 
Pestle Method.  
A) House keeping gene β-actin expressed as a CT value from cDNA generated either using a 
mortar and pestle (N=7) or Liberase™ digestion  (N=10). B) RNA purity determined by 260/280 ratio 
for RNA extraction via mortar and pestle, N=3 (Average of 5 cartilage sections per patient) or 
Liberase™ digestion, N=4 (Average of 6 cartilage sections per patient).                                     
Mann Whitney test P< 0.0001 ****.     
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Figure 3.3 mRNA Housekeeping Comparison β-Actin, 18s and GAPDH. 
 A) Housekeeping analysis of βactin and rRNA 18s, values shown as CT, N=4.  B) i. Housekeeping 
comparison for β-actin, GAPDH and rRNA 18s N=3. B) ii. Comparison of housekeeping genes β-
Actin, GAPDH and rRNA 18s  across non eroded (cartilage intact with no noticeable fissuring – 
Outerbridge score 0-1), and eroded (cartilage with fissuring and erosion typically down to the bone 
– Outerbridge score 2-4) tissue. Values shown as CT,  N=3.  
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As miRNA analysis was also desirable for this study, a normalization gene for 
miRNA work was also considered. The current gold standard for miRNA 
housekeeping is the small non coding RNA U6. Therefore U6 expression was 
investigated and it was found to be detectable with a mean CT value of 15 
(Figure 3.4A). When the cartilage was defined as either eroded and non-eroded, 
minimal variation was again observed between the CT values (Figure 3.4B). 
Finally, the expression of U6 was interrogated across all samples taken from the 
joint: femoral notch biopsy, DMC, DLC, PMC, PLC, MTP, LTP and synovial 
membrane (Figure 3.4C).  Variation was evaluated using standard deviation (SD). 
The average SD across all samples was 1.1, thus indicating relatively small 
differences in each compartment across 5 patients. Evaluation of an alternative 
housekeeping gene, U1, was also carried out (data not shown). Again, minimal 
variation was observed between and within the patients. Therefore, as U6 is the 
standard housekeeping for miRNA analysis in the lab and there were no 
additional benefits of using U1, it was decided that U6 would be taken forward 
as the miRNA normalization gene for the remainder of the study.  
Having established the most appropriate housekeeping genes for transcript and 
miRNA analysis, the next step was to determine the most optimal kit for cDNA 
synthesis with regards to mRNA detection. Ideally, the use of one cDNA synthesis 
kit that would allow for the detection of both miRNA and mRNA would be most 
practical. To this end, investigation of cDNA synthesised from affinity script (2 
phase reactions optimised for mRNA) or MiScript (one phase reaction optimised 
for both miRNA and mRNA) was carried out. Two chondrocyte specific genes, 
type II collagen (COL2A1) and MMP-13, and one BMP associated gene, BMP 
receptor ACVR1 (ALK2), were used to screen for variation between the two cDNA 
synthesis methods (Figure 3.5). cDNA synthesised from the one phase MiScript kit 
gave consistently higher CT values (CT value >30 ) than the affinity script kit 
(Figure 3.5A).  COL2A1, β- actin and ALK2 all showed substantial variance in CT 
values when comparing AffinityScript to MiScript.  
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Figure 3.4 U6 Housekeeping for miRNA Analysis 
A) U6 expression in cartilage shown as CT, N=10.  B) U6 comparison between non eroded 
(cartilage intact with no noticeable fissuring – Outerbridge score 0-1), and eroded (cartilage with 
fissuring and erosion typically down to the bone – Outerbridge score 2-4) tissue. Cartilage taken 
from a total of 7 areas of the joint over 2 patients. C) U6 analysis in cartilage taken from 7 different 
articular areas of the knee along with synovium from the corresponding joints, N=5. Error bar 
represents standard deviation (SD).  
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To determine whether the method of cDNA synthesis skewed the data, it was 
normalised to a housekeeping gene. The CT value for the housekeeping gene was 
subtracted from the CT value of the genes of interest before it was transformed 
to 2-ΔCT (2^- (CT gene of interest – CT house keeping)). If the cDNA synthesis method had no 
bearing on the results, it would be expected that the data would have a similar 
trend in expression despite any differences in the CT values. The data show that 
COL2A1 expression was similar in all chondrocytes regardless the cDNA kit used 
(Figure 3.5Bi), whereas ALK2 (Figure 3.5Bii) displayed clear disparity in 
transcript expression between kits. The MiScript kit showed significantly 
increased expression of ALK2 in the DMC and MTP compared to the PMC, whereas 
the AffinityScript kit showed consistent expression of this gene. Similarly 
disparity was observed in MMP-13 expression between the kits (Figure 3.5Biii). As 
there were noticeable inconsistencies in gene expression between the two 
different kits, it was not possible to rely on one kit for the analysis of both the 
miRNA and the mRNA. It was therefore decided that miScript would be used for 
all miRNA analysis, however affinity script would be used for all subsequent 
cDNA synthesis for mRNA analysis. The CT values obtained using AffinityScript 
were all consistently below 30 for the majority of the genes investigated, 
whereas the miScript cDNA reported CT values of up to 36 in this analysis. A CT 
value this high would normally indicate a gene that was not expressed. However, 
from the AffinityScript data, this is clearly not the case. 
 Chondrocyte Cultures for In Vitro Analysis. 3.3.2
As previously stated, part of this study will also focus on the effect of exogenous 
BMP-7 on chondrocytes in an in vitro setting. With this in mind, it must be 
considered that it has been widely reported that chondrocytes have a high 
tendency to lose their phenotype in culture (218). Therefore determining the 
most suitable time range for using cultured primary chondrocytes was a 
fundamental parameter in setting up this study. Three different culturing 
platforms were investigated: plastic alone, bovine collagen coated plastic or 
nanofibre plates.  The latter was chosen as the literature suggests that 
mimicking the ECM in culture can help the chondrocytes maintain their 
phenotype (219), (Figure 3.6).  
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Figure 3.5 AffinityScript and  miScript cDNA Synthesis Yield Different CT Values for mRNAs. 
cDNA was synthesised from cartilage (DMC, PMC, and MTP) and synovium with both AffinityScript 
and Miscript kits to enable direct comparisons of CT values (N=1). A) Table comparing the CT 
values for AffinityScript and MiScript cDNA over 4 different genes, ALK2, MMP-13, COL2A1 and 
housekeeping gene β-Actin. CT values for each cDNA synthesis kit are given along with the 
difference in CT values (miScript CT – AffinityScript CT). B) Expression of the three genes of 
interest shown as 2-ΔCT for both AffinityScript and Miscript cDNA. i) COL2A1 ii) ALK2  iii) MMP-13.  
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Previously, other groups have looked at the expression of COL2A1 (type II 
collagen) and aggrecan as positive markers of chondrocyte phenotype. COL1A1 
has also been studied, as up-regulation of this collagen is associated with 
dedifferentiation. Cells were plated for a maximum of 7 days, with daily analysis 
of the cells. The chondrocytes cultured on plastic plates appears to shown the 
least variation across time. The expression of COLA1 (type I collagen) in the 
plastic plates was stable for up the duration of the culture, whereas on the 
bovine coated plates it was altered by day 3 and on the nanofibre plates the 
expression was altered by day 5.  The expression of COL2A1 (type II collagen) 
was stable with the plastic culture plates for 4 days, after this the transcript 
expression dropped dramatically. The other platforms again showed slightly 
more variance in terms of the COL2A1 expression.  Finally aggrecan expression 
was assessed, it was observed that in both the plastic and bovine collagen plates 
there was a sharp increase in expression at day 4, which by day 5 had dropped 
back down below baseline, this was less pronounced in the nanofibre plate.   
In order to confirm cell viability and rule out cell death as a factor responsible 
to the change in transcript levels, cells were cultured for 96 hours and analysed 
using Flow Cytometry using the live dead marker DRAQ7. This demonstrated that 
chondrocytes kept in culture for 4 days displayed 80% cell viability at this time 
point (Figure 3.63B). It was therefore likely that the increased CT values were 
due to an altered transcript profile due to dedifferentiation rather than cell 
death due to prolonged culture. Analysis of the different platforms used for 
chondrocyte culture showed that there was very little variation in gene 
expression across the board and the cell behaved in a fairly similar fashion 
irrespective of the culture platform. Based on these finding chondrocytes were 
only kept in culture on plastic for a maximum of 4 days, as between 96 and 120 
hours, the transcript profile of the cells appeared to change, with a notable 
decrease in both COL2A1 and aggrecan.  
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Figure 3.6 Dedifferentiation of Primary Articular Chondrocytes in Culture After 5 Days. 
Chondrocytes cultured for 7 days in plastic, bovine collagen coated plastic or nanofibre plates. 
(N=1)  A) Fold change, (2-ΔΔCT,) was calculated for each gene of interest using the values at Day 1 
on each plate as a baseline, House keeping gene beta actin was used to calculate all  ΔCT values . 
i) Type I collagen ii) Type II collagen iii) Aggrecan .  B) i) Gating strategy to assess cell viability with 
DRAQ7 (APC-Cy7) data acquired using a MACSQuant Flow Cytometer and analysed using FlowJo 
Software.  ii) Percentage cell viability for 2 donors following a 4 day culture (donors are not the 
same as used in A).  
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3.4 Discussion 
From the data presented above, it was deemed that Liberase™ digestion was the 
optimal method for processing cartilage samples. Liberase™ gave the most 
consistent CT values for the housekeeping gene β-actin, and a significantly 
higher purity of the RNA compared to mortar and pestle processing (Figure 3.2).  
The most probable explanation for the increased purity of RNA from the 
Liberase™ digestion is the removal of the ECM matrix before lysis and spin 
column purification. With the mortar and pestle, both the chondrocytes and ECM 
components were ground into a powder in liquid nitrogen before being added to 
the column. Some literature states that spinning the samples for a prolonged 
period of time before ethanol is added increases RNA purity. The extra spinning 
step is used in order to try to remove some of the debris from the samples (213). 
As the samples here were not spun after, it is possible that the high salt solution 
added to facilitate RNA binding on the silica membrane is unable to efficiently 
distribute through the mixture and bind to the desired RNA due to the excess 
ECM debris present, thus giving rise to contaminated RNA. 
Assessment of housekeeping genes revealed β-actin, GAPDH and rRNA 18s were 
all detectable in the chondrocytes (Figure 3.3).  Expression of all three genes 
was consistent across three different donors. Classification of the cartilage via 
Outerbridge score as either non eroded (0-I) or eroded (II-IV) also had no impact 
on the expression of all three housekeeping genes. From these initial 
experiments, it was decided that β-actin would be the ideal house keeping gene 
to take forward. GAPDH was detected at a very late CT of around 34 and rRNA 
18s was detected at a very early CT of around 9, whereas β-actin was detected 
in range with the CT values for other genes of interest that had been 
interrogated.  MiRNA housekeeping genes U6 and U1 were also investigated. No 
difference in expression was noted between the eroded and non-eroded 
cartilage. All samples from the joint (femoral notch, DMC, DLC, PMC, PLC, MTP, 
LTP and synovial membrane) were analysed to check the consistency of U6 
between samples (Figure 3.4). Expression was found to be consistent across all 
samples.  As no differences were brought to light between consistency of U6 and 
U1 housekeeping gene expression, it was decided that U6 would be taken 
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forward as the normalisation gene for all miRNA analysis. This would also keep 
the study consistent with other miRNA work being carried out in the group.  
cDNA synthesis was carried out using either a two step reaction (AffinityScript) 
which is optimised for mRNA cDNA synthesis, or a one step reaction (MiScript) 
optimised for miRNAs and mRNAs. The transcript expression levels of ALK2, MMP-
13, COL2A1 and β-actin were investigated with both kits (Figure 3.5). It was 
hypothesised that any trends in the data would be present regardless of the 
manner in which cDNA was synthesised. This would be independent of any 
possible variation in CT values observed between the two types of cDNA (due to 
normalisation with a housekeeping gene). However, this was not the case, with 
obvious differences in the qPCR data generated.  MiScript one step reaction 
incorporates a poly A tail onto miRNAs, enabling oligo(dT) binding which initiates 
cDNA synthesis. At the same time the kit also uses random primers to create 
cDNA from mRNA transcripts. In this way it should be optimised for the detection 
of both miRNA and mRNA. AffinityScript uses a 2 step process with the first step 
denaturing the RNA and facilitating random primers annealing to the RNA at 
multiple points along the sequence. During the second phase of the reaction, 
primer extension occurs. The dNTPs and the reverse transcriptase enzyme are 
able to extend from the end of the primers sequence to the end to the RNA thus 
creating cDNA. Finally, termination of the reaction is carried out by a 70°C 
incubation.  The AffinityScript method uses a variety of temperature controlled 
steps to achieve optimal conditions for each stage of cDNA synthesis, whereas 
MiScript generates cDNA in a one temperature reaction. The use of a single 
temperature may not be as effective in creating cDNA from the mRNA present in 
the reaction. It is also possible the concentration of cDNA added to the qPCR has 
an impact. The miScript cDNA reaction is diluted to a final concentration of 
0.025ng/µl whilst the AffinityScript cDNA is diluted to 5ng/µl, which would 
account for the lower CT values (indicating higher levels of transcript 
expression) seen with AffinityScript. Without a clear answer for the differences 
obtained between the kits it was decided that for all analysis carried out on 
mRNA transcripts the AffinityScript kit would be used and for miRNA analysis the 
MiScript kit would be used.   
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It has been reported that chondrocytes in culture can dedifferentiate over time 
and lose their phenotype (215-217). Previous reports have shown that if 
chondrocytes are expanded in culture, expression of collagens and aggrecans are 
altered after the first passage (215). The main focus in the field thus far has 
been on phenotypic drift during expansion of the chondrocyte population in 
culture over several passages of the cells. This has been of interest 
therapeutically as these cells could potentially be grown in vitro, then be 
implanted into patients to promote extracellular matrix growth in areas where 
cartilage lesions have occurred. For the purpose of this study the 
dedifferentiation of chondrocytes was investigated over a shorter time period 
than in previous studies (7 days) and the cells were not encouraged to 
proliferate. The chondrocytes were cultured on plastic, bovine collagen coated 
plastic or nanofibre plates to determine if this had any effect on transcript 
expression. On all platforms the chondrocytes appeared to lose their 
transcriptional phenotype with regards to type II collagen expression after 96 
hours in culture  (Figure 3.6).  This is largely in agreement with the work carried 
out by Hamanda (2013), they also reported an increase aggrecan over time 
which is also see here most dramatically after 4 days in culture. From the data 
obtained showing alterations in gene expression after 96 hours, it was decided 
that the cells would only be kept in culture for 4 days. The viability of the 
chondrocytes after 4 days was also investigated (Figure 3.6) using a fluorescent 
live dead marker, which indicated that approximately 80% of the cells were 
viable after culture. This data further shows that keeping the cells in culture for 
4 days is optimal to enable in vitro functional assays to be carried out.  
 
In summary, the work carried out in this chapter has lead to the optimisation of 
RNA extraction methods from human articular cartilage for ex vivo analysis. 
Additionally, the best methods for molecular analysis of these chondrocytes has 
also been defined, including the most appropriate cDNA synthesis strategy for 
mRNA and miRNA analysis and the most suitable housekeeping genes for their 
normalisation. Furthermore, a chondrocyte culture system has been established 
in order to carry out in vitro analysis of these cells.
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4 Expression and Regulation of Endogenous 
BMP-7 and the BMP-7 Signalling Cascade in an 
Osteoarthritic Cohort.  
4.1 Introduction 
Bone morphogenetic protein 7 (BMP-7) is a member of the TGF-β superfamily 
and plays a number of key functions within the body; these range from kidney 
formation to osteoinduction in bone. Further to this, exogenous BMP-7 has been 
shown to be chondroprotective in several animal models of OA (1.2.4.1) 
(160,220,221).  However, little is known about the expression and role of 
endogenous BMP-7 and its signaling family in human OA tissue.  
In the early 2000’s, an initial study reported an increase in transcriptional 
expression of BMP-7 in OA cartilage compared to both healthy adult and 
neonatal tissue (147). This was later refuted in a subsequent study that 
suggested that BMP-7 transcript is only detected in foetal cartilage and not in OA 
or healthy adult articular cartilage (149).  In addition to the transcriptional 
discrepancies, there is also controversy surrounding the expression of the BMP-7 
protein within the joint. Depending on the studies, the level of soluble BMP-7 in 
synovial fluid is either reported to be elevated in OA  (153,228), or unaltered 
when compared to healthy controls (151). Protein within the chondrocytes has 
also been reported to be decreased in OA (150). It should also be appreciated 
that studies have looked at the level of BMP-7 in plasma, suggesting that it is 
elevated in OA, however, this is still open to interpretation due to the data 
presented being below the detectable range of the assay (153). These 
discrepancies currently seen in the literature may be due to a modification or 
regulatory mechanism that render the transcript undetectable with current 
techniques or preventing maturation into bioactive protein.  Methylation is one 
of these potential mechanisms (section 1.3.1.2), Loeser et al have shown that 
BMP-7 promoter methylation links to an age related decrease in BMP-7, (222). 
Another epigenetic regulatory mechanism that can target transcript for rapid 
degradation, thus making detection difficult, are AU rich elements (ARE) in the 
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3’ UTR (section 1.3.1.1). The ARE can be bound by the zinc finger protein 
tristetraproline (TTP) inducing instability of the mRNA and ultimately 
degradation (223). An alternative explanation for the disease-associated changes 
in the BMP-7 transcript are alterations in the epigenetic environment.  Several 
studies have highlighted altered miRNA expression profiles in OA 
(194,224,232)(section 1.4.4). MicroRNAs (MiRNAs) are small non-coding RNA 
molecules that over the past decade have been widely investigated and have led 
to a greater understanding of the epigenetic control in many disease associated 
pathways (section 1.4). MiRNAs are approximately 22 nucleotides in length and 
function to maintain homeostasis in cells by controlling protein expression (225). 
MiRNAs can work to inhibit protein synthesis by targeting the 3’UTR of mRNA, 
causing either translational repression or mRNA degradation.   
A previous link between miR24 and OA has been established by work carried out 
by Philipot et al, showing a decrease in the expression of the miRNA in OA 
compared to healthy cartilage (195). Philipot et al went on to further elucidate 
a role for this miRNA with regards to OA, suggesting it is involved in the 
regulation of cell senescence marker p16INK4a  (section 1.4.1.1). The most recent 
data confirming the link between miR24 3p and OA reports that this miRNA was 
increased in the synovial fluid in end stage disease compared to early stage 
(210). Other miRNA, such as let7e, were also brought to the forefront as 
predictive markers for the need for arthoplasty in OA by Beyer et al  (209). They 
also identified miR342 3p as an OA associated miRNA, however, they found no 
evidence for a correlation between this miRNA in circulation and the need for 
arthoplasty. 
Despite the uncertainty regarding the presence of BMP7 in the joint, the 
signalling cascade for this protein has been relatively well defined to date 
(Figure 4.1). Firstly, BMP-7 is cleaved from an inactive pro-form to its functional 
conformation by the enzyme furin at the furin type consensus cleavage site 
(112). Upon cleavage, the mature form of BMP-7 can fold and, via displuphide 
linking, either homodimerise or heterodimerise with other mature BMPs (112).  
These mature ligands can then bind to receptors initiating the subsequent 
signalling cascade. There are two types of BMP serine-threonine kinase 
receptors, type I and type II . BMP-7 has affinity for several type I receptors 
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including ALK6 (BMPR1B), ALK2 and ALK3, (226,227). It also has affinity for more 
than one type II receptor, however preferentially binds (BMPR2) over ActRII or 
ActRIIB (227,235), (Figure 4.1). Ligand activation of these tyrosine kinase 
receptors leads to the recruitment and phosphorylation of Smads 1/5/8, which 
interact with Smad 4 before translocating to the nucleus where gene specific 
promoter activation can occur (Figure 4.1). This BMP-7 mediated promoter 
activation has been linked to the extracellular matrix homeostasis (234) via the 
up-regulation of hyaluronic acid and its receptor CD44, both of which have been 
implicated in matrix synthesis (Figure 4.1), (156), however little more is known 
about its anabolic role in the cartilage (115).  
It is well characterised that BMP-7 can be regulated by antagonistic proteins 
(Section 1.2.1.4) such as follistatin and gremlin (162).  A disease-associated 
increase in both gremlin and follistatin has been observed in an experimental 
model of OA in dogs (236).   
Despite the considerable work in elucidating the expression of BMP-7 in disease, 
the expression of the BMP-7 signalling family as a whole, including BMP 
receptors, inhibitors and accessory signalling components such as CD44, remains 
ill defined in human OA cartilage.  
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Figure 4.1 BMP-7 signalling cascade 
Basic depiction of the BMP-7 signalling cascade: pro BMP-7 is cleaved by furin releasing the 
mature BMP-7 protein. BMP-7 signals via type I (BMPR1B/ALK2) and type II (BMPR2) BMP 
receptors. Phosphorylation of the receptors then leads to subsequent SMAD phosphorylation and 
translocation to the nucleus. Here, gene activation can occur resulting in ECM production. 
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4.2 Aims 
The aims of this chapter were three fold, in the first instance, the aim was to 
resolve discrepancies within the literature regarding BMP-7 expression in 
articular chondrocytes. Secondly, given the protective role of exogenous BMP-7 
in animal models of OA, here it has been hypothesised that altered expression of 
members of the BMP-7 signalling family cascade, along with other BMP-7 
associated genes, may have an impact on how individuals with OA would respond 
to BMP-7 therapy. Thus, the second aim of the work in this chapter was, for the 
first time, to evaluate the expression of the BMP-7 signalling family cascade, 
along with other BMP-7 associated genes, in the same cohort of OA patients. 
Finally, it has been hypothesised that miRNA  predicted to target both BMP-7 
and its signalling family,  may be altered in disease.  Therefore, the studies in 
this chapter will aim to identify whether these are altered and have a role in the 
regulation of this anabolic pathway.   
 
To this end, the aims of this chapter are to: 
1. Determine the expression and localisation of BMP-7 within OA cartilage 
and synovium.  
2. Deduce if the expression of certain BMP-7 signalling family members 
varies between different grades of OA cartilage.  
3.  Delineate the expression of BMP-7 regulating miRNA in the OA cohort and 
determine if any of the signalling components are direct targets of these 
miRNA. 
115    
 
  
4.3  Results 
 BMP-7 Transcript Analysis in Primary Human Cartilage.  4.3.1
In an attempt to settle the current disparity in the literature with regards to the 
expression of BMP-7 transcript in human articular cartilage, a variety of 
techniques were implemented to locate and quantify BMP-7 mRNA.  All primary 
cells used within this study were isolated from patients who had given informed 
consent at the time of TKR surgery for end stage OA. Cartilage erosion was 
scored ex vivo using the Outerbridge scoring system (section 2.1).  In the first 
set of studies, self-designed primers were used in standard qPCR analysis. 
Primers were designed using the publically available mRNA FASTA sequence 
(National Centre for Biotechnology Information (NCBI) website). The primers 
were subjected to BLAST analysis (NCBI) (section 2.7.2.4), assessing their 
specificity to the mRNA they were designed to identify.  Synthesis of cDNA from 
chondrocytes (section 2.6.5) residing in either non-eroded (Outerbridge score 0 -
I) or eroded (Outerbridge score II-IV) cartilage was carried out and the product 
was subject to PCR with the self-designed primers. The data was presented as a 
cycle threshold (CT) value. In an initial study, samples from both the eroded and 
non-eroded sections of tissue show that BMP-7 was detected in the cartilage; 
CT>30 with the NTC ranging from a CT of 36 to undetermined (Figure 4.2). These 
initial results suggest that only very low levels of transcript are present within 
the cartilage; CT values were close to that of the NTC in some cases.  
Importantly, expression of the housekeeping gene β-actin was consistent across 
the eroded and non-eroded cartilage confirming that the PCR was successful 
(Figure 4.2A) and that technical error did not account for the high CT values. As 
the published data could not robustly be replicated in this instance it was 
decided to evaluate the expression of BMP-7 in a positive control. To this end, 
human embryonic kidney (HEK) 293 cells were evaluated along with human 
articular cartilage, using manufacturer validated TaqMan™ primers for BMP-7. 
Thus testing if the previous data were simply a product of poorly designed 
primers. HEK 293 cells were expected to produce the transcript due to its 
essential role on kidney development and maintenance (237).  
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Figure 4.2 BMP-7 Transcript Not Detected in Human Primary Chondrocytes Using qPCR.  
All cartilage was obtained from patients with end stage disease. A) Sections from non-eroded 
(Outerbridge score 0-I) or eroded cartilage (Outerbridge score II-IV) taken from either the MTP or 
the LTP.  N=1 for each section (analysed in technical triplicate). Self-designed primers were used 
to probe for BMP-7 with SYBR green master mix. B) HEK293 cell and cartilage (both N=1), were 
probed for BMP-7 using TaqMan™ primers  along with TaqMan™ universal master mix, (no UNG) 
C) Cartilage from 2 patients, 1 total knee and 1 unilateral knee replacement. Six sections from the 
total knee were investigated, DMC, DLC, PMC, PLC, MTP and LTP and two sections from the 
unilateral knee, PMC and MTP (N=2).  TaqMan™ primers were used to probe from both BMP-7 
and BMP-6, with TaqMan™ universal master mix, (no UNG).  All values shown as CT (cycle 
threshold) and β-actin was used as a housekeeping gene for each with self-designed primer (A) 
and TaqMan™ Primers (B/C). Self designed primer NTC was a CT value of 36 and undetermined, 
TaqMan NTC was undetermined.  
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The cell line, as predicted, produced a CT value below 20 (Figure 4.2B) using the 
Taqman™ primers in this particular assay. The CT values obtained for BMP-7 
transcript within the cartilage were consistent with the self designed primers, 
giving rise to CT values ranging from 33 -37, indicating extremely low levels of 
expression. BMP-6 expression was also evaluated in the samples as a another 
positive control, as it has previously been reported to be highly expressed in 
human adult cartilage (149). BMP-6 transcript was present in the same two 
patients that had previously been interrogated with the TaqMan™ primers for 
BMP-7 expression (Figure 4.2C), confirming that previously published data could 
be replicated using patient samples from this study (149). In order to rule out 
any patient variation, a further two patients were interrogated for BMP-7 
expression (Table 4.1), however, the CT values were again in excess of 30. 
Cartilage from other donors also displayed CT values similar to that of the NTC 
in separate analysis (data not shown). Therefore, both the self-designed and the 
validated TaqMan™ primers were only able to detect very low levels of BMP-7 in 
the chondrocytes in some of the cartilage samples examined suggesting that low 
level BMP-7 expression may be patient specific.    
The data above suggests that, contrary to some of the literature, cartilage may 
not be a ready source of the BMP-7 transcript within the joint, therefore, other 
possible sources were also investigated. To this end, the synovium, bone and 
bone marrow of OA patients were interrogated. The CT values for BMP-7 in 
synovium of the three patients investigated were  lower, by 3 CT’s, (Table 4.1) 
than those observed in the cartilage and were below the CT values detected in 
the NTC, indicating that the synovium can produce low levels of transcript 
within the joint.  Whereas the CT values for transcript expression in both the 
bone and bone marrow demonstrate lower expression than that of the cartilage 
suggesting that these were not likely sources for the transcript (Table 4.1).  
All of the methods utilised up this point in the study had been for relative 
quantification of transcripts and were all unsuccessful in robustly reproducing 
the previously published findings. To address this, absolute quantification by 
digital PCR was implemented as an alternative, more sensitive, detection 
method. Digital PCR offers an ultrasensitive platform determining the number of 
copies of a transcript present per oil emulsion droplet generated (Figure 4.3A). 
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Cartilage (PMC)   Synovium   Bone Bone Marrow  
P44 35          
34      
35 
 P32 37     
31     
31 
P52 
(PMC) 
34    
33     
33 
P53 UND    
UND   
UND 
  
P43 35    
33     
33 
P47 33    
32     
32 
P52 
(MTP) 
34    
34    
34   
    
  P48 29     
30    
30 
    
 
Table 4.1 BMP-7 Expression in Cartilage, Synovium, Bone and Bone marrow.   
PMC shown as a representative section of the cartilage, N=2, where P number## represents 
different patients. Synovium values N=3; Bone samples, N=2; bone marrow, N=1. Technical 
triplicate values shown for all samples run with Taqman primers.  All NTC were undetermined with 
the exception of the synovium, which varied between 36 and undetermined. All data shown as CT 
value. UND = Undetermined 
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The cDNA is equally distributed between the 20,000 oil droplets, with only a 
proportion of the droplets being positive for the genes of interest, thus creating 
two populations, one positive and one negative.  Housekeeping gene β-actin 
could be detected in a robust manner with a good separation between the 
positive and negative populations (Figure 4.3B).  Detection of positive control 
gene BMP-6 along with BMP signalling receptor, BMPR2, was successful using the 
digital PCR (Figure 4.3C/D). When BMP-7 was interrogated with the system, it 
could not reliably be detected across cartilage from 5 patients and synovium 
from 2 patients (Figure 4.3E).  There could be very low levels of transcript 
present in the T2 synovium, however it is hard to determine, as the number of 
samples examined were not significant.  Thus, the digital qPCR suggests that 
BMP-7 mRNA maybe present at very low level in some of the synovium samples, 
but not the cartilage, in the small number of patients investigated.  
As a final attempt to replicate the data that had been published by Chubinskaya 
et al in 2002, demonstrating that articular chondrocytes have detectable BMP-7 
transcript, their published nested PCR approach was adopted.  Primers for BMP-7 
mRNA were designed against the FASTA sequence, the product of this PCR was 
then used in order to create a second inner pair of primers, which would be run 
with the resultant product from the initial RT PCR reaction.  No bands were 
observed at the expected weight of 216bp in the initial PCR with the outer 
primers (Figure 4.4). However, after the nested reaction, bands could be 
visualised in all of the samples. The housekeeping gene  β-actin could also be 
clearly observed in all of the samples after one round of RT PCR.  NTCs were run 
for the outer primers and were also carried over to be subject to the nested 
PCR, in order to check that DNA contamination had not occurred: the control 
was negative at each stage of the reaction.  These data suggest that along with 
the initial qPCR data there may be very low levels of BMP-7 transcript produced 
from the primary chondrocytes, however the data from the digital PCR analysis 
did not support this and it may be patient specific.  
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Figure 4.3 BMP-7 mRNA Was Not Detected Using Digital PCR.  
A) Schematic representation of the digital qPCR assay system. The distal medial condyle (DMC) 
from 5 patients along with synovium from 2 patients were analysed for B) β-actin, BMP-6, BMPR2 
and BMP-7. The pink line in each of the plots represents the separation between the positive 
(green/blue) and negative (black) droplets. A negative control lacking the cDNA (NTC) was also run 
for each transcript. All primers used in the analysis were TaqMan™.  
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Figure 4.4 BMP-7 Can be Found in Human Primary Chondrocytes Using Nested Primers.  
Cartilage from each section of joint from a single patient was subject to nested PCR.  Firstly 5 µg 
cDNA was subject to 35 rounds of PCR with outer BMP-7 primers, expected product size 216 bp.  
A second round of PCR (again 35 cycles) was carried out on the product from the 1st PCR resulting 
in a 200 bp product. Products from both the 1st and 2nd rounds of PCR with the outer and inner 
primers respectively were run on a 1.8% agarose gel for 45 mins. β-actin was used a loading 
control and was run on the gel after an 1st round of PCR.    
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 BMP-7 Protein Quantification and Localisation in OA 4.3.2
Cartilage 
As only low levels of BMP-7 transcript expression were observed in a patient 
specific manner in the cartilage, an investigation was carried out to determine if 
the protein could be either quantified or qualified.  Firstly, an antibody raised 
against the pro-peptide of BMP-7 was used to investigate protein levels (Figure 
4.5A). Chondrocytes from OA patients were lysed in RIPA buffer before being 
subject to gel electrophoresis, transferred to nitrocellulose membrane and 
probed with BMP-7 specific antibody (section 2.10). In total 4 patients were 
investigated.  Cartilage taken from several areas within the joint were all 
digested together from 3 patients and chondrocytes lysed in RIPA buffer. For the 
4th patient each specific area harvested from the joint was digested and lysed 
individually (U8: PMC and MTP). The transcript data (section 4.2.1) would 
suggest that only low levels of BMP-7 protein should be present within the 
cartilage. Accordingly in order to maximize the detection of any expressed 
protein, the maximum concentration of protein was loaded into the gel (this was 
based on sample volume). Incubation with the BMP-7 antibody, raised against 
the pro-domain of the BMP-7 peptide (Figure 4.5A), revealed faint bands in all 
samples at the expected molecular weight of approximately 40 kDa.  
Housekeeping protein GAPDH, which was used as a positive control, was also 
detected in all the samples. (Figure 4.5B).  Human recombinant BMP-7 was run 
as a negative control for the antibody, as this does not contain the pro-domain 
of the protein (Figure 4.5A); as expected no band was detected in the negative 
control, (Figure 4.5B).  
After confirming that the BMP-7 antibody binds to the pro-domain of the BMP-7 
protein and detects the full-length peptide in the OA chondrocytes (as shown by 
the weight at which it detected BMP-7), the antibody was used to determine the 
cellular and anatomical location of the protein, via immunohistochemistry (IHC).  
The evaluation of the BMP-7 protein in the cartilage required optimisation of the 
IHC technique. This was due to the inherent properties of the tissue that 
resulted in the cartilage becoming non-adhered from the slide during the 
staining process. This mainly occurred during antigen retrieval, a process critical 
to the IHC analysis.  Antigen retrieval is carried out in order to unmask epitopes 
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that have become cross-linked during the fixation process, thus facilitating 
antibody binding. Heat induced antigen retrieval with citrate buffer is the 
standard antigen retrieval method, however, in the case of cartilage mounted 
sections, this resulted in almost all of the sections falling off the slides. Any 
sections that did remain on the slides after this process were only ever partially 
adherent, which gave rise to reagents accumulating under the section which in 
turn caused issues in the analysis due to unspecific staining. Therefore, it was 
essential to find an alternative form of antigen retrieval for this tissue before 
BMP-7 analysis could begin. To this end, UNI-TRIEVE, a solution that does not 
require high temperature or extreme pH, was assessed as an alternative. This 
resulted in a vast improvement in the number of sections remaining adhered to 
the slides post antigen retrieval. Some of the sections were however still only 
loosely adhered meaning that the section could freely move around the slide 
whilst others still fell off the slides and were lost in the antigen retrieval buffer.  
The same antibody raised against the pro-region of the BMP-7 peptide, that had 
been used in the WB analysis, was also employed with IHC to investigate the 
expression and localisation of the protein in cartilage.   As BMP-7 is essential in 
kidney development and maintenance, the antibodies were initially optimised in 
rat kidney (Figure 4.6). The BMP-7 antibody was evaluated at several 
concentrations - 4, 6 or 8 µg/ml, in order to identify the optimal concentration 
for use in IHC (Figure 4.6A).  From the images obtained with the various 
concentration it was decided that 6 µg/ml was the optimal concentration to take 
forward as the 4 µg/ml staining was too faint and the 8 µg/ml gave rise to 
artificial edge staining.  Next, BMP-7 protein expression (Figure 4.7) was 
investigated in human OA articular cartilage.  Following incubation with the 
BMP-7 antibody, clear staining (brown deposits) was observed in the PMC from 
three patients. The staining was abundant in areas close to cartilage lesions 
where characteristic stress clustering of the chondrocytes (229) was apparent 
(Figure 4.7A).  Furthermore, cartilage sections from the patients were also 
positive for intracellular BMP-7 staining (Figure 4.7A), which was confirmed by 
using digested chondrocytes cytospun onto slides and stained for BMP-7 (Figure 
4.7B). This staining suggests that these cells can produce the protein in times of 
cellular stress and as only a small proportion of these cells appear to be in this 
OA typical cluster formation, this may account for the low transcript abundance 
previously observed (section 4.2.1). A second antibody, raised against the whole 
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BMP-7 peptide, was used in order to confirm if the initial staining observed in 
the cartilage would remain consistent (Figure 4.8). BMP-7 was most abundantly 
observed again in areas of chondrocytic stress (Figure 4.8) and intracellular 
staining could also be observed (Figure 4.8) thus confirming the initial staining 
patterns observed.  Taken together, the data obtained for BMP-7 staining in the 
cartilage suggests that BMP-7 protein is discretely detected in the intracellular 
regions of the chondrocytes and is also prominent in areas of chondrocytic stress 
determined by chondrocyte cluster formations and cartilage lesions.  Thus, the 
low level of transcript expression in the cartilage may account for the moderate 
levels of protein observed.   
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Figure 4.5  BMP-7 Protein can be Visualised Using Western Blotting.  
A) Shematic showing the region on the BMP-7 protein that the antibody is raised against.               
B) Cartilage from 3 patients (all cartilage from each patient digested together) was lysed in RIPA 
buffer producing patient specific protein lysates.  From a  4th patient lysates were creating by 
digested the cartilage according to the sections of the joint the cartilage was excised from (i.e. a 
separate lysate for both PMC and MTP).  Samples were loaded by volume onto a 4 -12% bis tris 
polyacrylamide gel. Following electrophoresis, the protein was transferred onto a nitrocellulose 
membrane using iBlot system. BMP-7 antibody (ab56023 rabbit polyclonal) was used at 1 µg/ml. 
Recombinant BMP-7 was used as a negative control for the antibody and GAPDH was probed as a 
loading control.     
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Figure 4.6 Validation of BMP-7 Antibody on Rat Kidney. 
Sections were prepared for staining using the HEAT induced antigen retrieval technique. A) Three 
concentrations of the BMP-7 antibody (raised against the pro domain of the peptide) were added to 
the sections (ab56023 rabbit polyclonal) - 4 µg/ml, 6 µg/ml and 8 µg/ml. Isotype used was rabbit 
polyclonal DA1E mAB IgG. Isotype is shown at a 10X magnification, with all BMP-7 staining being 
shown at 10X and 40X magnification. All images were taken with an Olympus BX41 microscope 
and analysed using Olympus cell B imaging software.  
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Figure 4.7 BMP-7 Positive Staining in OA Cartilage 
A) Cartilage from three patients (OA1, OA2 and OA3) was subject to UNITRIEVE antigen retrieval 
before being stained with BMP-7 antibody, raised against the pro-domain of the protein (ab56023 
rabbit polyclonal) at 6 µg/ml. Isotype shown at 10X magnification, BMP-7 staining shown at both 
10X and 40X magnification. Isotype used was rabbit polyclonal DA1E mAB IgG. B) Isolated 
chondrocytes were cytospun onto slides before being subject to HEAT induced antigen retrieval 
and BMP-7 staining with the BMP-7 antibody raised against the pro-domain of the protein 
(ab56023 rabbit polyclonal) at 6 µg/ml. Isotype and BMP-7 shown at 10X and 40X magnification. 
All images were taken with an Olympus BX41 microscope and analysed using Olympus cell B 
imaging software.   
 
  
128    
 
  
 
Figure 4.8 Validation of BMP-7 Staining in the Cartilage with an Alternative Antibody.  
Cartilage sections from 3 patients were subject to UNITRIEVE antigen retrieval before being 
stained with BMP-7, raised against the whole peptide for BMP-7 (ab54904, mouse monoclonal 
antibody). Isotype - Mouse IgG1 negative control.  Representative sections from three different 
patients (OA1, OA2 and OA3)  stained with 6 µg/ml total BMP-7 antibody at either 10X or 40X 
magnification. Isotype shown at 10X magnification. All images were taken with an Olympus BX41 
microscope and analysed using Olympus cell B imaging software.      
 
 
 
 
 
 
 
 
129    
 
  
              BMP-7 Localisation in Synovium 4.3.3
From the transcript analysis (section 4.3.1), it was shown that BMP-7 mRNA was 
detectable in the synovium (Table 4.1). Therefore, it was decided to further 
investigate this finding by determining the specific location of BMP-7 within the 
synovial tissue. Initial staining was carried out on the synovium from 4 OA 
patients with end stage disease. The results show intense BMP-7 staining around 
the endothelial cells of the blood vessels (Figure 4.9). This staining pattern was 
again confirmed with a second antibody, which has been raised against the 
whole peptide as opposed to the pro-region of the protein (Figure 4.10) in a 
further 6 OA synovial tissues.  BMP-7 staining was also observed in areas of 
higher cellular density (Figure 4.10), thus both the transcript and protein can be 
detected within the synovium of the OA patients.    
In order to confirm if the BMP-7 staining in the synovium was specific to OA, 
synovial sections from RA patients were also probed with BMP-7 antibody.  OA 
tissue was used as a positive control for all RA tissue staining (Figure 4.11).  In 
the RA sections investigated, no staining was observed around the blood vessels 
in the synovium (Figure 4.11).  However, the control OA staining was consistent 
with the previous findings (Figure 4.9 and Figure 4.10). These data potentially 
suggest that the expression of BMP-7 protein is not limited to the cartilage but 
may have other roles within the synovium; however, further investigation is 
required to fully elucidate any of these roles.      
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Figure 4.9  BMP-7 Staining in the Synovium of OA Patients 
A) Synovial sections from 4 OA (OA1, OA2, OA3 and OA4) patients prepared from staining using 
HEAT induced antigen retrieval. Sections were stained with BMP-7 antibody (ab56023 rabbit 
polyclonal), raised against the pro-domain of BMP-7, at 6 µg/ml. Isotype used was rabbit polyclonal 
DA1E mAB IgG.  Both the isotype and BMP-7 antibody shown at 10X magnification.  All images 
were taken with an Olympus BX41 microscope and analysed using Olympus cell B imaging 
software.     
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Figure 4.10 Validation of BMP-7 Staining in the Synovium with an Alternative Antibody.   
Synovial sections were prepared for IHC using HEAT induced antigen retrieval. A) Representative 
sections from 6 OA patients (OA1, OA2, OA3, OA4, OA5 and OA6)  stained with total BMP-7 
antibody (ab54904, mouse monoclonal antibody) at 6 µg/ml. Isotype Mouse IgG1 negative control.  
Images shown at both 10X and 40X magnification.  Isotype shown at 10X magnification. All images 
were taken with an Olympus BX41 microscope and analysed using Olympus cell B imaging 
software.   
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Figure 4.11 BMP-7 is Not Present in the RA Synovium.   
BMP-7 staining (ab56023 rabbit polyclonal) in 1 OA patient and 2 RA patients (RA1/RA2). All 
isotype images shown at 10X magnification, whilst all other sections are shown at both 10X and 
40X magnification. All images were taken with an Olympus BX41 microscope and analysed using 
Olympus cell B imaging software.      
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 BMP-7 Protein in OA Plasma and Synovial Fluid 4.3.4
As BMP-7 protein could be found in the synovial membrane and cartilage of the 
OA patients, it was of interest to investigate the levels of soluble BMP-7 in both 
the plasma and synovial fluid of the OA patients. There are again discrepancies 
in the literature around the concentration of BMP-7 present in the plasma, as 
one group reported concentrations in the region of ng/ml and another reported 
concentrations on the region of pg/ml.  In this study an ELISA based approach 
was used in order to determine the concentration of the BMP-7 in OA synovial 
fluid along with comparator synovial fluids from RA, psoriatic arthritis (PsA) and 
ankylosing spondilytis (AS).  OA plasma was also investigated along with 
comparator RA plasma and healthy (aged-matched) plasma. The samples were 
all subject to a heteroblock® incubation in order to prevent non-specific binding 
of rheumatoid factor, from the RA samples. The lower limit of detection of the 
ELISA was 62.5 pg/ml (Figure 4.12).  In all the samples measured, the levels of 
BMP-7 were markedly below the detection limit of the assay. Thus no conclusion 
could be made regarding the soluble concentrations of BMP-7 within the plasma 
or synovial fluid.  
 Disconnect Between BMP-7 Transcript and Protein 4.3.5
Expression.  
This study has so far demonstrated that BMP-7 protein can be observed in human 
articular cartilage from OA patients, however transcript expression is very low. 
To provide some insight into the regulation of BMP-7, in silico analysis of the 
3’UTR of BMP-7 was carried out identifying any regions, such as AU rich 
elements, likely to be targeted for modification that may account for these 
inconsistencies (Figure 4.13).   AU rich regions are often bound by ARE binding 
proteins that are able to affect transcript stability and translational capacity 
(230). The expression of the AU binding regions is not the sole factor for 
attachment of the ARE-binding proteins. Recent advances (both experimentally 
and computationally) have confirmed that the presence of AU motifs along with  
structural accessibility of the mRNA are vital to this mechanism (230). The 
internet resource AREsite is the first predictive algorithm that combines multiple 
factors in order to determine AU elements that may be bound, allowing 
134    
 
  
modification of transcript expression. Here AREsite has been utilised to identify 
5 predicted ATTA regions on the 3’ UTR of the BMP-7 transcript which could 
potentially be targeted by AU binding proteins (Figure 4.13).  As previously 
alluded to (section 1.3.1.1 ), the binding of these proteins targets the transcripts 
for rapid degradation. Interestingly, it is currently thought that tristetraproline 
(TTP) may act as a bridge between the AU rich element on the mRNA and the 
elements used for decay of the transcript by the recruitment of decay enzymes 
(231).  Given the predicted sites for binding (Figure 4.13), these regions could 
potentially be responsible for rapid degradation of the mRNA by factors such as 
the zinc finger protein, TTP, hence rendering the transcript undetectable. Due 
to time constraints the in silico analysis could not be taken forward for 
verification using in vitro techniques.   
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Figure 4.12 BMP-7 Protein Cannot be Detected in SF or Plasma from OA, RA, PSA or AS 
Patients or Healthy Controls.   
A) Standard curve was generated using recombinant human BMP-7 from the commercially 
available ELISA B) Samples from OA synovial fluid (N=5), OA plasma (N=5), RA synovial fluid 
(N=5), RA plasma (N=5), Healthy plasma (N=10), PsA synovial fluid (N=5) and AS synovial fluid 
(N=5), were screened for BMP-7 protein expression.  The sensitivity of the assay as defined by the 
standard curve was 62.5 pg/ml, represented by the broken line.  
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Figure 4.13 In Silico Analysis of BMP-7 3’UTR: Identificaton of Predicted TTP Binding Sites.  
Analysis carried out and images taken using the AREsite software courtesy of the University of 
Vienna and E!Ensemble (ENST00000395863). AREsite have predicted 5 ARE’s in the 3’UTR of 
BMP-7, shown by the blue triangles,  
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 Patient Cohort Analysis: Expression of the Endogenous 4.3.6
BMP-7 Signalling Cascade in OA Cartilage.  
4.3.6.1 OA Patient Demographics  
For BMP-7 to elicit a signalling response as a therapeutic agent, components of 
the signalling family would need to be expressed at the sites where the therapy 
would be administered i.e. the joint environment; specifically the cartilage. A 
strong case has already been provided in the literature for the 
chondroprotective properties of exogenous BMP-7 in the treatment of OA (23), 
however, the expression of the receptors and accessory molecules involved in 
the BMP-7 signalling cascade have not previously been evaluated all together in 
OA.  To this end the following were assessed in the cartilage of a small cohort of 
OA patients: anabolic components (BMP receptors BMPR1B, ALK2 and BMPR2; 
cleavage enzyme furin; and accessory receptor CD44), ECM components (type II 
collagen; type I collagen; and aggrecan) and catabolic/BMP inhibitory 
components (MMP-13; BMP-7 inhibitors follistatin and gremlin).  Tissue was 
obtained from individuals with end stage OA, who had given informed consent at 
the time of TKR at the Glasgow Royal Infirmary.  The characteristics of the full 
cohort are detailed in (Table 4.2).   
The whole cohort contained 6 males and 5 females, however due to prolonged 
timing of the sample collection, the cohort was analysed in two batches.  This 
was broken down as follows; T1, T2, T3, T4 and T5 (red) and T10, T11, T12 and 
T13 (green).  The first group contained 4 male patients and 1 female. The mean 
age of the group was 79.5 years.  The second cohort consisted of 2 males and 2 
females and had a mean age of 60.75 years. Patients T6 and T7 (black) were 
collected for cohort analysis, however the only viable samples obtained were 
peripheral blood and synovial fluid these therefore could not be included in 
either cohort for cartilage analysis.  The majority of the patients suffered from 
some degree of synovial inflammation, as assessed by the surgeon at the time of 
joint replacement. Most of the patients also suffering from multi-compartmental 
disease as defined by the modified Kellgren and Lawrence X-ray scoring system 
(1.1.10.2) (84,238).  Cartilage damage was also scored ex vivo using the 
modified Outerbridge scoring system (1.1.10.3) (88) and was either defined as 
non-eroded (Outerbridge 0-1), or (eroded, Outerbridge 2-4). All the cartilage 
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acquired from the 1st cohort had an Outerbridge score of ≥ 2 and was therefore 
all classed as eroded.  The second cohort had a wider range of Outerbridge 
scores, thus giving a range of samples in both the eroded and non-eroded 
subgroups. Whether the patients had any former arthroplasty or not was also 
noted from the patient records.  
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 OA Cohort: Cartilage Analysis of the BMP-7 Signalling 4.3.7
Family 
Cartilage was taken from 6 areas of the joint that are routinely removed during 
knee replacement surgery. These include: four sections from the femur DMC, 
DLC, PMC and PLC and two sections from the tibia, MTP and LTP (Figure 2.1).  
Each sample of cartilage was graded according to the Outerbridge scoring 
system, as previously described (Table 2.1). With each patient having 6 samples, 
some of these had equivalent grading’s and thus in these instances the results 
for the same grade were averaged and represented as one data point for that 
patient. The overall transcript expression of the main components of the BMP-7 
signalling pathway were initially determined in the OA cartilage using qPCR.  It is 
thought that there may be decreased BMP-7 expression within the OA joint 
(150), thus there is no ligand to bind to the receptor. Therefore, if 
replenishment of BMP-7 is beneficial in treating OA, the expression of the BMP 
receptors will be of interest as administration of exogenous BMP-7 would first 
lead to a receptor- ligand interaction with subsequent activation of relevant 
associated signalling cascades.  To this end, BMP-7 receptors ALK2, BMPR2 and 
BMPR1B were analysed in the cartilage (Figure 4.14A). Results revealed that the 
receptors were readily detectable within the cartilage: ALK2 (CT range 19-22), 
BMPR2 (CT range 21-28) and BMPR1B (ALK6) (CT range 24-28).  In addition to 
BMP-7 receptors, the expression of ECM fibres, type I/II collagens and aggrecan 
were interrogated as both type II collagen and aggrecan are essential ECM 
components that have been shown to be induced by BMP-7 (160,233,234) (Figure 
4.14B). The expression of the ECM associated type II collagen (CT range 15-18), 
aggrecan (CT range 16-18) (CT range 15-24) were found to be abundant within 
the cartilage. Variation in the abundance of  Type I collagen was noted with over 
a 3 log order difference in expression between the samples analysed, which may 
reflect the heterogeneity of the disease.  Finally, the BMP-7 antagonists gremlin 
and follistatin were analysed (Figure 4.14C) showing that follistatin (CT range 
16-19) and gremlin (CT range 18-22) could be detected in articular cartilage.  
After confirming that the transcripts of interest were present within the 
cartilage, further analysis was carried out by subgrouping the patients according 
to the Outerbridge score (Figure 4.15).  Due to the Outerbridge scores of all the 
cartilage collected in this subgroup being greater than 2, all of the cartilage 
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analysed here is considered eroded. The expression of the BMP-7 receptors were 
not significantly different across the Outerbridge scores (Figure 4.15A).  
Furthermore, the accessory components, follistatin and gremlin, along with 
hyaluronic acid receptor CD44, were also not significantly different across the 
Outerbridge scores (Figure 4.15B).  Both follistatin and CD44 potentially 
decrease as cartilage erosion becomes more severe, and thus it is possible that 
based on sample size there is a type II error, resulting in a false negative result 
in the data. Finally, expression of type I and type II collagen along with aggrecan 
was analysed (Figure 4.15C), with only aggrecan potentially decreasing with 
increased severity in erosion, however there was no statistical significance in 
this observation. 
As there was no significant difference between the different grades of eroded 
cartilage it was decided that an investigation with another cohort with a larger 
range of Outerbridge scores would be conducted. In the second cohort, the 
cartilage was analysed in 2 groups - non-eroded (Outerbridge score 0-1) or 
eroded (Outerbridge score 2-4) as opposed to looking at each grade individually 
due to the small size of the cohort. 
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Figure 4.14 Transcript Expression Validation in Human Articular Cartilage.  
Cartilage taken from 5 OA patients with a total of 6 sections were taken from each joint, DMC, 
DLC, PMC, PLC, MTP and LTP (one patient missing the DLC and another missing MTP). A variety 
of transcripts were investigated to assess if they were detectable within the cartilage. All data 
shown as CT values.  
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Figure 4.15 Initial Cohort Analysis Reveals no Changes in Transcript Expression in Eroded 
Cartilage.  
Cartilage taken from 5 OA patients with a total of 6 sections were taken from each joint, DMC, 
DLC, PMC, PLC, MTP and LTP (with one patient missing the DLC and another missing MTP).  
Each section was given an Outerbridge score; all data from sections obtained from one patient with 
the same score were averaged.  A) Expression of BMP receptors i) BMPR2, ii) BMPR1B and iii) 
ALK2. B) Expression of components associated with BMP-7 signalling i) CD44, ii) Follistatin and iii) 
Gremlin. C) Expression of extracellular matrix constituents, i) Type I collagen, ii) Type II collagen 
and iii) aggrecan. All normalised to β-actin and shown as 2-ΔCT.  Statistical analysis carried out 
using a Kruskal Wallace test. 
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All transcripts were displayed as fold change using the average value of the non-
eroded cartilage samples, grades 0-I, for all patients as a baseline, (Figure 4.16). 
Expression of both type I BMP receptor, ALK2 and type II receptor, BMPR2 were 
analysed (Figure 4.16A). Some samples had over a 2-fold increase in expression 
of both BMPR2 and ALK2 in the eroded cartilage, however, in other samples 
there was no change in expression (Figure 4.16A). Hyaluronic acid receptor, 
CD44, also showed modest increases in expression when calculated as fold 
change over the non-eroded cartilage (Figure 4.16B), however, there was no 
increase in the expression of cleavage enzyme furin.  All other transcripts 
investigated showed no alteration between the eroded and non-eroded 
cartilage, with the exception of Type II collagen which was increased at least 2 
fold in over half of the samples interrogated. None of these observation were 
statistically significant, most likely due to the small size of the cohort. The 
observed increase in type II collagen and the receptors suggests that these 
chondrocytes may be up-regulating anabolic pathways in the eroded cartilage. 
However, the expression of the BMP-7 signalling family remains statistically 
unaltered between the eroded and non eroded cartilage.      
In order to further investigate the increase in type II collagen, ALK2 and BMPR2 
as the spread of the data in these transcripts displayed similar patterns in 
expression (Figure 4.16), linear regression analysis was carried. Thus allowing 
any correlation between these transcripts in the patient cohort to be 
determined.  It was found that a strong positive correlation existed between the 
BMPR2 and ALK2 within the patient cohort, R2 0.62, P<0.0001 (Figure 4.17). A 
significant correlation also exists between type II collagen and both BMPR2, R2 
0.47, p=0.0004 and ALK2, R2 0.33, p=0.0051 (Figure 4.17). Thus this potentially 
suggests intact anabolic signalling in some of the patients as those who have an 
up regulation in the expression of the receptors also displayed increased ECM 
component type II collagen.  No significant correlation was found with furin, 
despite its similar expression profile.  
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Figure 4.16 Expression of BMP-7 Signalling Components in Non-Eroded and Eroded 
Cartilage.   
Cartilage taken from 4 OA patients (T10, T11, T12 and T13). With a total of 6 sections were taken 
from each joint, DMC, DLC, PMC, PLC, MTP and LTP (with one patient missing the PMC and 
another missing LTP).  Each section was given an Outerbridge score; all data from sections 
obtained from one patient with the same score were averaged. Fold change, 2-ΔΔCT, was calculated 
using the mean of all of the Healthy tissue (Outerbridge 0-1) as a baseline. The ΔCT normalisation 
was calculated using β-actin. A) Expression of direct BMP-7 signalling components i) BMPR2, ii) 
ALK2 and iii) Furin. B) Expression of non-direct BMP-7 signalling components i) CD44, ii) follistatin 
and iii) Gremlin. C) Expression of extracellular matrix components i) Aggrecan, ii) Type II collagen, 
iii) Type I collagen and iv) matrix degradation enzyme, MMP-13.  All analysis carried out using 
SYBR green.  Statistical analysis carried out using Mann Whitney  T-test. 
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Figure 4.17 Positive Correlations Exist Between the Expression of BMPR2, ALK2 and Type II 
Collagen Within the OA Patient Cohort.  
Linear regression analysis of all samples cartilage taken from T10, T11, T12 and T13. 
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 MiRNA Expression in OA Cartilage  4.3.8
In this study, patient variation within the transcript expression has been shown 
across the BMP-7 signalling cascade in a small cohort of OA patients. Therefore, 
to begin to address why these patients have differential expression of these 
transcripts, studies to investigate the epigenetic regulation of BMP-7 and the 
BMP-7 signalling family members were conducted. This was based on the growing 
literature which provides evidence that dysregulation of certain miRNA’s are 
associated with OA (194,202,232). Human TargetScan is an internet based 
mathematical algorithm that is used to predict miRNA targeting of mRNA based 
on the seed region complementarity to the 3’UTR.  Using the BMP-7 signalling 
cascade as a starting point, miRNA that were predicted to regulate more than 
one key member of the BMP-7 signalling pathway were identified.  To this end, 
miR24 3p, miR342 3p and miR342 5p were highlighted as potential miRNA’s of 
interest (Figure 4.18).  It is predicted that miR24 3p will target BMP-7, the 
cleavage enzyme furin, BMP receptor ALK2, BMP inhibitor follistatin and 
intracellular proteins SMAD1/5/4.  While miR342 3p is predicted to target BMP-7, 
BMP receptor BMPR2 and SMAD1/5. Finally, miR342 5p is predicted to target 
cleavage enzyme furin and BMP inhibitor gremlin. In this instance, a biopsy that 
had been taken from the non-weight bearing femoral notch of each OA knee 
(Figure 2.1) was simultaneously analysed along with the other cartilage from the 
OA cohort (Table 4.2), thus providing an internal control for each patient.  It is 
understood that this internal control is still exposed to the same disease 
environment as the rest of the cartilage, however, this area is not exposed to 
any form of mechanical loading, thus it can control for any mechanical related 
changes in the disease process. All three miRNA’s  were detected in cartilage 
(Figure 4.19). MiR24 3p was detected within a CT range of 14-20, miR342 3p 
within a CT range of CT 17-25, and miR342 5p within a CT range of CT 21-28. 
Interestingly, OA associated Let7e, a miRNA whose plasma levels negatively 
correlate with risk of arthroplasty (209), could not be detected within 
chondrocytes (data not shown). No differences in miRNA levels were observed 
between the weight bearing cartilage and the non-weight bearing femoral notch 
internal control (Figure 4.19). 
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Figure 4.18  Schematic of miRNA Targeting of the BMP-7 Signalling Family as Predicted by 
Human TargetScan.    
Basic depiction of the BMP-7 signalling cascade highlighting the miRNAs that are predicted via 
human TargetScan to target members of the BMP-7 signalling family. MiR24-3p is predicted to 
target; BMP-7, furin, BMPR2, BMPR1B, follistatin, SMAD1/5 and SMAD4. MiR-342-3p is predicted 
to target: BMP-7, BMPR2 and SMAD1/5. Mir342-5p is predicted to target; furin and gremlin and 
miR140 is predicted to target gremlin.  
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Figure 4.19 Unaltered miRNA Expression in OA Patient Cartilage using an Internal Non-
Weight Bearing Control.  
Cartilage taken from 5 OA patients with a total of 6 sections were taken from each joint, DMC, 
DLC, PMC, PLC, MTP and LTP, with one patient missing the DLC and another missing MTP along 
with a punch biopsy from the femoral notch.  Each section was given an Outerbridge score, all data 
from sections obtained from one patient with the same score were averaged. Data is shown as fold 
change (2-ΔΔCT) with an average value of the femoral notch samples from all the patients used as 
baseline. MiRNA analysis was carried out with validated primers from Qiagen, the following miRNA 
were analysed within the cohort, A) miR24 3p B) miR342 3p and C) miR342 5p. ΔCT calculated 
using U6 as a normalisation gene. All analysis carried out with MiScript SYBR green from Qiagen. 
Statistical analysis; Mann-Whitney test.  
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 MiRNA Targeting of BMP-7 Signalling Transcripts 4.3.9
As the miRNA’s that were predicted to target BMP-7 signalling family members 
were detected in the cartilage of the OA patients, it was decided that 
investigation into the potential of these miRNA’s to directly modulate the 
expression of the BMP-7 signalling family would be of interest. Despite the fact 
that OA related changes in their expression could not be confirmed due to a lack 
of healthy controls. Primary chondrocytes were excised from cartilage with an 
Outerbridge score of ≤1 from three individuals suffering from end stage OA 
(Section 2.3). Cells were plated in plastic culture plates and given time to 
acclimatise and recover from the stress caused when removed from the ECM; 
timings determined from the optimisation experiments carried out in Chapter 3 
(Figure 3.6). Following the rest period, chondrocytes were transfected with 
either miR24 3p mimic or miR342 3p mimic for 24 hours.  To ensure that the 
transfections were specific to the 3p isoform of the miRNA that was chosen for 
this investigation, qPCR was conducted. (Figure 4.20). It is clearly demonstrated 
that the cells transfected with either miR24 3p or miR342 3p mimic (Figure 4.20 
A/B) display increased expression of the miRNA for that isoform only. Further to 
this, they also show that the control mimic (CM) has no effect on the expression 
of the miRNA compared to the untransfected cells. The effect of the 
transfection protocol with regards to the endogenous expression profiles of the 
mRNA of interest (BMP-7, IL-1β, BMPR1B, ALK2, BMPR2, furin, follistatin and 
gremlin ) was also evaluated (Figure 4.21).   IL-1β, follistatin and BMPR2 
displayed modest alterations following transfection; however these were not 
significant. This confirmed that CM transfection had a negligible impact on the 
expression of the genes of interest and could subsequently be used as the 
baseline for future analysis.   Leading on from the initial optimisation, cells were 
transfected with either miR342 3p mimic or miR 24 3p mimic (Figure 4.22) and 
(Figure 4.23) respectively. The observed data show that the miR342 3p mimic 
had no repressive impact on any of the genes of interest (Figure 4.22) suggesting 
no direct interactions between the miRNA and the transcript.  However, there 
was an increase in the expression of gremlin following miR342 3p mimic 
transfection, possibly suggestsing some form of indirect interplay between 
miR342 3p and this mRNA (Figure 4.18).  MiR24 3p mimic analysis was also 
carried out for the transcripts of interest, (Figure 4.23). Here some direct 
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interactions between miRNA and mRNA were observed (Figure 4.18). With one of 
these interactions having been predicted by human target scan, BMPR1B 
repression, and one having not, ALK2 repression. The data show a 60 – 90%  
inhibition in BMPR1B receptor expression and between 40% - 50% inhibition of 
ALK2 following treatment with the miR24 CM. IL-1β and BMP-7 were also 
substantially down-regulated in two out of the three chondrocyte donors, 
suggesting heterogeneity in the chondrocyte ability to respond to this miRNA.   
Given that the data suggests a direct relationship between the miRNA and the 
mRNA of both BMPR1B and ALK2, it was decided to go back to the OA cohort to 
conduct correlation analysis of the miRNA and mRNA in the patients (Figure 
4.23J).  A negative correlation was observed between the expression of the 
miRNA and ALK2 in the OA patients, surprisingly a correlation was also found 
between miR24 and BMPR2 even though it did not seem to have a profound 
effect on the transcript in the transfection assay, 30% inhibition in 2 of the 
chondrocyte donors. No correlation was observed between miR24 and BMPR1B. 
For the first time, a role for miR24 3p in the regulation of BMP receptor 
expression has been demonstrated, implicating this miRNA in some form of 
regulatory network for the BMP-7 signalling pathway.  In the future a luciferase 
assay would be needed in order to confirm direct targeting of receptors by 
miR24 3p.       
 
152 
 
  
 
Figure 4.20 Validation of Isoform 3p Specificity in Mimic Transfections.  
Primary chondrocytes from three cartilage donors (N=3) undergoing TKR surgery, Outerbridge 
score ≤1 were plated at 1X105/ml. Following 48 hours acclimatisation, the cells were transfected 
using Dharmafect transfection reagent with 10ng of either control mimic (CM) miR24 3p mimic 
(24M) or miR342 3p mimic (342M). Cells were transfected for 24 hours before media was changed 
and the cells were harvested 48-hour post transfection. qPCR analysis was carried out to assess 
the uptake of the mimic into the cells. All fold change (2-ΔΔCT) was calculated using the CM as a 
baseline. A) MiR24 3p expression B) miR342 3p expression C) miR24 5p expression D) miR342 5p 
expression.  
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Figure 4.21 Minimal Differences Observed in the Gene Expression of the Control Mimic Cells 
Compared to the Untranfected Cells 
Primary chondrocytes from three cartilage donors (N=3) with an Outerbridge score ≤1 were plated 
at 1X105/ml. Following 48 hours acclimatisation, the cells were either transfected using Dharmafect 
transfection reagent with 10ng control mimic (CM) or placed in control media (no transfection 
reagents). Cell were transfected for 24 hours before media was changed and the cells were 
harvested 48-hour post transfection. qPCR analysis was conducted comparing the ΔCT value (CT 
value gene of interest – CT value housekeeping (β-actin)) for the CM transfected and 
untransfected cells.  All relevant genes of interest were analysed A) BMP-7, B) IL-1β, C) BMPR1B, 
D) ALK2, E) BMPR2, F) Furin, G) Follistatin and G) Gremlin. Statistical analysis; Wilcoxon test  
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Figure 4.22 miR342 3p has an Indirect impact on the Expression of BMP-7 Signalling Family 
Member Gremlin 
Primary chondrocytes from three cartilage donors (N=3) with Outerbridge score ≤1 were plated at 
1X105/ml. Following 48 hours acclimatisation, the cells were transfected using Dharmafect 
transfection reagent with 10ng of either control mimic (CM) or miR342 3p mimic (342M). Cell were 
transfected for 24 hours before media was changed and the cells were harvested 48-hour post 
transfection. All fold change (2-ΔΔCT) was calculated using the CM as a baseline. Genes 
interrogated were A) BMP-7, B) Furin, C) IL-1β, D) BMPR1B, E) AK2, F) BMPR2, G) Gremlin H) 
Follistatin.  The housekeeping gene used for ΔCT was β-actin. Statistical analysis; Wilcox test. 
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Figure 4.23 miR24 3p has a Direct Effect on Gene Expression Across the BMP-7 Signalling 
Family.  
Primary chondrocytes from three cartilage donors (N=3) with Outerbridge score ≤1 were plated at 
1X105/ml. Following 48 hours acclimatisation, the cells were transfected using Dharmafect 
transfection reagent with 10ng of either control mimic (CM) or miR342 3p mimic (342M). Cell were 
transfected for 24 hours before media was changed and the cells were harvested 48-hour post 
transfection. All fold change (2-ΔΔCT) was calculated using the CM as a baseline. Genes 
interrogated were A) BMP-7, B) Furin, C) IL-1β, D) BMPR1B, E) AK2, F) BMPR2, G) Gremlin H) 
Follistatin. The housekeeping gene used for ΔCT was β-actin. Statistical analysis; Wilcoxon test.   
J) Correlation analysis of miR24 3p with i) ALK2, ii) BMPR1B and iii) BMPR2, was conducted using 
ΔCT values for the mRNA (ΔCT = mRNA Ct value - β-actin CT value) and the miRNA (ΔCT = 
miRNA CT value – U6 CT value). Cartilage was taken from 5 OA patients at the stage of TKR, 
(total of 6 sections were taken from each joint, DMC, DLC, PMC, PLC, MTP and LTP, with one 
patients missing the DLC and another missing MTP) each section was given an Outerbridge score. 
All sections obtained from one patient with the same score were averaged. Linear regression 
analysis with 95% confidence was applied using the line of best fit to determine the R2 value.  
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 miRNA Expression in Plasma 4.3.10
Recent studies have shown differences in the plasma expression of miRNA in OA 
(32). Based on this published work it was decided that the miRNA of interest in 
this study would also be investigated in the plasma of the OA patients compared 
to healthy aged matched controls. For the purpose of this investigation blood 
was taken from all patients on the morning of their surgery.  Beyer et al have 
previously suggested that Let7e may be a predictive marker for arthroplasty 
(209): negatively correlating miRNA plasma levels and the number of joint 
replacements. Levels of Let7e in our OA cohort demonstrated that compared to 
healthy controls (Figure 4.24A) there is less circulating Let7e. This is consistent 
with the findings reported in the Beyer study; where Let7e levels in the plasma 
were decreased in those who went on to develop OA. The expression of miR24 
3p and miR342 3p that are predicated to modulate the BMP-7 signalling cascade 
were also interrogated in the plasma, (Figure 4.24C/D). There was a significant 
decrease in both miRNA in the OA cohort compared to the controls.  MiR140 was 
of also of interest as it has been predicted to target the BMP inhibitor gremlin 
(Figure 4.18). Furthermore, it has also has been linked to OA with decreased 
expression being associated with disease and overexpression being shown to be 
protective in animal models of disease (191,239).  The cartilage specific miR140  
is also decreased in OA compared to the healthy control plasma (190) (Figure 
4.24B). Despite the fact that a statistical difference was observed in all of the 
miRNA’s of interest, there is still a lack of validation of the OA specificity of 
these changes.  As OA shares several common features with other 
musculoskeletal diseases such as RA, other disease controls would be needed in 
order to verify if these miRNA alterations are OA specific.   
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Figure 4.24 Decreased Levels of miRNA in the Plasma of OA Patients Versus Healthy 
Controls.  
Plasma was collected in EDTA collection tubes from OA patients on the day of TKR surgery, N=9, 
mean age 69.6 years or from healthy, age and sex matched controls, N=9, mean age 69.5 years. 
C. Elegans specific miRNA, miR39, was used as a spike in control for normalisation at 1.6 X 108 
copies/µl. Fold change (2-ΔΔCT) was calculated using the average of the healthy plasma samples as 
a baseline value. Analysis was carried out for the following miRNA A) Let7e B) miR140 C) miR24 
3p and D) miR342 3p.  Statistical analysis; Unpaired T-Test *P < 0.05, **P< 0.01. 
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4.4 Discussion 
 Summary of Results 4.4.1
This chapter was designed to address three key aims, with the first being the 
determination of BMP-7 and its signalling components expression in an OA 
cohort. In addressing this it was found that BMP-7 mRNA could not be robustly 
detected using conventional methods for molecular analysis. Only very low levels 
of mRNA appear to be expressed raising the question of the physiological 
relevance of this transcript. Additionally, these low levels of expression were 
only detected in some of the samples analysed suggesting donor specific 
expression of this transcript. Protein was qualified using IHC within the 
cartilage, confirming that the protein is present. Furthermore, it was found that 
BMP-7 was expressed at high levels in the vascular endothelial cells in the 
synovium of OA patients. This was not observed in the RA synovium, thus 
highlighting the molecular differences between these two disease states. The 
second aim addressed the expression of BMP-7 signalling cascade members and 
other BMP-7 associated genes in a small cohort of OA patients. No significant 
changes were observed between eroded and non eroded cartilage, possibly due 
to the cohort being underpowered. It was found that there were strong 
significant correlations between the expression of the BMP receptors, BMPR2 and 
ALK2, along with type II collagen within the cohort. This suggests that intact 
anabolic capacity in an OA setting may be patient specific, displaying 
heterogeneity in the small cohort with respect to this.  Finally, the work 
conducted in this chapter aimed to delineate the expression of BMP associated 
miRNA in OA and furthermore validate if any of the signalling components were 
direct targets of these miRNA’s. It appears that 4 miRNA’s are differentially 
regulated in the plasma of OA patients compared to age matched controls; 
Let7e, miR140, miR24 3p and miR342 3p.  Furthermore, it was also shown that 
miR24 3p may have a direct effect on the expression of BMP receptors; with a 
strong negative correlation in the OA cohort between miR24 3p and the 
expression of ALK2 being shown, potentially highlighting a regulatory role for 
miR24 in OA pathogenesis.   
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 The On-Going Debate Over BMP-7 Expression  4.4.2
Expression of BMP-7 transcript has been reported in primary human chondrocytes 
(147,148). However, validation of this expression by other groups using qPCR has 
not been successful (149), thus leaving discrepancy in the published literature 
over the expression of this transcript in articular cartilage. This study confirms 
that BMP-7 transcript is difficult to detect in primary human chondrocytes using 
conventional molecular analysis such as qPCR, thus supporting the work of Chen 
et al (2006). Previous studies that report BMP-7 expression in articular 
chondrocytes used very sensitive methods such as in situ hybridisation or nested 
PCR. Thus it is not surprising that the conventional methods of mRNA analysis 
were unable to recapitulate these findings and the different techniques 
deployed offer an explanation for the discrepancies between the findings of 
Chubinskaya (2000) and Chen (2006). Data generated in this chapter did, to some 
extent, verify the expression of BMP-7 transcript using nested PCR methodology. 
However, validation of the nested PCR was not successful using other 
hypersensitive readouts such as digital PCR. The negative results obtained only 
give rise to more doubt as to the expression of the transcript in chondrocytes 
and thus leave the unanswered question; can chondrocytes robustly express 
BMP-7 transcript?  
BMP-7 protein can be visualised within the joint in both the articular cartilage 
and synovium.  It would appear to be most abundant in areas of chondrocytic 
clustering typical in OA/stress (240)(241).  It is plausible that certain mediators 
that are released in response to stress may be able to induce BMP-7. Data 
obtained here regarding the expression of BMP signalling components such as 
receptors, cleavage enzyme furin and type II collagen may further support this.  
All three of these mediators appear to increase modestly at the transcript level 
in the eroded cartilage, which would be regarded as more stressed, when 
compared non-eroded OA cartilage. It was also found that when patients were 
investigated individually, those with higher levels of the receptors also had 
higher expression of Type II collagen suggesting that this signalling pathway may 
still be intact in some of the patients. It is feasible that these stressed cells 
attempt to increase BMP-7 signalling in order to enhance anabolic repair. 
Furthermore, as these stressed cells are sparsely divided throughout the 
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cartilage it may be very hard to pick up the small levels of BMP-7 transcript 
produced, hence why only nested primers are able to be successful in detecting 
the mRNA.  With this in mind, it still does not account for the lack of validation 
from the digital PCR.   
 Variance Between the Expression of BMP-7 Transcript and 4.4.3
Protein.  
Computational data from this study may suggest that the BMP-7 transcript has a  
short half-life, potentially due to degradation by regulators such the zinc finger 
protein TTP. Again making detection at the level of the transcript very difficult. 
TTP has been shown to be modified by miRNA in the other forms of arthritis such 
as RA, where Bruton’s tyrosine kinase (Btk), a negative regulator of TTP, is 
negatively regulated by miRNA 346 (242). This suggests that miRNA 346 may have 
an anti-inflammatory role via indirect up-regulation of TTP, which has further 
been shown to down regulate TNFα.  Futhermore, miR 346 has been reported to 
be elevated in RA synovial fibroblast (243).  Based on these studies, it is not 
inconceivable for TTP expression to be altered in OA as it is in RA, causing 
changes in effector transcripts, such as BMP-7.  Alternatively, it may be 
influenced indirectly by miRNA’s that are altered as a result of the disease, as 
has been shown with miRNA 346 in RA.  Many groups have now identified a 
collection of miRNA’s that are deregulated in OA (186,194,244), therefore one of 
these may lead to a similar situation with regards to TTP as to the one observed 
in RA. MiR140 has been reported to be down-regulated in OA (202) and is 
predicted to target TTP (prediction via human target scan), therefore a disease 
associated decrease in these miRNA may result in an subsequent increase in TTP.  
It may be beneficial to compare TTP expression in the OA and normal cartilage, 
thus providing evidence as to whether it is altered in disease. From here work 
could be carried out to identify miRNA that may be involved in disease 
regulation of TTP.  Furthermore, as various splice variants of BMP-7 exist, it 
would be of interest to investigate which of these are more commonly expressed 
in OA, as some will have more TTP binding sites than others, thus impacting 
their potential for TTP targeted regulation.      
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Another explanation for the presence of the BMP-7 protein, despite the lack of 
transcript, could be that the observed protein may be latent and the transcript 
may have been produced at an earlier point in the disease process. It must be 
considered that one of the major caveats of this study was that only diseased 
tissue could be accessed. It has been reported in the literature that if  BMP-7 is 
not processed to its mature form then the prodomain is able to anchor the 
protein complex to the N terminal of the ECM component fibrillin 1 (112) thus 
creating a store of inactive protein. Further to this it has also been suggested 
that the mature protein could be stored in a similar fashion, as it has been 
reported that after cleavage the pro-region can remain non-covalently 
associated with the mature protein; again facilitating binding to the ECM (111). 
Therefore, it is possible that when the protein is required the cleavage enzyme 
furin may be up-regulated, activating the latent ‘pro’ protein and initiating 
signalling.  The data presented above (Figure 4.16) would offer support to this, 
as furin was increased in some of the donors in the eroded cartilage compared to 
the non-eroded cartilage suggesting that these cells may be trying to activate 
the anabolic capacity of the BMP signalling pathway at this time of stress. If the 
study had been adequately powered (power calculation suggests that the study 
was significantly underpowered) then perhaps this increase in furin would have 
reached significance.  There is further evidence to support the idea that the 
BMP-7 detected is latent and may be the remnants’ left from the chondrocytes 
last anabolic stand before the catabolic insurgence took over the joint; with 
work carried out using osteoblasts suggesting that BMP-7 expression is correlated 
to ECM production (245). Therefore, with the anabolic/catabolic battle featured 
in OA it could be speculated that as the catabolic influences take over the joint 
there is an associated decrease in ECM synthesis and therefore a decrease in 
BMP-7 expression.  This idea would also support the data that was generated 
reporting a decrease in BMP-7 in the cartilage of those with OA (150).  However, 
discrepancies existing in the literature cannot be ignored with some groups 
reporting an increase in the levels of BMP-7 in synovial fluid, plasma and 
cartilage, as disease progresses (153,228), whilst others have published 
unaltered BMP-7 levels in the synovial fluid of healthy controls and OA patients 
(151).  
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 The data generated from this study can confirm neither of the previous findings 
with regards to plasma and synovial fluid expression and would in fact suggest 
that BMP-7 is not present within the plasma at concentrations detectable with 
commercially available ELISAs.  Most other groups that have measured BMP-7 by 
ELISA have utilised an in house method (148,151,246,247), with only two other 
groups having used commercialised ELISA kits in quantifying the protein. 
Honsawek et al show that BMP-7 could be detected using an R&D systems kit, 
although they report values below the limit of detection for the assay used, 
(153). They also state that the synovial fluid levels, as well as the plasma levels, 
are increased in OA compared to the control. However, the only control samples 
appear to be from the plasma and therefore the synovial fluid had no 
appropriate control and a true comparison could not be made.   Schmal et al 
used another R&D systems kit and reported detection the protein, however, it 
must be considered that their samples were taken from ankle OA which may be 
different with respect to BMP-7 expression. The remaining groups used non 
commercially validated self-designed ELISAs; three of the groups use a method 
that is detailed in a publication by Chubinskaya in 2002 (148), utilising 2 capture 
antibodies, a polyclonal and a monoclonal antibody raised against BMP-7, thus 
perhaps giving rise to a more sensitive method of detection. The fourth group 
used an alternative protocol for their in house ELISA (247).  Chubinskaya et al 
detail the validation of their assay through the generation of a standard curve 
with recombinant BMP-7, however the other group do not demonstrate the use 
of appropriate standards or controls.  Some of these self-designed ELISAs report 
BMP-7 levels in the regions of  50 ng/ml in OA, which has been reported as 
comparable to control expression levels (151). They further report that BMP-7 
protein expression is increased in RA, 100 ng/ml, when compared to the OA and 
control fluids.  Additionally those reporting success in quantifying BMP-7 protein 
expression using the commercially available kits have yielded concentrations of 
approximately 50 pg/ml, giving a discrepancy of 3 log orders.  Therefore, once 
again, there appears to be disparity in the literature over the quantifiable levels 
of BMP-7 in both the plasma and synovial fluid.   
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 Alternative Roles for BMP-7 – BMP-7s Role in the 4.4.4
Vasculature 
From the data generated in this study alone, the most likely source of the BMP-7 
is the synovium, as both the transcript and protein were readily detectable in 
the tissue using qPCR and IHC respectively.  This staining is predominantly in the 
endothelial cells of the blood vessels. Despite the published literature detailing 
the transcript expression of BMP-7 in the synovium (248), this is the first time 
that the localisation of BMP-7 has been shown using  IHC. BMP-7 has been shown 
to up-regulate the expression of vascular endothelial growth factor (VEGF) at 
both the transcript and protein level in both human and bovine ovarian granulosa 
cells (249,250) therefore, its presence in the inflamed, highly angiogenic OA 
synovium (46) may not be all that unexpected due to VEGFs involvement in 
angiogenesis.  
In health, it is possible that the presence of BMP-7 in the vasculature may be a 
protective mechanism preventing vascular calcification. An inverse relationship 
has been reported between single nucleotide polymorphisms (SNPs) in the BMP-7 
gene and the associated components of both vascular calcification and reduced 
bone mineral density (252). In addition, it has been demonstrated that BMP-7 
offers protection against vitamin D induced vascular calcification (253). The 
results from this chapter report that qualitatively there appears to be more BMP-
7 staining in the vasculature of OA patients compared to RA patients, thus 
suggesting that mechanisms involved in RA associated angiogenesis may be 
different to that of OA.  These differences may contribute to the strong 
correlation between RA and cardiovascular disease (254). The fact that there 
appears to be more BMP-7 present in the vasculature of the OA synovium is 
consistent with the fact that the prevalence of coronary heart disease is only 
27% in OA compared to 49% in RA (255). Despite the lower prevalence in OA, 
work has begun to try and better understand CVD and OA using cross sectional 
and longitudinal studies. Overall most have reported a correlation between OA 
and heart disease, however, it must be taken into account that some groups 
have not corrected their analysis to reflect BMI (256). It has also been shown 
that obesity is a strong determining factor for hand OA, and may be the 
contributing factor to the CVD co-morbidity (257). A recent study noted that 
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when data was adjusted for several risk factors including BMI, a correlation 
between OA and CVD still existed. However, the study relied on patient self-
reported data and therefore lends itself to bias from false positive and negative 
results (256). Even with these caveats, a relationship between OA and CVD 
appears to be consistent and is an area where investigation into biological 
mechanism is required. With a lack of non-diseased synovium, no analysis can be 
conducted into altered BMP-7 expression in the endothelial cells in OA.   
 MiR24 Dysregulation as a Driving Factor of Disease 4.4.5
Progression.  
The expression of the three miRNA’s of interest miR24-3p, miR342 3p and 
miR342 5p were unaltered in the cartilage when compared to a non-weight 
bearing internal control.  This may not be surprising as all the cartilage was from 
an OA disease environment and the femoral notch is only a true control for 
mechanical loading on the cartilage. If OA origin stems from a more global 
cause, then it would be suspected that all of the cartilage would be affected by 
the driving factors of disease and not just the areas exposed to excessive 
loading.  These may include age related changes in gene expression within the 
cartilage (222) or obesity leading to increased fat accumulation, adipokine 
production and pro-inflammatory mediator secretion (258).  
Studies have been carried out to investigate the expression of miR24 in the 
cartilage of OA patients and healthy controls, these show that there is a disease 
associated decrease in miR24 expression (195). They go on to further suggest 
that a decrease in this miRNA is a driving factor in disease.  It is stated that a 
decrease in miR24 results in a reciprocal increase in the cell senescence marker 
p16INK4a and thus an increase in the senescence-associated secretory phenotype 
SASP secretome (Section 1.4.4.4). This can contribute to enhanced cartilage 
degradation through the expression of matrix degradation enzymes such as MMP-
1 and MMP-3.  In this chapter, the level of plasma miR24 is consistent with the 
finding of Philipot et al, however, the functional data generated within this 
chapter does not support their hypothesis.  The observed over-expression of 
miR24 3p in this chapter resulted in the down-regulation of two BMP receptors, 
ALK2 and BMPR1B,  both of which are involved in anabolic aspects of matrix 
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remodelling. Further to this in the OA patients investigated, a significant 
negative correlation existed between the expression of miR 24 and the receptor 
ALK2.  Therefore, if this miRNA were suppressed in the cartilage, it would 
suggest that the cartilage is attempting to increase anabolism in order to combat 
on-going destruction. Whereas Philipot et al would suggest dampening of this 
miRNA is a driving factor perpetuating OA. The caveat to both studies is the use 
of ex vivo chondrocyte culture systems, therefore, the true disease environment 
can no longer be recapitulated as OA is a multifactorial disease of the joint not 
just of cartilage.  
Philipot et al claim the initial decrease in the miR24 controlling the p16INK4a is a 
result of aberrant IL-1β expression. However, in other experiments conducted in 
this study (data shown in chapter 5), no changes in the expression of miR24 were 
observed following IL-1β stimulation. It is possible that culture method of the 
chondrocytes could lead to differing results, as the chondrocytes in this study 
were cultured in plastic as opposed to pellet cultures which were used by 
Philipot et al.  
In order to begin to understand the complex role this miRNA may play in disease, 
a summary of the work carried out in this study and the data published by 
Philipot et al was generated (Figure 4.25A). Firstly Philipot et al suggest that 
miR24 is expressed in normal cartilage tissue and has a role in regulating 
p16INK4a, which in turns dampens the SASP secretome (Figure 4.25A) (195). In 
disease states, such as OA, an initial increase in IL-1β, either from an acute 
tissue injury or from other disease associated molecular dysregulation, results in 
senescent chondrocytes which facilitate an IL-1β mediated down-regulation of 
miR24. This results in increased P16INK4a and therefore an increase in the SASP 
secretome (Section 1.4.4.4), leading to catabolic destruction of the joint. The 
hypothesis generated from this study is based on the miR24 mimic data, as 
healthy cartilage could not be obtained.  This suggests that at the end stage of 
disease miR24 3p is able to target the BMP receptors thus blocking BMP signalling 
(Figure 4.25B). As previously mentioned, there are strong negative correlations 
between the miRNA expression and the expression of the target mRNA, ALK2, in 
the cohort investigated in this study; supporting this in vitro observation. 
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However, data regarding expression of the targets in healthy cartilage remains a 
vital yet unanswered piece of the story.   
Both studies focus predominantly on end stage disease and therefore have 
missed another massive piece of this disease-derived jigsaw. At some point 
between the onset of disease and the symptomatic diagnosis of OA there is a 
battle between anabolic and catabolic processes within the joint. Here the 
anabolic factors work to suppress the increasing catabolic destruction.  The 
levels of miR24 at these early stages of disease would be of great interest, as it 
would provide pivotal information as to the overall role of this miRNA in the 
disease process.  
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Figure 4.25 Predicted Functions of miR24 3p in Healthy and OA Cartilage. 
A) MiR24 3p’s regulation of p16INK4a in both healthy and OA chondrocytes. MiR24 3p is able to 
repress the expression of p16INK4a in healthy cells, however in OA expression of miR24 3p is 
dampened by IL-1β leading to increased p16INK4a and therefore increased MMP-1 and MMP-3. 
Schematic is based on work carried out by Philipot et al (195). B) MiR24 3p regulation of BMP 
receptors leading to a decrease in anabolic capacity in OA compared to healthy cartilage via 
diminished BMP-7 signalling. Schematic based on the data generated in this study and speculation 
of miR24 3p regulation of the BMP receptors from the miR24 expression data in healthy cartilage 
provided by Philipot et al. C) Potential differential mechanisms of miR24 3p control over the course 
of OA disease from onset through to end stage disease. MiR24 3p is potentially down-regulated by 
an initial insult to the joint (IL-1β mediated) leading to an initial increase in catabolic activity. During 
the interim phase of disease it is possible that the expression of the miRNA is increased in order to 
dampen the increasing anabolic activity (through the BMP receptors) that is trying to outcompete 
the catabolism occurring within the joint space. Finally, by the point of end stage disease the 
miRNA expression has again been decreased facilitating both anabolic and catabolic activity 
depending on the cells producing the miRNA.  It would be assumed by this stage that some of the 
chondrocytes may be apoptotic and no longer able to signal effectively.    
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It is possible that the data generated from both this study and Philipots et al  
may in fact hold true with regards to OA, despite the fact they appear to be 
contradictory (Figure 4.25C).  Firstly, it must be considered that the miRNAs 
result in the fine tuning of protein expression and furthermore it has been 
suggested that they may have various opposing functions depending on the 
microenvironment that they are exposed to (251). Therefore, it would be 
hypothesised that initial trauma to the joint would result in IL-1β production as 
suggested by Philipot  et al, this could dampen miR24 expression allowing a 
pathological environment to arise that facilitates an increase in the SASP 
secretome via by P16INK4a (first panel, purple). It is then well established that the 
joint attempts to withstand this catabolic insult for as long as possible. If the 
catabolic mediators are to continue outcompeting this anabolic fight back, 
subtle alterations in the local environment may be beneficial. To this end 
increased expression of miR24 could lead to a decrease in BMP receptor 
expression and ultimately the dampening anabolic signalling events; thus giving 
the catabolic mediated erosion an advantage (second panel, orange). By the 
point of end stage disease, it is hard to determine if the articular chondrocytes 
are still fully functional, therefore, it must be considered that not all 
chondrocytes will behave in a homogenous fashion. The cells from the most 
eroded areas may be taking advantage of the miR24 dampening by up-regulating 
BMP signalling and trying to facilitate anabolic actions, as supported by the 
modest increase in receptor expression observed in the eroded cartilage shown 
in this chapter.  However, other cells may be perpetuating the catabolic activity 
by increasing P16INK4a and its associated catabolism (third panel, red). This 
hypothesis is supported by data detailing altered expression of  miR24 in the OA 
synovial fluid in early and late stage disease (210). The data suggested that 
miR24 has lower expression in early disease which would agree with the Philipots 
increased SASP secretome.  However, in late stage disease the expression of 
miR24 is shown to be greater therefore this increase may dampen anabolic 
signalling via targeting of the BMP receptors supporting the data shown in this 
study (210).  
To eradicate any bias in the culture system it would be interesting to investigate 
the role of miR24 in OA using chondrocyte specific, miR24 conditional knock out 
mice. This would allow confirmation of whether the miRNA is a confounding or 
169 
 
  
protective factor in OA progression. Using these mice, investigation into both the 
expression of p16INK4a and the BMP receptors BMPR1B and ALK2 could be 
examined over the course of the disease.   
It is possible and very likely that miR24 targets all of these transcripts. Work has 
been carried out suggesting that a miRNA may have opposing roles on the 
expression of a transcript that are dependent on the cell cycle stage (251).  It 
has been suggested that certain miRNA in proliferating cells repress the 
expression of TNFα, whereas cell cycle arrest facilitates translational activation.  
Two features have been suggested for this alternative regulation by the miRNA; 
firstly under cell cycle arrest recruitment of micronuclear proteins are required 
for interaction with the mRNA and secondly, argonaute 2 (AGO2) tethering which 
is required to facilitate translational activation (251).  It could therefore be 
considered that miR24 may have a dual capacity, differentially regulating 
transcripts and therefore disease stage may not be the only factor that is 
controlling miR24 expression or its effector function. Cell cycle stage could also 
have a role in controlling the function of the miRNA, however this remains to be 
confirmed. The work undertaken here along with that of Philipot et al would 
suggest that miR24 3p is decreased at end stage disease when chondrocytes may 
no longer be functioning properly, or more likely not functioning in a 
homogeneous fashion, which could potentially result in some cells responding to 
the down regulation in an anabolic manner and others in a catabolic manner. It 
must be taken into consideration that neither study has looked at the expression 
of this miRNA at disease onset or over the course of the disease.  This is likely 
due to our inability to pinpoint the onset of disease in humans, which to date 
remains one of the major challenges in the field.  It therefore falls to animal 
models of disease to elucidate if this miRNA is differentially regulated 
throughout disease progression.   
 Circulating miRNA Signature in OA 4.4.6
The OA field is in need of biomarkers that are indicative of disease onset before 
symptomatic disease develops. Currently intervention only occurs at the point of 
diagnosis (which is when symptoms develop) and may not be as successful due to 
the extent of damage already exerted on the joint.  Here, four miRNA’s have 
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been shown to be downregulated in the plasma of OA patients with end stage 
disease compared to aged matched healthy controls, providing a valid non-
diseased control to make a comparison against, something that has been lacking 
throughout all of the chondrocytic analysis conducted so far.  This by no means 
should be taken as a biomarker signature at this current juncture; however, with 
further work and validation it may prove useful in the future.  Some of the 
miRNA’s used in this study had previously been shown to be associated with OA, 
such as the Let7e, which has been highlighted as a negative indicator in the 
need for arthoplasty, (209).  Here it was found that this miRNA was significantly 
down-regulated in patients under-going knee arthoplasty compared to healthy 
control, validating the findings of Beyer et al.  Furthermore it has been 
suggested that miR342 is actually increased within the cartilage of OA patients 
compared to healthy controls (186), where in this study a converse finding has 
been observed within the plasma. It is worth noting that the isoform of the 
miRNA that was investigated by Jones et al is not disclosed making it very 
difficult to draw a real comparison. It must also be considered that the 
expression in the circulation may not always match that of the cartilage due to 
tissue specific microenviromental influences on miRNA expression. The data 
presented above also did not corroborate the findings regarding miR342 3p 
expression from the Beyer et al paper, as they reported no changes in the 
expression in OA (209) in the plasma. The data generated here, with regards to 
miR24 3p expression, was recapitulated in the cartilage by a study carried out by 
Philipot et al. Synovial fluid analysis of miR24 3p in early and late stage disease 
did not show the expected decrease, but instead displayed an increase of the 
miRNA in the OA synovial fluid as the disease progressed (210).  miR140 was the 
last miRNA in the potential signature to be uncovered. It was primarily 
investigated since it has been implicated in cartilage homeostasis and OA 
(191,232). It was also highlighted as a miRNA of interest with regards to OA in 
the Beyer cohort.  Here it has been shown to be down-regulated in OA compared 
to age matched control plasma. This would be expected, as if this miRNA does 
indeed play a role in the maintenance of the cartilage, patients presenting with 
end stage OA are most likely not going to display characteristic well controlled 
cartilage homeostasis.  
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There are several hurdles to be overcome before these miRNAs can be 
considered a ‘signature’. Firstly, their expression in other musculoskeletal joint 
diseases including RA, AS and PsA would need to be interrogated, establishing 
the disease specificity these findings.  Also, contributing factors to OA such as 
obesity, age and acute joint damage would have to be investigated to assess 
their impact on the expression of these miRNA in isolation.  Finally, it must be 
understood that all data presented here represents end stage disease, it would 
be hoped that this signature may be observed at an early stage in disease onset, 
thus allowing it to be used to identify those with disease before irreversible joint 
destruction occurs.   All together these data provide insight into miRNA 
deregulation in the plasma of OA patients that one day may help to inform a 
diagnostic circulating signature in OA, however, there is still a vast amount of 
work to be undertaken before this would be clinically relevant. 
 Limitation of the Study 4.4.7
The study is limited in several areas. Firstly, the study is considerably 
underpowered for determining significant trends in molecular components of the 
BMP-7 signalling pathway.  Due to cost and practical constraints a larger cohort 
was regrettably not obtainable.  Furthermore, lack of a control tissue (non-
diseased cartilage) was also a major hindrance to the study, as without this 
resource only internal control comparisons could be made. Several attempts 
were made at obtaining a source of non-OA cartilage but none were ever 
brought to fruition.   
Relative quantification was possibly not the optimal qPCR technique to screen 
transcript expression. Instead absolute quantification may have been a more 
useful and informative tool, as this would have given exact values for expression 
of the transcripts straight from their physiological environment. Cartilage 
adhesion to the IHC slides was also an inhibitory factor within the study, as 
linked patients analysis was impossible due the random nature by which the 
sections adhered to the slides.   
Finally, due to time constraints it was not possible to validate the mRNA 
transcripts as direct targets of miR24 3p through luciferase assays, which would 
have given greater significance to this finding in this study. 
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  Conclusion 4.4.8
From this chapter it can be confirmed that there is still no conclusive evidence 
that BMP-7 is produced at the transcript level by primary human chondrocytes. 
What was apparent, however, was the localisation of the BMP-7 protein in the 
cartilage, especially in areas of typical OA cell clustering (240) . It has been 
suggested here, through in silico analysis, that TTP degradation of the transcript 
may play a role in the evasiveness of the transcript from most of the molecular 
detection methods employed here. It is possible that BMP-7 protein has 
remained bound to the ECM by the ‘pro’ domain of the protein, thus the protein 
is detectable and not the transcript. Furthermore, subtle changes in BMP-7 
signalling family members were observed within the OA cartilage when 
comparing eroded and non-eroded sections of tissue. As with most of the study, 
a lack of healthy control tissue was a major hindrance in the interpretation of 
the data. The study was also underpowered and therefore the statistical 
significance of these changes could not be elucidated.  MiRNAs that were 
predicted to target members of this signalling family of interest were also 
expressed within the cartilage. Moreover, miR24 3p has now been shown to 
regulate BMP receptors and has also been shown to have a significant negative 
correlation to their expression in a cohort of OA patients. Finally, plasma 
analysis of disease-associated miRNAs has revealed a deregulation of 4 miRNAs in 
OA patient plasma, however the disease specificity remains to be clarified.  
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5 Elucidating the Impact of Exogenous BMP-7 on 
Chondrocytes. 
5.1 Introduction 
In the previous chapter, characterisation of the BMP-7 signalling family in end 
stage OA cartilage was undertaken and suggested that all of the necessary 
components are present in OA patients for subsequent response to BMP-7 
therapy.  Whilst it is essential to understand if individuals have the capacity to 
respond to BMP-7, it is also essential to understand this response at a molecular 
level, as this adds to the current understanding of OA and may also help in the 
development of future therapeutics.    
Exogenous BMP-7 has been shown to be an effective therapeutic agent in several 
animal models of OA and cartilage damage (158,159,160,220),  however, the 
precise mechanisms responsible for this BMP-7 mediated protection remain 
unclear.  One mechanism that has been suggested is BMP-7 mediated up-
regulation of collagen, thus helping to maintain cartilage integrity 
(158,159,220,233). BMP-7 has been reported to up-regulate the CD44 receptor 
and hyaluronic acid synthase, both of which are known to be implicated in the 
production of extracellular matrix (156). Moreover, if CD44 is knocked down 
then a higher concentration of BMP-7 is required to elucidate an anabolic ECM 
synthetic response from chondrocytes(156). Therefore, CD44 mediated ECM 
production may be one of the ways in which BMP-7 is able to maintain the ECM.  
BMP-7’s role in maintaining ECM and as a therapy for OA does not seem to be 
solely based in the anabolic properties of this protein.  An anti-catabolic effect 
of BMP-7 has been proposed and may have a comprehensive role in preventing 
disease development through suppression of catabolic activity. Takahashi et al 
suggest that prophylactic BMP-7 can prevent the initial IL-1β response that 
occurs in the first 24 hours after tissue insult with zymosan.  They also suggested 
that continued treatment with BMP-7 results in an increase in the 
immumomodulatory cytokine IL-10, which is often regarded as having anti-
inflammatory properties.  Furthermore, their data suggests that the addition of 
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BMP-7 into the joint can up-regulate BMP-7 protein in articular chondrocytes and 
within the synovium. BMP-7 was also reported to prevent macrophage infiltration 
into the synovium, which occurred following zymosan injection in the control 
animals (158).   
The observation that BMP-7 can work to supress IL-1β (158) is of great interest, 
as it is one of the most studied pro-inflammatory cytokines in OA. The 
importance of its role has been highlighted in mouse models, where monoclonal 
antibodies that block both IL-1β and it’s receptor IL-1Rα are sufficient to 
prevent disease progression.  Additionally, IL-1β rapidly (i.e. within 4 hours)  up-
regulates several early response genes including the matrix degrading enzyme 
MMP-13 (260). It was observed that these early responses are maintained for up 
to 24 hours post stimulation (261) which may account for an IL-1β driven 
catabolic attack on the joint leading to pathological changes and ultimately 
disease. Furthermore, an inductive role for IL-1β has been shown (263), where 
IL-1β will promote an up-regulation of its own transcript. This can be important 
in certain circumstances, such as wound healing(262), however, it must be 
regulated so as not to lead to chronic IL-1β signalling that could be damaging 
and aid disease progression (264).   
Elucidating the role of exogenous BMP-7 with regards to chondrocytes is one of 
the primary aims of this study. There are a variety of cell lines that can be used 
to mimic the actions of chondrocytes: CHON-001 a foetal derived long bone cell 
line, ATDC5 a teratocarcinoma mouse cell line and SW1353, a human derived 
chondrosarcoma cell line. One major advantage of using a cell line for 
preliminary work as opposed to primary cells is the homogeneity and 
proliferative capacity. The SW1353 chondrosarcoma cell line has been shown to 
be an ideal cell line for investigating catabolic regulation of chondrocytes. For 
example, their response to IL-1β is the same to that of primary chondrotyes 
(265). Moreover, the expression profile of catabolic genes such as MMPs 1,3 and 
13 is similar in both SW1353 and primary cells(265). However, it is important to 
note that some characteristic chondrocytic genes (i.e. extracellular matrix 
components including collagens type II, III and XI as well as aggrecan) are not 
expressed in this cell line and thus they cannot mimic the actions of the primary 
cell completely (265). As primary chondrocytes are a limited resource and 
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cannot be cultured long term due to dedifferentiation (Chapter 3), a cell line is 
an ideal starting point for the generation of preliminary data.   
It is unlikely that the exogenous effect of BMP-7 will be restricted to 
chondrocytes alone, and it is possible that other cells in the OA joint will also 
respond to exogenous BMP-7. This could include fibroblast-like synoviocytes 
(FLS), endothelial cells or infiltrating leukocytes (i.e. monocytes/macrophages). 
Interestingly, it has previously been shown that BMP-7 can skew the THP-1 cell 
line (monocytic cells) to an M2-like (anti-inflammatory) macrophage (144). THP-
1 cells express the BMP receptor BMPR2, which is subsequently up-regulated 
following stimulation with exogenous BMP-7(144). Furthermore, upon stimulation 
with BMP-7 these cells secrete the anti-inflammatory cytokine, IL-10(144).  
Despite all the work into investigating BMP-7 mediated macrophage polarisation, 
there is nothing in the literature that indicates if this cell line phenomenon 
manifests itself in primary human macrophages.    
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5.2 Aim 
Whilst the roles for endogenous BMP-7 have already been intensively studied in 
animal models within the literature, there is still much that is not understood 
about the exogenous effects of this growth factor in humans. This study 
hypothesised that BMP-7 may not only regulate CD44, but may also have an auto-
regulatory impact promoting the up-regulation of itself and its own signalling 
family. Additionally this study further hypothesised that BMP-7 may have an 
inhibitory effect on any IL-1β modulation that may occur with BMP-7 itself or the 
related signalling family members. Finally due to the work carried out by Roche 
et al, it has been hypothesised that BMP-7 will polarise primary macrophages 
towards an M2 anti-inflammatory phenotype. Accordingly, this chapter aims to: 
1. Delineate BMP-7’s effect on both BMP-7 and the BMP-7 signalling family in 
the SW1353 cell line and primary chondrocytes. 
2. Deduce if BMP-7 is protective against IL-1β mediated catabolic destruction 
in the SW1353 cell line and primary human chondrocytes. 
3. Define any role for BMP-7 in the polarisation of primary macrophages.   
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5.3 Results 
 Effects of Exogenous BMP-7 on the BMP-7 Signalling 5.3.1
Cascade: SW1353 Cell Line 
It has previously been demonstrated that the chondrocytic cell line SW1353 is a 
particularly useful tool in investigating catabolic processes (265). However, the 
usefulness of this cell line for the interrogation of the BMP-7 signalling family 
has yet to be established. It was therefore critical to characterise the 
endogenous expression of the BMP-7 signalling family members prior to 
performing any additional studies. Accordingly, the expression level of BMP-7, 
ALK2, BMPR2 and furin -along with accessory components, follistatin and CD44- 
were established in the SW1353 cell line. Effector components (type II collagen 
along with two catabolic mediators, (MMP-13 and IL-1β) were also investigated. 
QPCR revealed that all of the genes were detected (Figure 5.1) within the 
confines of the assay (i.e. have values less than that of the NTC), with the 
exception of type II collagen as it is not expressed in the cell line (265) and IL-
1β, which was detected at similar levels to the NTC- a finding that had already 
been reported with the cell line (265). 
Having established that the SW1353 cell line expresses members of the BMP-7 
signalling family it was also important to validate the catabolic response of the 
cell line. This was achieved by stimulating the cells with IL-1β and verifying the 
induction of MMP-13. Stimulation of SW1353 with 10, 50 and 100ng/ml IL-1β 
resulted in an increase in MMP-13 transcript expression (Figure 5.2), which was 
most consistently up-regulated at both 50 and 100ng/ml. Thus, in all subsequent 
studies, stimulation with IL-1β at 100ng/ml was used. Furthermore, due to the 
variation seen in IL-1β mediated MMP-13 up-regulation (Figure 5.2), it was 
decided that MMP-13 was a necessary positive control in each experiment to 
allow validation of each stimulation with this cytokine.  
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Figure 5.1 Endogenous Expression of BMP-7 Signalling Family Members and Other 
Associated Transcripts in the SW1353 Chondrosarcoma Cell Line.   
Gene analysis for β-actin, ALK2, BMPR2, BMP-7, follistatin, type II collagen, MMP-13, IL-1β, 
furin and CD44 in the SW1353 cell line. Cells from 1 passage were plated in triplicate, each of 
these technical replicates are shown on the graph as CT values. NTC values shown for both 
type II collagen and IL-1β as the observed CT values for these genes were very close to the 
NTC.   
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Figure 5.2 IL-1β Induction of MMP-13 is Observed in SW1353 Cells.   
MMP-13 transcript analysis for SW1353 cells stimulated with 10ng/ml, 50ng/ml or 100ng/ml IL-
1β for 24 hours. Data is shown as fold change (2-ΔΔCT) using the unstimulated cells as a 
baseline.  Cells from 4 different passages were stimulated in 4 separate experiments, technical 
replicates were pooled, for each passage,  in order to generate 1 point, N=4. Statistical 
analysis was conducted using Kruskal Wallis, Dunn’s multiple comparison post test.  
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To investigate if the modulation of the BMP-7 signalling family by a variety of 
cytokines that have been related to OA, was an early or late response 
mechanism, cells were stimulated for 3 or 48 hours with either: IL-1β, BMP-7, 
TNFα or IL-6. Validation of the cells lines response to stimulation was assessed 
via IL-1β up-regulation of MMP-13 as discussed previously. At the 3 hour time 
point, the only early response gene significantly up-regulated was the IL-1β 
transcript in response to IL-1β stimulation (Figure 5.3A). Interestingly, BMP-7 
stimulation caused an up-regulation of IL-1β transcript in the cell line (between 
2 and 20 fold increase), however, due to the variance in this response it did not 
reach significance. BMP-7 had no effect on any of the other genes at this time 
point. TNF and IL-6 also had no significant impact on any of the transcripts 
investigated at the three hour time point. At the 48 hour, late response, time 
point IL-1β displayed a significant increase in its own transcript expression, with 
the transcript increasing between 10 and 50 fold (Figure 5.3B). MMP-13 was also 
up-regulated between 8 and 10 fold by IL-1β stimulation as expected. BMP-7, 
TNF and IL-6 had no significant effect on any of the transcripts investigated at 
the late response time point.   
As BMP-7 was unable to modulate it’s own anabolic signalling pathway in the 
SW1353 cell line, it was decided that its ability to prevent IL-1β’s up regulation 
of catabolic (MMP-13) and inflammatory (IL-1β) mediators should be 
investigated. Furthermore, as IL-1β had previously displayed the potential to 
increase BMP-7 expression, BMP-7 transcript analysis was also carried out with 
regards to co-stimulation.  Cells were stimulated with IL-1β, BMP-7 or IL-1β plus 
BMP-7, and RNA was harvested at 8, 24 or 48 hours post stimulation to evaluate 
transcripts expression (Figure 5.4). As expected, IL-1β stimulation led to an up-
regulation of both MMP-13 and its own transcript at all three time points.  
Furthermore, at the 8 hour time point IL-1β stimulation induced a 2-fold 
increase on BMP-7 expression (Figure 5.4B), which was consistent with the 
previous experiment (Figure 5.3B). BMP-7 alone had no impact on the expression 
of MMP-13, however at 24 hours post stimulation it down-regulated IL-1β 
expression by 25%. BMP-7 also appeared to cause a 50% inhibition of its own 
transcript expression at 24 and 48 hours, which was not observed in the previous 
stimulations. Co-stimulation with both IL-1β and BMP-7 had no impact on BMP-7 
expression. However, after 48 hours BMP-7 co-stimulation inhibited IL-1β 
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mediated MMP-13 up-regulation by 50% and was able to completely inhibit the 
expression of IL-1β. In order to elucidate if the inhibition of IL-1β was specific to 
BMP-7, the cells were co-stimulated with another TGFβ superfamily member, 
TGFβ3 ( Figure 5.4 D). The SW1353 cells responded as expected to various 
concentrations of IL-1β. However, co-stimulation with a range of concentrations 
of both IL-1β and TGFβ3 had little effect on the MMP-13 expression. This 
suggests that the dampening of IL-1β induced MMP-13 up regulation is not a 
global TGFβ superfamily mechanism.  
 The data produced by the cell line was not consistent, with BMP-7 having 
different effects. It either had no effect or caused a 50% inhibition of it’s own 
transcript and that of IL-1β between different experiments (Figure 5.3/Figure 
5.4).  Significant variation between replicates in each experiment could also be 
observed. Further work was undertaken in order to reduce this variation; cells 
were synchronised in relation to cell cycle stage, using serum starvation, 
however this had no impact on the variation in the results (data not shown).  
Cells from a lower passage were also obtained and again had no bearing on the 
variation of the results  (data not shown). In order to overcome this 
inconsistency with the cell line, primary cells were used in subsequent 
experiments for in vitro analysis.  
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Figure 5.3 SW1353 Early and Late Response to Cytokine Stimulation. 
SW1353 cells stimulated with either IL-1β, BMP-7, TNFα or IL-6, all at 100ng/ml, for either  A) 
3 hours  time point with 5 different passages of the SW1353 cells were run in technical 
triplicates then pooled, N=5 or B) 48 hour time point ) 4 different passages of the SW1353 cells 
were run in technical triplicates then pooled N=4. Cells were stimulated in two batches; the 
average of the unstimulated cells from each batch was used in order to generate a baseline 
value for fold change analysis (2^-ΔΔCT). The following genes were analysed using SYBR green 
qPCR: BMPR2, BMP-7, MMP-13, IL-1β, follistatin (FST),  furin,  CD44. Statisitcal analysis was 
conducted using Kruskal Wallace test with Dunn’s multiple comparison post test.  ** P<0.01,    
* P<0.05 
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Figure 5.4 SW1353 Responses to Co-Stimulation with IL-1β and BMP-7.  
SW1353 cells stimulated with either IL-1β (100ng/ml), BMP-7 (100ng/ml) or both together for 
either,  8 hours,  24 hours or 48 hours, N=2 and the following genes were quantified using 
qPCR (SYBR green): A) MMP-13, B) BMP-7 and C) IL-1β. The data is shown as fold change 
over the unstimulated cells (2-ΔΔCT). D) SW1353 cells were also stimulated with 100ng/ml, IL-1β 
or TGFβ3 or both. MMP-13 expression was quantified using qPCR (SYBR green) and data 
shown as fold change (2-ΔΔCT) using the unstimulated cells as baseline, N=3. Kruskal-Wallace, 
Dunn’s multiple comparison post test was used to asses statistical significance, * P<0.05 
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 Effect of Exogenous BMP-7 in Primary Articular 5.3.2
Chondrocytes 
The cell line provided limited, variable and non-reproducible data as well as 
expressing only a limited number of genes. It was therefore decided that all 
further investigations should be carried out in primary human chondrocytes. 
Non-eroded cartilage (Outerbridge score 0-1) was taken from OA patients (who 
had given informed consent) at the time of total knee replacement surgery at 
the Glasgow Royal Infirmary. The cartilage was digested (section 2.2.2), 
releasing the chondrocytes from the matrix, which were then washed and plated 
for 48 hours, allowing acclimatisation before stimulation, described in chapter 3.  
Initial experiments examined the effect of exogenous BMP-7 on the BMP-7 
signalling family members.  Previous studies have shown that the BMP-7 protein 
was up-regulated by addition of exogenous BMP-7 in an animal model of OA 
(158). These studies investigated protein expression via IHC and thus did not 
determine whether or not this was due to transcriptional enhancement or just 
exogenous BMP-7 up-take by chondrocytes at the time of injection. In order to 
address this, analysis of the BMP-7 transcript was carried out following 
stimulation with BMP-7. Here it has been hypothesised that BMP-7 will not only 
induce its own expression, but also that of the transcripts of its own signalling 
family. To this end, cells were stimulated with BMP-7 at 100ng/ml for either 8 or 
24 hours, before being placed in cytokine free media. Analysis was carried out 
using qPCR in order to allow the necessary verification of this auto-regulatory 
mechanism at the level of the transcript (Figure 5.5A). To take into account the 
very low levels of endogenous BMP-7 transcript, which is close to the non-
template control samples, all data generated for this gene is displayed as 2-ΔCT. 
In explanation, fold change (2-ΔΔCT) analysis requires the unstimulated control to 
be within the normal range for the assay, as this would be used to calculate a 
baseline value. If this lies to close to the NTC then the data cannot be 
transformed without introducing error. The 2-ΔCT shows that 8 hours post 
stimulation there are no changes in the expression of the BMP-7 transcript. 
However, at the 24 hour time point almost all of the donors displayed an up-
regulation in BMP-7 transcript (Figure 5.5B); although this increase did not reach 
significance.  
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Figure 5.5 Effect of BMP-7 on the Expression of BMP Signalling Family in Primary OA 
Chondrocytes.   
Primary chondrocytes plated at 1.5X105/well were stimulated with 100ng/ml, BMP-7 for 8 hours 
before media was replenished with a cytokine free replacement. Cells were lysed at either A) 8 or 
B) 24 hours post stimulation in Qiazol™. Each dot on the graph represents an individual 
chondrocyte donor from which cartilage was taken at the time of TKR surgery from areas of 
Outerbridge score ≤I. Both BMP-7 and IL-1β transcript analysis is shown as 2-ΔCT, with limit of 
detection defined by the average NTC values of all the experiments conducted for that gene of 
interest. The limit of detection for BMP-7 is 2-ΔCT = 0000153 and for IL-1β limit of detection is 2-ΔCT = 
00006104. Transcript analysis for ALK2,  BMPR2,  furin, CD44, Type II collagen and  MMP-13 are 
all shown as fold change (2-ΔΔCT) using the unstimulated cells at each time point as the baseline 
value.  Statistical analysis was carried out using Wilcoxon T-Test.   
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It could therefore be concluded that the chondrocyte response to BMP-7 is subtle 
and a larger cohort would be required in order to gain significance. IL-1β was 
the next transcript to be analysed. In most of the donors an up-regulation of the 
IL-1β transcript was observed 8 hours post BMP-7 stimulation  (Figure 5.5A).  
After 24 hours, IL-1β was up-regulated in all of the donors, however, this 
increase did not reach significance (Figure 5.5B).   
Having noticed that BMP-7 has the ability to up-regulate its own transcript in a 
subtle manner, it was decided to investigate how other members of the BMP-7 
signalling family would respond to 8 or 24 hour BMP-7 stimulations (Figure 
5.5A/B).  These genes included BMP receptors, BMPR2 and ALK2, along with the 
BMP-7 cleavage enzyme furin. Accessory components related to extracellular 
matrix synthesis, CD44 and type II collagen were also investigated along with the 
cartilage degradation enzyme, MMP-13. BMP-7 stimulation had little effect on all 
of the transcripts 8 hours post stimulation. Some of the transcripts, BMPR2, CD44 
and furin, were modulated in a patient dependent manner 24 hours post 
stimulation. The BMP-7 mediated increase observed in MMP-13 expression was 
surprising as previous publications had reported that BMP-7 can inhibit MMP-13 
expression (266). BMP-7 increased MMP-13 expression in all of the donors, 
ranging from a 1.5 - 66 fold increase, however, due to the variance in response 
this did not reach significance.  
This suggests that exogenous BMP-7’s effect on its own signalling family and 
other catabolic mediators varies between donors. This is supported by the data 
generated in the previous chapter (Figure 4.17), which showed that the 
expression of the BMP-7 signalling components varied between patients.  
In the previous chapter it was shown that miR24 3p, miR342 3p and miR342 5p 
were present in the articular cartilage. Further to this it was also shown that 
miR24 3p mimic was able to supress the expression of BMP receptors.  Thus, it 
was decided to investigate whether or not exogenous BMP-7 affects the 
expression of these miRNA in primary chondrocytes. The results concluded that 
there were no effects on the expression of the miRNA following stimulation with 
100ng/ml BMP-7 for either 8 or 24 hours (Figure 5.6).  
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Figure 5.6 Effect of BMP-7 on the Expression of BMP Associated miRNA in Primary OA 
Chondrocytes.   
Primary chondrocytes plated at 1.5X105/well were stimulated with 100ng/ml, BMP-7 for 8 hours 
before media was replaced with a cytokine free alternative. Cells were lysed at either A) 8 or B) 
24 hours post stimulation in Qiazol™. Each dot on the graph represents an individual 
chondrocyte donor from which cartilage was taken at the time of TKR surgery from areas of 
Outerbridge score ≤I. Transcript analysis for miR342 3p, miR342 5p and  miR24 3p, shown as 
fold change (2-ΔΔCT) using the unstimulated cells at each time point as the baseline value.  
Statistical analysis was carried out using Wilcoxon T-Test.   
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 BMP-7s Impact on IL-1β Mediated Effects in Primary 5.3.3
Articular Chondrocytes 
As BMP-7 had shown wide variation in it’s direct regulatory capacity for some of 
the genes of interest in this study, it was decided to further investigate BMP-7’s 
indirect regulatory capacity. Accordingly, investigation into BMP-7’s ability to 
negate any modulation to genes of interest that may be caused by IL-1β was 
conducted. It was hypothesised that IL-1β would have a negative effect on the 
anabolic transcripts of interest as it is considered a pro-inflammatory cytokine 
that is catabolic in the context of OA. It was further hypothesised that BMP-7 
would be able to inhibit any IL-1β induced suppression of the BMP-7 related 
anabolic genes. This hypothesis was originally tested on the SW1353 cell line, 
however, due to a number of issues that arose with the cell line satisfactory 
conclusions could not be drawn (Figure 5.4).  
Primary chondrocytes were stimulated for 8, 24 and 48 hours and again 
endogenous levels of BMP-7 and IL-1β mRNA were close to that of the NTC  and 
thus 2-ΔCT was used to evaluate their expression (Figure 5.7A). Unexpectedly, IL-
1β stimulation resulted in an increase in BMP-7 transcript expression in a donor 
specific manner 8 hours post stimulation  (Figure 5.7A) and not the hypothesised 
decrease. This appeared to be an early response, as there were no effects 
observed at either 24 or 48 hours post stimulation ( Figure 5.7 C/D). Upon 
analysis of the IL-1β transcript (following IL-1β stimulation) the expected 
increase was observed at all time points, although this increase was noted to be 
variable depending on the donor that the chondrocytes were isolated from (all 
donors did display an increase in transcript in at least one of the three time 
points, analysis not shown).   Again, contrary to the hypothesis, BMP-7 had no 
impact on the IL-1β mediated increase of its own transcript. IL-1βs inability to 
negatively regulate the BMP-7 transcript was surprising due to it’s association 
with OA disease progression.  Therefore, it was hypothesised that IL-1β may play 
a role in the down-regulation of BMP-7 signalling components, thus causing 
disruption to BMP-7 mediated anabolic signalling events. The data again show 
that IL-1β does not have the expected negative impact on the transcripts but 
rather, increases the expression of almost all of the transcripts of interest.  
Specifically, CD44 is significantly increased following stimulation with IL-1β for 
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either 8 or 48 hours. The same trend is also observed at the 24 hour time point, 
however this did not reach significance.  MMP-13 was also increased following 
stimulation with IL-1β at all time points as had already been shown in the 
literature (260). Other genes of interest such as ALK2 and BMPR2 were notably 
increased in some of the donors at both 24 and 48 hours post stimulation.  Furin 
also displayed increased expression in some of the donors 48 hours post 
stimulation.  The only gene that was down regulated via IL-1β was type II 
collagen and again this down regulation was only seen in some of the patients 48 
hours post stimulation. Co-stimulation with BMP-7 had no effect on the 
transcripts investigated (Figure 5.8).  Taken together this data suggests that in 
this in vitro system IL-1β is not a negative regulator of the BMP-7 signalling 
family.  However, there appears to be an IL-1β induced decrease in type II 
collagen expression in some of the donors.     
As previously mentioned, IL-1β is thought to be a major driver of catabolic and 
pro-inflammatory events in OA disease pathogenesis.  Therefore, as the 
preceding data (Figure 5.8) demonstrated that IL-1β stimulation has no 
deleterious effects on the expression of BMP-7 signalling family members, it was 
hypothesised that perhaps IL-1β does not directly affect the expression of these 
transcripts.  Rather, it may modulate miRNAs that have been predicted to target 
members of the BMP signalling family. In chapter 4 it was shown that miR24 3p 
inhibits the expression of BMP receptor ALK2. Thus, it is of interest to 
investigate IL-1β’s ability to modulate any of the miRNA that have been 
identified as of interest in this study, specifically, miR24 3p, miR342 3p and 
miR342 5p. It was found that IL-1β stimulation has no impact on the expression 
of any of the miRNA investigated at any of the time points analysed (Figure 5.9).  
Furthermore, co-stimulation with both IL-1β and BMP-7 also had no impact on 
the expression of miR24 3p, miR342 3p or miR342 5p (Figure 5.9). Thus neither 
BMP-7 (Figure 5.6) nor IL-1β (Figure 5.9) regulate these miRNA in this in vitro 
system.   
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Figure 5.7 Effect of  BMP-7 on IL-1β Mediated Alterations of the BMP-7 and IL-1β 
Transcripts in Primary OA Chondrocytes.   
Primary chondrocytes plated at 1.5X105 were stimulated with either 100ng/ml IL-1β or 
100ng/ml IL-1β and BMP-7 for 8 hours before being washed and cultured in cytokine free 
media. Cells were lysed at either A) 8, B) 24 or C) 48 hours post stimulation. Each dot 
represents a different chondrocyte donor from which cartilage was taken at the time of TKR 
surgery from areas of Outerbridge score ≤I, N=5.  BMP-7 and IL-1β transcript analysis shown 
as 2-ΔCT, with limit of detection defined by the average NTC values of all the experiment for that 
gene then applying the formula 2-ΔCT to the averaged value.  Limit of detection for BMP-7 is 2-
ΔCT = 0000153 and the limit of detection of IL-1β is 2-ΔCT = 00006104. Statistical analysis; 
Friedman ANOVA, Dunns multiple comparisons post test, *= P<0.05.    
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Figure 5.8 Effect of  BMP-7 on IL-1β Mediated Alterations of the BMP-7 Signalling 
Cascade and Accessory Components on Primary OA Chondrocytes.  
Primary chondrocytes were stimulated with either IL-1β or IL-1β/BMP-7 all at 100ng/ml for 8 
hours before media was replaced with cytokine free media. Cells were then lysed at either 8 
hours, 24 hours or  48 hours. Data was analysed as fold change (2-ΔΔCT) over the unstimulated 
cells (baseline = 1). Each dot represents one chondrocyte donor, from which cartilage was 
taken at the time of TKR surgery from areas of Outerbridge score ≤I, N=5. Genes analysed 
following stimulation were BMPR2, ALK2, furin, CD44,  COL2A1 (type II collagen) and  MMP-
13.  Statistical analysis; Friedman ANOVA, Dunns multiple comparisons post test,* = P<0.05. 
** = P<0.01.    
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Figure 5.9 Effect of  BMP-7 on IL-1β Mediated Alterations of the BMP-7 Associated miRNA in 
Primary OA Chondrocytes 
Primary chondrocytes stimulated with either IL-1β or IL-1β/BMP-7 all at 100ng/ml for 8 hours 
before cells were placed in cytokine free media. Cells were then lysed at either A) 8 hours, B 24 
hours or C) 48 hours.  Genes analysed following stimulation were miR 342 3p,  miR342 5p and 
miR24 3p.  Data was analysed as fold change (2-ΔΔCT) using the unstimulated cells as a baseline. 
Each dot represents one chondrocyte donor, from which cartilage was taken at the time of TKR 
surgery from areas of Outerbridge score ≤I, N=4. Statistical analysis; Friedman ANOVA, Dunns 
multiple comparisons post test, 
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 The Effect of BMP-7 Stimulation on Pro-inflammatory 5.3.4
Cytokine Production from Chondrocytes.  
Due to the interesting observation that BMP-7 can mediate the induction of both 
MMP-13 and IL-1β (Figure 5.5), further investigation into the ability of BMP-7 to 
modulate other pro-inflammatory cytokines was carried out.  A Luminex assay 
was used in order to examine a panel of pro-inflammatory cytokines, 
determining if BMP-7 stimulation had any effect on their release from the 
primary chondrocytes. The supernatants were taken from the unstimulated cells 
and those stimulated with BMP-7 for 24 hours. The following cytokines were 
quantified by Luminex: IL-1β, IFNα, IL-6, IL-12, RANTES, MIP-1α, MIP-1β, GM-
CSF, MCP-1, IL-1Ra, IL-17, IP-10, IL-2R and IL-8. The effect of BMP-7 was not 
consistent across all of the donors investigated but it appeared to promote the 
production of several immune-modulatory cytokines, including IFNα, IL-6, IL-12, 
MCP-1, IL-1Ra, IL-7, IP-10 and IL-2R (Figure 5.10), in a donor dependent manner. 
The interleukin 1 receptor antagonist (IL-1Ra), which is a natural inhibitor of IL-
1β, was the only mediator significantly up-regulated by BMP-7.  
The effect of BMP-7 on the IL-1β induced up-regulation of these mediators was 
also investigated (Figure 5.11). As expected, IL-1β significantly up-regulated all 
of the proteins of interest, however BMP-7 displayed no anti-inflammatory 
effects against the IL-1β mediated cytokines.  
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Figure 5.10 Secretion of Pro-Inflammatory Cytokines Following BMP-7 Stimulation of 
Primary OA Chondrocytes.   
Chondrocytes stimulated with BMP-7, 100ng/ml for 8 hours, before media is replaced with 
cytokine free media.  Supernatants were harvested 24 hours post stimulation and added onto a 
30-plex luminex plates for analysis. Data is shown as pg/ml. Proteins analysed: IL-1β, TNFα, 
IL-6, IL-12, RANTES, MIP-1α,  MIP-1β, GM-CSF,  MCP-1, IL-Rα, IL-17, IP-10, IL-2R and IL-8.  
Statistical analysis was carried out using a Wilcoxon T-test, * P<0.05   
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Figure 5.11 Secretion of Pro-Inflammatory Cytokines Following IL-1β±BMP-7 Stimulation 
of Primary OA Chondrocytes.   
Chondrocytes stimulated for 8 hours with IL-1β or IL-1β/BMP-7 all at 100ng/ml, media is 
replaced after 8 hours with cytokine free media. Following 24 hours stimulation the 
supernatants were harvested and added onto a 30-plex luminex plates for analysis. Data 
shown as pg/ml. Protein analysed: IL-1β, TNFα, IL-6, IL-12, RANTES, MIP-1α,  MIP-1β, GM-
CSF,  MCP-1, IL-Rα, IL-17, IP-10, IL-2R and IL-8. Statistical analysis, carried out using 
Friedman ANOVA, Dunns multiple comparisons post test, * P<0.05.     
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 Effect of BMP-7 on Primary Human Macrophages.  5.3.5
Previously published data demonstrates that BMP-7 can drive THP-1 cells 
towards an anti-inflammatory M2 phenotype (144). To determine if the findings 
in the THP-1 cells could be reproduced in primary cells, an investigation into the 
phenotype of primary macrophages exposed to BMP-7 was conducted.  Firstly, 
the presence of agranular leukocytes (monocytes or macrophages) was 
confirmed in the cartilage using IHC to identify any CD68 positive staining. CD68 
is a known marker of monocytes and macrophages ( 
 
Figure 5.12), thereby demonstrating the presence of these cells in OA cartilage. 
For the purpose of this investigation, macrophages were assigned into 3 different 
groups: inactivated (M0) cells, classically activated pro-inflammatory (M1) cells 
(exposed to IFNγ) or alternatively activated anti-inflammatory (M2) cells 
(exposed to     IL-4).  In order to elucidate the cellular response to BMP-7 in 
macrophages, it was critical to ensure that the receptors required for signal 
transduction were also present on the cells. Accordingly, BMP receptors, BMPR2 
and ACVR1 (ALK2), were visualised with end point PCR (Figure 5.13A). Both 
receptors were present in all three types of macrophage.  
In order to illuminate any quantitative differences in receptor expression 
between these phenotypes of macrophage, qPCR analysis was also conducted 
(Figure 5.13).  It was shown that the M1 macrophages had the most abundant 
expression of both receptors and of BMP-7 transcript.  The CT values were also 
shown (Figure 5.13C), with the BMP receptors having an average CT value of 23 
and 24 for the ACVR1 (ALK2) and BMPR2 receptors respectively.  The BMP-7 
transcript was less abundant with a CT value of 31.  
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Figure 5.12 CD68 Positive Cells Present in the Cartilaginous Lesions in OA. 
Sections were prepared for staining using the UNITRIEVE antigen retreival technique. CD68 
(monoclonal mouse antibody - anti-human CD68, clone PG-M1, LOT 0052978) was used at a 
concentration of 1µg/ml.  CD68 positive staining can be seen in brown with DAB substrate 
solution.  The isotype was a  Mouse IgG1 (DAKO, LOT 200117491), shown as 10X 
magnification. CD68 images are shown as both 10x and 40x magnification. All images were 
taken with an Olympus BX41 microscope and analysed using Olympus cell B imaging 
software.    
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Figure 5.13 BMP Receptor Expression on M0 (inactivated), M1 (inflammatory) and M2 
(Anti-Inflammatory) Macrophages.   
CD14+/CD16+ cells were isolated from buffy coats (by either Simone Kidger or Lewis Rodgers) 
and plated at 1x106/ml. Cells were matured for 6 days in M-CSF 100ng/ml.  On day 6 M1 cells 
were treated with IFNγ O/N. On day 7 the cells were either given 100ng/ml M-CSF (M0), media 
alone (M1), or IL-4 (M2). A) cDNA was generated for the cells, M0, M1(+LPS), M2 M0+LPS, 
M2+LPS, using AffinityScript. End point PCR was conducted using primers for BMPR2 (120Kb)  
and  ALK2 (77kB) and house keeping gene βactin, products were run on an ethidium bromide 
agarose gel and visualised using Gel logic 200imaging system.  qPCR analysis (with SYB 
green) was also condicted in the M0, M1 and M2 cells for B) ALK2 (ACVR1), C) BMPR2 and 
C) BMP-7. All qPCR data was analysed as  2- Statistical analysis was carried out using 
Frieidman test (ANOVA), with Dunn multiple comparison test.  
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Next the impact of a gram negative bacterial cell wall component, 
lipopolysaccharide (LPS) was assessed on the expression of BMP-7 and BMP 
receptors ( Figure 5.14). LPS is a toll-like receptor 4 (TLR4) ligand and is a well 
established activator of monocytes and macrophages. An increase in both 
receptors (BMPR2 and ALK2) was observed following LPS stimulation in the M0’s   
Figure 5.14A), however, LPS had no robust bearing on the expression of BMP-7. 
LPS addition to the M1 pro-inflammatory cell was only able to induce BMPR2 
expression ( Figure 5.14B). It is plausible that up-regulation OF BMP-7 AND 
ACVR1 (ALK2) in this phenotype may not have been possible due to the baseline 
expression in the M1 cells (induced by IFNγ) already being higher than that of 
the other subtypes of macrophages.  Finally, the impact of LPS on the M2 anti-
inflammatory cells was interrogated (Figure 5.14C). Again there was a consistent 
up-regulation of both ALK2 and BMPR2. BMP-7 transcript was also up-regulated in 
two out of three of the macrophage donors in response to LPS. It can be deduced 
from these data that macrophages have the ability, through adequate receptor 
expression, to respond to BMP-7. Additionally, LPS can further induce the 
expression of both receptors in the M0 and M2 (anti-inflammatory) macrophages 
and to a lesser extent the M1 (pro inflammatory) macrophages.  
With the macrophages expressing the appropriate receptors to respond to BMP-7 
stimulation, it was of interest to investigate the cytokines that would be 
produced following BMP-7 stimulation. Previously it has been reported that the 
macrophage-like cell line, THP-1, adopt an anti-inflammatory phenotype 
following BMP-7 stimulation.  The macrophages were matured for 6 days before 
being polarised with BMP-7 (Figure 5.15). The BMP-7 polarised cells were found 
to secrete the same concentration of IL-6, IL-10 and TNFα as LPS stimulated 
cells.  Therefore the primary chondrocytes would appear to behave in a 
different manner when compared to the THP-1 cells exposed to BMP-7.   
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 Figure 5.14 LPS Induction of BMP Receptors in M0 and M2 Macrophages 
CD14+/CD16+ cells were isolated from buffy coats (by either Simone Kidger or Lewis Rodgers) 
and plated at 1x106/ml and matured for 6 days in M-CSF 100ng/ml on day 6 M1 cells were 
treated with IFNγ O/N. On day 7 the cells were either given 100ng/ml M-CSF (M0), media 
alone (M1), or IL-4 (M2). If LPS stimulation was included it was also added at this point at 
15ng/ml. qPCR analysis (using SYBR green) was conducted in the  A) M0, B) M1 and C) M2 
macrophages for ALK2 (ACVR1),  BMPR2,  BMP-7.  Statistical analysis; Wilcox t-test.  
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Figure 5.15 BMP-7 Polarisation of Macrophages Resulted in the Same Cytokine Secretion as 
LPS Stimulation.  
CD14+/CD16+ cells were isolated from buffy coats (by either Simone Kidger or Lewis Rodgers)  and 
plated at 1x106/ml and matured for 6 days in M-CSF 100ng/ml on day 6. On day 7 the cell were 
either given 100ng/ml M-CSF M0, 100ng/ml M-CSF and 15ng/ml LPS or BMP-7 100ng/ml.  
Supernatants from the macrophages cultures were harvested on day 8 and subject to ELISA 
analysis for either  IL-10, IL-6 or TNFα. Statistical analysis was carried out using Friedman test 
(ANOVA), with Dunn multiple comparison test. * = P<0.05. 
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5.4 Discussion  
 Summary of Results  5.4.1
This chapter aims to elucidate potential mechanisms of action for exogenous 
BMP-7 including; regulation and modulation of its own transcript and those of its 
associated signalling family. Furthermore, the idea that BMP-7 may be an anti-
catabolic agent was also addressed. Overall it was found that BMP-7 could 
modulate its own expression as well as that of some accessory signalling 
molecules in both chondrocytes and macrophages. In chondrocytes this 
regulation was patient specific and therefore not observed to the same extent in 
all donors. BMP-7 has shown both catabolic and anabolic effects: induction of IL-
1β and catabolic enzyme MMP-13 along with increased expression of glycoprotein 
CD44 receptor (which is key in mediating ECM production). BMP-7 also regulates 
macrophage polarisation resulting in the production of pro-inflammatory TNFα, 
IL-6 and anti-inflammatory IL-10.  
 SW1353 Cell Line Response Differs from Primary 5.4.2
Chondrocytes.  
The SW1353 cell line was initially utilised as a valuable research tool due to the 
fact that it can often be difficult to get adequate numbers of primary 
chondrocytes. It has been established that the cell line SW1353 can reliably 
reproduce the IL-1β mediated up-regulation of catabolic factors such as MMP-13 
(265). In this current study, some initial optimisation issues arose with the IL-1β 
stimulations as the SW1353 cells did not respond as expected with MMP-13 
transcript up-regulation - neither cell cycle phase nor age of the cells had an 
impact on these results. It must also be considered that when compared to the 
primary chondrocyte, response to BMP-7 stimulation was consistently different in 
the SW1353 cells. Reassuringly the more robust finding from the cell line data - 
induction of IL-1β transcript by BMP-7 was also confirmed in the primary cells. 
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It is possible that the SW1353 cells, due to their oncogenic background, simply 
do not respond in a similar fashion to the primary cells with regards to BMP-7 
signalling components. 
 Exogenous BMP-7 – Mechanism of Cartilage Protection.  5.4.3
5.4.3.1 Indirect ECM Induction via CD44 Up Regulation 
Historically, extensive research has been carried out investigating the effect of 
exogenous BMP-7 on primary cells in vivo, however, without the use of in vitro 
cultures it is hard to unravel all the potential mechanisms that may be targeted 
for further pharmaceutical intervention. CD44 is a key candidate for BMP-7 
mediated chondro-protection, resulting in ECM repair and maintenance. The 
data generated in this study show that there is indeed a BMP-7 mediated up-
regulation of CD44 at a transcriptional level in 3 out of the 5 chondrocyte 
donors. This suggests that there may be donor specific variation in the response 
to BMP-7.  One of the shortcomings of this study would be that there was no 
validation of BMP-7’s effect on hyaluronic acid synthase or hyaluronic acid as 
both are required for CD44 mediated ECM synthesis (156).  Furthermore, 
translation of the CD44 transcript into functional protein following stimulation 
with BMP-7 should also be carried out in future studies. From the data presented 
above, there was a strong positive correlation between the expression of the 
CD44 and BMP-7 transcript (data not shown), however a larger cohort would be 
required in order to confirm this. Previous publications also report that 
inhibition of BMP-7 via antisense oligonucleotides resulted in an decrease in 
CD44 transcript (155) with other studies supporting this concept, as an increase 
in CD44 expression is evident following incubation with BMP-7 for 1, 3 or 7 days 
(156,259).  Validation of CD44’s role in BMP-7s signalling has previously been 
carried out, demonstrating that knocking down CD44 resulted in increased 
concentrations of BMP-7 ligand being required to induce Smad phosphorylation 
(267). The increased concentration that was required in order to induce 
phosphorylation in the absence of CD44 was also not sufficient enough to induce 
aggrecan synthesis. In order to see an increase in aggrecan, an even higher 
concentration of BMP-7 had to be used. (267).  Taken together this strongly 
suggests that both BMP-7 and CD44 work synergistically in order to produce ECM. 
This work has shown that BMP-7 can mediate CD44 production in some 
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individuals at the level of the transcript in the cartilage.  Therefore, this study 
supports previous finding that BMP-7 therapy may be beneficial in increasing 
CD44 receptor expression which could subsequently increase ECM synthesis in a 
patient specific manner.  
5.4.3.2 Direct Up Regulation of BMP-7 signalling components. 
To date, this is the first study to show the auto-regulatory capacity of BMP-7 on 
its own transcript and receptor, specifically BMPR2 (Figure 5.5) by addition of 
exogenous ligand. This mechanism however, appears to be donor dependent (as 
demonstrated by the variation within the data) and therefore was not found to 
be significant.  Previous studies show that BMP-7 protein is up-regulated in the 
cartilage following therapeutic injection in animals (158,159), however, this is 
the first study to confirm transcriptional up-regulation, therefore showing that 
this is not just a result of latent protein potentially being trapped following 
therapeutic administration. It is therefore plausible that exogenous BMP-7 may 
be able to regulate its own signalling pathway, kick-starting the endogenous 
signalling that was speculated to be lost with the progression of the OA (153). 
Furin, the enzyme required for the cleavage of pro BMP-7 into its mature and 
active form is again up-regulated by over 3 fold in three out of the five 
chondrocyte donors (Figure 5.5) (one after 8 hours and 2 after 24 hours) helping 
to facilitate BMP-7 signalling within the cartilaginous environment. As a 
functional readout to determine if increased furin along with BMP-7 and BMP-7 
receptors could lead to increase ECM production, type II collagen expression was 
analysed, however, no consistent trends in transcript expression were observed. 
It must be noted that previously aggrecan has been the ECM component analysed 
with regards to BMP-7 stimulation, despite the fact that type II collagen has also 
been reported to respond to BMP-7 (220). It would therefore have been 
beneficial to quantify the expression of aggrecan as well as type II collagen in 
this study, thus allowing a more in-depth analysis of the ECM component 
response to exogenous BMP-7 stimulation.   
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 Modulation of Catabolic Factors and Pro-Inflammatory 5.4.4
Cytokines in Primary Chondrocytes. 
5.4.4.1 IL-1β Driven Anabolic Process in Chondrocytes.  
As BMP-7 is thought to be down-regulated as a result of OA pathogenesis (150), it 
was considered that IL-1β may be the key regulator of this inhibition, however, 
this study has generated no data that supports this hypothesis. Conversely, it 
was found that IL-1β induced BMP-7 transcript expression, validating largely 
ignored data that was published over a decade ago using rabbit chondrocytes 
(268) and work carried out in human cells where low dose IL-1β results in an 
increase of both BMP-7 transcript and protein (246). In these human studies, high 
dose IL-1β results in a greater increase in transcript but not protein, as it is 
surmised that the active protein in this case is secreted into the surrounding 
media (246). Taken together, these data suggest that IL-1β may not be 
responsible for disease-associated diminution of BMP-7. Based on these results, 
further studies were undertaken to investigate whether or not a lack of BMP-7 
signalling components may result in altered BMP-7 signalling associated with OA.  
Therefore, if the receptors required for signalling were down-regulated by IL-1β 
then this would in effect break the signalling loop. To this end the effect of IL-
1β on the expression of these signalling components was investigated and 
demonstrates that IL-1β induced each component (Figure 5.8) as opposed to the 
hypothesised inhibition. Additionally, co-stimulation with IL-1β and BMP-7 had 
no additional impact, neither synergistic or inhibitory. These data would 
therefore suggest that IL-1β is not involved in the diminished BMP-7 signalling, 
either by directly inhibiting BMP-7 or indirectly, via inhibition of the BMP-7 
signalling family, in the short term in vitro system used here. The observed 
induction of BMP-7 signalling components following IL-1β stimulation in these 
short term cultures may be a normal response to tissue damage. The idea that 
IL-1β induces anabolic factors  has already been suggested in the inflammatory 
response to tissue injury, thus these findings should actually not come as that 
much of a surprise (269). Whereas chronic exposure to IL-1β, or possibly a milieu 
of cytokines over decades during disease progression may cause alterations in 
BMP signalling. Due to study design, only short term cultures with IL-1β could be 
conducted and not the more appropriate long term cultures.  It is possible that 
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long-term chondrocyte cultures would have been more informative in validating 
the role of chronic IL-1β exposure on primary chondrocytes, which would have 
been more representative of OA.  Long-term cultures of chondrocytes are 
however, not practical as the cells dedifferentiate over time as shown in chapter 
3. Stem cell differentiation into chondrocytes within ECM scaffolds may also 
have been an appropriate platform in order to understand the long-term effects 
of IL-1β, as it has been demonstrated that these cells are more likely to hold 
their phenotype; giving rise to more viable, phenotypically relevant cells in long-
term culture (270-272).  
5.4.4.2 BMP-7 Driven Inflammatory and Catabolic Responses in 
Chondrocytes.   
This study not only suggests that BMP-7 does not have an anti-
inflammatory/catabolic effect, but goes onto suggest that BMP-7 may drive an 
inflammatory/catabolic response in chondrocytes. A review published in 2007 
stated that (to date) there has been no evidence of BMP-7 mediated MMP-13 
modulation (234). However, there is disparity in the literature as a study in 2003 
used luciferase reporter assays in immortalised chondrocytes in order to 
demonstrate that BMP-7 could prevent IL-1β induced MMP-13 up-regulation 
(273). The data presented in this chapter agrees with neither of these previous 
statements, as no such inhibition of IL-1β induced MMP-13 was observed. 
Instead, here it has been demonstrated for the first time that BMP-7 itself has a 
robust impact, increasing MMP-13 expression in primary human chondrocytes 
(Figure 5.5), with the peak response observed 24 hours post stimulation. The 
extent of the up-regulation was donor dependent, ranging from a 1.5-fold to a 
66-fold increase.  BMP-7’s inability to inhibit any IL-1β mediated effects during 
co-stimulation could be a result of the high concentration of IL-1β used in the 
assay, therefore it is possible that if the cytokine had been titrated then BMP-7 
may have had an impact.   
Additionally, BMP-7 also modulated the expression of IL-1β (Figure 5.5), a 
phenomenon observed in all of the chondrocyte donors.  This observation is 
contradictory to previously published data that show a significant decrease in IL-
1β in the synovium of rat joints treated with BMP-7 (158). This attribute of BMP-
7 has also been observed in proximal tubule epithelial cells from the kidney 
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(274). It is possible that this anti-IL-1β effect is only present in certain subsets of 
cells, such as the ones previously reported in the literature (fibroblast like 
synoviocytes and proximal tubule epithelial cells), thus suggesting that 
chondrocytes are simply a cell that cannot produce this response. As the data 
here does not support the literature and the synovium was not investigated in 
this particular study, the potential of BMP-7 to protect the joint environment via 
modulation of IL-1β remains unconfirmed.    
This BMP-7 modulation of catabolic processes may be considered to be part of 
normal homeostatic regulation. It is likely to be a perfectly normal physiological 
reaction from the chondrocytes in the same way that IL-1β production of 
anabolic process is likely to be part of the normal physiological response to 
injury. From the literature, BMP-7 is thought to be up-regulated in order to 
maintain tissue homeostasis and repair. As part of this role, promotion of 
moderate inflammation and catabolic activity in order to restore cartilage 
homeostasis following acute injury, would be expected.  
It is also interesting that a significant BMP-7 mediated up-regulation of IL-Ra (a 
natural inhibitor of IL-1β) was shown (Figure 5.10). Further highlighting BMP-7s 
homeostatic role as not only can it promote the expression of IL-1β, aiding in the 
repair of the tissue but also promotes the termination of this response through 
the up-regulation of inhibitors for these mediators, such as IL-Ra. Thus 
preventing chronic IL-1β signalling that could promote pathological destruction.  
 BMP-7 Activation of Macrophages  5.4.5
Discrete CD68 staining was observed in the cartilage of several of the OA 
patients investigated in this study. CD68 is classically regarded as a macrophage 
marker, however, it has also been shown that this glycoprotein is also expressed 
in fibroblast like synoviocytes (275). Unfortunately, without further analysis it is 
impossible to determine if these are infiltrating macrophages, cleaning up the 
debris left by the catabolic processes, or invasive FLS that have begun to 
intertwine with the cartilage aiding the destruction process.  FLS have been 
reported to invade the cartilage in RA and this is thought to be in part due to 
local disease associated pro-inflammatory mediators, including IL-1 and TNFα 
(276). Further to this, RA fibroblasts have been shown to maintain their invasive 
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phenotype once removed from the joint.  This was also shown in OA, however 
the extent of the invasiveness was significantly reduced when compared to RA 
(277).    
If macrophages are present in the cartilage, then the literature would suggest 
that BMP-7 may have the potential to differentiate these cells into an anti-
inflammatory M2 cell (144). Despite all of the efforts that have been deployed 
into defining the effect of BMP-7 on the phenotype of THP-1 cells, there is no 
published data of the effects on BMP-7 on primary macrophage differentiation. 
Data in this chapter (Figure 5.15) would suggest that BMP-7 stimulated 
macrophages are similar to that of LPS challenged cells (Figure 5.15), and not 
the previously stated M2 – like cells.  There are clearly discrepancies between 
the data generated in this study and the previously published literature, 
however, it must be considered that the previously published data was carried 
out on a cell line and also a concentration of 660ng/ml BMP-7 was used to 
stimulate the cells. In this current study a much lower concentration of 
100ng/ml was used on primary macrophages. Therefore it has been concluded 
that macrophages that are exposed to BMP-7 have the same cytokine output as 
those who have been exposed to LPS in vitro, thus they do not behave in the 
same manner as the THP-1 cell line in response to BMP-7.  
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Figure 5.16 Potential mechanisms of Action for Exogenous BMP-7 Therapy. 
Schematic depicting the potential mechanisms of action exerted by BMP-7 at sites of acute 
tissue damage: BMP-7 and IL-1β have been shown to work in a similar fashion to resolve 
injury and repair the tissue as well as to both promote the expression of each other. Anabolic 
factors, BMP-7 and BMPR2 are up-regulated by  BMP-7, these anabolic factors are thought to 
work synergistically with CD44 to produce ECM. BMP-7 can also modulate an inflammatory 
response via IL-1β in the area of damage which will aid the recruitment of the appropriate 
immune cells in an attempt to further repair the tissue. BMP-7 has also been shown to promote 
MMP-13 that will help to remove any damage tissue. Here BMP-7 can promote the production 
of TNFα and IL-6 from macrophages, which will help in the repair efforts for the tissue. 
Furthermore, BMP-7 polarised macrophages can also produce IL-10, which may be of 
importance in dampening the IL-1β response following the resolution of the damage.  IL-1RA 
can also be induced by BMP-7 from the chondrocytes, further helping to terminate IL-1β 
response following resolution.  This in turn may attenuate the up-regulated BMP-7 signalling 
that was increased in response to damage.  
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 BMP-7’s Role in Response to Tissue Injury.  5.4.6
This study set out to investigate the role of exogenous BMP-7 signalling in the 
modulation of anabolic events within the context of OA. However, the data 
presented in this chapter has highlighted a role for BMP-7 in the promotion of 
inflammatory and catabolic events from the chondrocytes. The chondrocytes 
from this study have been excised from an OA joint, but here it has not been 
confirmed if they maintain a disease like phenotype after isolation from the 
joint, as no healthy chondrocytes were available as a comparator. Also with a 
number of mediators and external factors (i.e mechanical stress) missing the in 
vitro studies have not recapitulated the disease environment and this system has 
consequently not closely mimicked OA. Therefore, the studies conducted in this 
chapter are more likely to be investigating how chondrocytes would react under 
normal circumstances to BMP-7 or IL-1β stimulation. Thus, in exposing the 
chondrocyte to short term cultures, it is possible that the cells are responding as 
they would to a short burst of inflammatory stimuli than they would be exposed 
to in the event of mild to moderate tissue injury and not a chronic disease state.       
These data have shown that BMP-7 may have anabolic potential (via modulation 
of its own signalling family and CD44 mediated ECM synthesis) however, it would 
appear that BMP-7 also modulates the expression of the pro-inflammatory 
cytokine IL-1β, along with catabolic mediator MMP-13. Furthermore, BMP-7 has 
the capacity to modulate other pro-inflammatory cytokines and activate 
macrophages to the same extent as LPS.  Under normal physiological 
circumstances, it is likely that this pro-inflammatory recruitment is a mechanism 
of homeostatic repair that BMP-7 may have the ability to ‘switch off’ via the up-
regulation of IL-1β inhibitor IL-1Ra.    
Cartilage can be damaged in three ways: disruption of the matrix, fissuring of 
the cartilage causing a partial defect, or erosion of the cartilage through to the 
subchondral bone resulting in a full thickness defect (278).  In the first instance 
it has been suggested that if the cartilage is disrupted the remaining viable 
chondrocytes are able to repair the ECM, however as with all sites of injury, this 
most likely involves some form of immune intervention.  From the data 
generated, it can be surmised that IL-1β  may up-regulate the expression of 
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BMP-7 from the chondrocytes in the initial insult.  From here, BMP-7 has the 
capacity to mediate anabolic processes via CD44 leading to ECM production.  
However, as with most tissue insults, damage associated molecular patterns 
(DAMPS) are released leading to the recruitment of immune cells such as 
monocytes to the site of injury (with the most likely point of entry for the 
immune cells being the highly angiogenic synovium). BMP-7 has also been shown 
to modulate IL-1β expression, which may lead to the downstream generation of 
chemotactic cytokines such as: RANTES, MIP-1α, MIP-1β, MCP-1 and IP-10, also 
facilitating the recruitment of these cells to the site of injury.  These cells can 
then further produce cytokines on exposure to BMP-7, that may aid the healing 
process, such as IL-6, which has been shown to promote healing in the skin via 
regulation of leukocytes and collagen accumulation (279). These cells may also 
help in the resolution of the inflammatory and reparative process as the 
macrophages have been shown to produce IL-10 under the influence of BMP-7, 
which has been shown to down-regulate IL-1β expression in monocytes (280). 
Further to this, BMP-7 can also promote the IL-1β antagonist IL-1Ra           
(Figure 5.10).  Together these would help to dampen the pro-inflammatory 
cytokine signalling as well as hindering IL-1β’s ability to promote BMP-7 
expression, thus terminating the signalling loop. This model has been 
summarised in Figure 5.16.  This type of response may also occur in partial 
cartilage defects, however, full repair of the cartilage is unlikely to occur in this 
sort of injury (278), with the reasoning for this incomplete repair remaining 
elusive.  
 Limitations of the Study.  5.4.7
As outlined above, one of the main experimental drawbacks of this study was 
chondrocyte culture time.  In order to recapitulate a disease environment, long-
term cultures would have to be established. However, due to chondrocyte 
phenotypic drift in an in vitro setting, this is problematic.  Hence why short-
term cultures were chosen for this study. As a result, answering questions 
regarding BMP-7’s role in OA proved difficult, however, elucidation of BMP-7s 
potential role in dealing with acute injury in the chondrocytes was possible and 
proved to be rather fruitful in aiding our current understanding.  Other 
limitations included the narrow repertoire of genes analysed throughout the 
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study. Due to limited time and finance it was decided to focus on a small cohort 
of genes of interest.  If further resources had been available, then a wider range 
of genes may have been analysed to fully elucidate the role of BMP-7 outwith its 
own signalling family.  
 Conclusion 5.4.8
Here it has been demonstrated that BMP-7 is able to modulate its own 
expression and that of the BMP-7 signalling family, showing for the first time 
that BMP-7 can modulate its own receptor (Figure 5.5) in primary human 
chondrocytes from a subset of individuals.   Furthermore, the role of BMP-7 in 
the modulation of IL-1β and MMP-13 was also demonstrated in this study. Taken 
together this evidence suggests a more comprehensive role for BMP-7 in the 
homeostatic regulation of cartilage; not only as an inducer of anabolic processes 
but also the inflammatory and catabolic processes that must also be 
implemented for repair and homeostasis to occur.  In addition to the 
chondrocyte centric pathway, it was observed that there was a cross-talk 
between chondrocytes and macrophages, which has already been reported in the 
literature.  Here, however, it is suggested that via potentiation of IL-1β, BMP-7 
may attract monocytes/macrophages to sites of cartilage damage. BMP-7 may 
also be able to switch off this signalling loop via the production of IL-1β 
anatagonist IL-1Ra.  Here further evidence to support a complex signalling loop 
has been presented with BMP-7 and IL-1β being key in the maintenance of 
cartilage integrity.   
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6 General Discussion 
This thesis has investigated the role and regulation of BMP-7 and its signalling 
family in OA. Previous studies have pointed towards a disease associated 
decrease of BMP-7 (153), however data generated here suggests that BMP7 
transcript is not robustly expressed in the OA cartilage. BMP-7 family member 
transcripts however, are readily detected in the cartilage and further to this 
here it has been shown that disease associated miR24 3p can repress the 
expression of the BMP receptor ALK2.  Additionally, a correlation was reported 
between the expression of ALK2 and miR24 3p in the OA cohort investigated in 
this study. Thus giving disease significance to this observation. Analysis of 
primary chondrocytes revealed heterogeneity in both the endogenous expression 
and stimulated modulation of the BMP signalling family members. Despite this 
heterogeneity in response to stimulation, BMP-7 was still shown to regulate IL-1β 
and its inhibitor IL-1Rα in a robust manner. In this thesis, due to the short nature 
of the in vitro stimulations, conditions were unlikely to recapitulate those seen 
in an OA setting. Instead, acute inflammatory insults were carried out, 
investigating the role of the BMP-7 family in this setting. The data display a role 
for BMP-7 in the regulation of anabolic and catabolic processes along with 
macrophage polarisation in acute response to inflammatory insults.  
6.1 Low Level BMP-7 Expression in Primary 
Chondrocytes.  
 The transcriptional and protein expression of BMP-7 in OA was extensively 
investigated in chapter 4.  It was found that only very low levels of BMP-7 mRNA 
were expressed in a donor dependent manner in OA patient cartilage and 
synovial tissue. This was further confirmed using nested PCR analysis.  The 
discrepancies observed in the studies undertaken in this thesis and those 
previously reported in the literature could be due to the sensitivity of the 
scientific technique employed for detection. Post-transcriptional regulation of 
BMP-7 may also allow for the differences observed. One plausible explanation 
was discussed in chapter 4,  BMP-7 transcript contains AU rich elements (AREs) in 
the 3’UTR that are predicted to contribute to transcript stability. The zinc finger 
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protein TTP can bind these AU rich regions and induce rapid degradation of the 
transcript (Figure 4.13). Further studies are required in order to confirm this, 
including a luciferase assay to measure the direct binding of TTP to the AU rich 
elements in the 3’UTR of the transcript. If TTP can directly bind to the 3’UTR of 
BMP-7 then it would be important to investigate whether there are any 
variations in the 3’ UTR of BMP-7 transcripts in chondrocytes from patients with 
OA. Transcript variation could occur via alternative splicing or mutations in the 
AU rich region.  Thus the splice variant(s) or mutations produced by the cell 
could have an impact on how many ARE sites are available for binding via TTP, 
which would impact transcript stability. A technique known as rapid 
amplification of cDNA ends (RACE) could be utilised in order to look at the 
variance in the 3’UTR of the BMP-7 transcripts found in the chondrocytes. In this 
way, BMP-7 from OA and healthy chondrocytes could be compared to look for 
disease associated variation that could have an impact on transcript stability and 
expression.  The presence of splice variants could also alter the way in which the 
transcripts respond to miRNA regulation.  Studies in this thesis have shown that 
both IL-1β and BMP-7 are down-regulated in two out of three chondrocyte donors 
when transfected with miR24 3p mimic.  It is possible that this response to 
miR24 3p is due to patient specific 3’UTR variation.   
6.2  Heterogeneity in the Expression of the BMP-7 
Signalling Family in OA Cartilage.  
At the beginning of this study it was hypothesised that BMP-7 would stimulate its 
own expression and also induce the expression of other BMP-7 related transcripts 
such as BMPR2, ALK2, CD44, FST, GREM and type II collagen. Based on the data 
presented in chapter 5, this hypothesis could not be confirmed. The impact of 
BMP-7 on these genes varied between donors. The variability in the results 
observed from both the BMP-7 stimulation and the analysis of the transcript 
expression in the OA cohort suggest that there is significant heterogeneity with 
regards to these genes in OA patients. Despite this variation, a significant 
positive correlation was found between the expression of BMPR2, ALK2 and type 
II collagen in the patients investigated. This suggests that some of the 
individuals in this study have intact anabolic BMP-7 signalling that results in 
collagen production, whilst other do not possess this capacity. This gives rise to 
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the hypothesis that molecular responses to the progression of OA may differ 
from patient to patient. This may be dependent upon the aetiology of the 
disease or possibly due to variation in genetic susceptibility. Thus highlighting 
the need for further evaluation of the BMP-7 signalling pathway in OA, as this 
may provide new targets for treatments or biomarkers for patient stratification.     
6.3 Expression and Role of miR24 3p in OA 
One of the major findings from this study was the regulation of the BMP receptor 
ALK2 by miR 24 3p. Despite the variation in the transcript expression observed in 
chapter 4, a significant negative correlation was discovered in OA patients 
between the expression of miR24 3p and ALK2. One limitation of the work 
undertaken in this thesis is the lack of healthy cartilage, as the disease 
specificity of this correlation remains undetermined. However, the functional 
studies performed in primary cells confirm an interaction between miR24 3p and 
ALK2. OA chondrocytes transfected with synthetic miR24 3p led to a 40% - 50% 
decrease in expression of the receptor. Thus for this first time this study has 
highlighted ALK2 as a target for miR24 3p. To confirm the regulatory role of 
direct binding of the miRNA to the 3’UTR of the target mRNA further work 
should be undertaken, such as luciferase assays.  Nonetheless, based on the fact 
that this miRNA targets a receptor that is required for anabolic signalling, the 
current data does provide support for its role as a driver of disease 
pathogenesis. It should be appreciated, however, that contradictory data does 
exist (195). Although, it is feasible that both interpretations are in fact true 
(Figure 4.25), this miRNA may indeed be decreased in the end stage of disease, 
but this may not reflect the levels of this miRNA in early disease pathology 
(figure 4.25). More work is required to profile the temporal kinetics of this 
miRNA during OA evolution. Animal models of OA (DMM, ACLT) could be adopted 
in order to define the kinetic expression of this miRNA and its targets at both the 
onset and during the development of the pathology. Furthermore miR24 3p KO 
or conditional KO mice could be utilised to assess the impact this miRNA may 
have on driving OA-like disease in mice.     
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6.4    Impact of BMP-7 on Primary Macrophage 
 A hypothesis regarding the ability of BMP-7 to inhibit IL-1β mediated effects (on 
the BMP-7 signalling family) was also proposed in this study, as it has previously 
been shown that BMP-7 can prevent IL-1β mediated up-regulation of MMP-13(1). 
The data presented in chapter 5 disagrees with this literature.  Importantly, 
BMP-7 stimulation actually led to an up-regulation of IL-1β at the level of the 
transcript (Figure 5.5). Moreover, the studies also revealed that macrophages 
respond to BMP-7 in a similar fashion to LPS stimulation, with increased 
expression of IL-10, IL-6 and TNFα.  Taken together these data suggest a role for 
BMP-7 in the activation of both pro-inflammatory and anti-inflammatory 
responses. This has led to the testable concept that BMP-7 may up-regulate 
anabolic, catabolic and inflammatory mechanisms in homeostatic repair (Figure 
5.16).  
As BMP-7 has an emerging role in the regulation of immune factors in the joint, 
it is possible that its role in OA may be more complex than was initially 
suggested.  Its role is not to solely induce anabolic signalling events that would 
lead to ECM formation, but also to regulate a catabolic and inflammatory 
responses to damage. With all of the factors working in tandem the tissue can be 
returned  to its homeostatic state after an insult or injury.  Further work is 
needed to expand these findings and to elucidate the entirety of BMP-7s role in 
the cartilage and joint.   
6.5 Future Work 
In order to verify these findings, there is a massive need for the acquisition of 
healthy cartilage in order to have an appropriate control tissue.  Here, all of the 
cartilage used for in vitro analysis was taken from areas of cartilage with an 
Outerbridge score of 0-1. However it is known that OA is a disease of the whole 
joint and all the cartilage is exposed to a diseased environment for potentially 
decades before it is surgically removed and used in these studies. This brings 
into question the validity of using cartilage from a diseased joint as a control. 
Healthy cartilage would be needed in ordered to compare the phenotype of the 
disease chondrocytes, observing if they behave differently in vitro than the OA 
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derived cells.  Healthy cartilage would also add significance to the patient 
cohort data that suggests that some changes may occur in the eroded cartilage 
compared to the non-eroded.  
This study initially aimed to investigate the impact of BMP-7 on the associated 
signalling family, as it had been previously reported that therapeutic BMP-7 up-
regulated endogenous BMP-7 protein expression in an animal model. The data 
generated here showed little impact on either BMP-7 or the associated signalling 
family following stimulation with exogenous BMP-7. Furthermore, the reported 
ability of BMP-7 to negate the effects of IL-1β was also not observed here. Thus, 
the mechanism by which BMP-7 confers protection remains ill-defined. Further 
work is required in order to determine exactly how BMP-7 mediates protective 
effects in the context of OA. In the future a wide scale transcriptomic and 
proteomic approach could be adopted, to analyse the full effect of BMP-7 across 
a wider range of genes and proteins. This would give a better indication into the 
pathways involved in this protection. This approach would be best adopted in 
the animal models first, as their response to BMP-7 appears to be more 
homogenous than that seen in primary chondrocytes, perhaps due to genetic 
similarity.  Any findings would then need to be validated in human primary 
chondrocytes to ensure relevance in humans.   
6.6 Conclusions 
In conclusion, this thesis has identified that the BMP receptor ALK2 can be 
regulated by miR24 3p and that its expression is significantly correlated in OA 
patients. This highlights miR24 3p as a potential regulator of cartilage 
homeostasis and changes in the expression of this miRNA over the course of OA 
disease progression may be involved in driving disease pathogenesis. In addition 
to the reported anabolic role of BMP-7, data herein suggests BMP-7 also has the 
capacity to promote the expression of IL-1β and its antagonist IL-1Ra in OA 
derived chondrocytes. Further to this it also promotes the secretion of IL-10, 
TNFα and IL-6 in primary macrophage cultures. In combination, this suggests 
that BMP-7 contributes to the promotion of inflammation and subsequent 
associated repair as part of the cartilage homeostatic mechanisms
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